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Abstract 
 Neuropilins (nrps) and plexins (plxns) are transmembrane (TM) proteins that form co-
receptor complexes to guide neuronal, vascular, lymphatic, and bone development as well as 
cancer metastasis.  While it is understood that nrp serves as the extracellular ligand-binding 
receptor and plxn as the signal-transducing portion of the complex, little is understood about the 
mechanism of activation of the signal transduction cascade beyond ligand binding.  
Understanding the mechanisms of plxn and nrp activation may provide insight necessary for 
rational design of novel cancer therapeutics. 
Co-receptor clustering is believed to induce activation.  Previous studies suggest deletion 
of the plxn extracellular domain leads to a constitutively active plxn, but lack of membrane-
anchorage of the cytosolic domain yields inactivity, implying a role for the plxn TM and 
juxtamembrane (JM) domains in clustering and subsequent activation.  We demonstrate that a 
heptad repeat in the cytosolic JM domain modulates Danio rerio PlxnA3 homodimerization of 
the TM + JM domains in a bacterial membrane via the AraTM homodimer assay and of the TM + 
JM domains with a full extracellular domain intact via a bioluminescence resonance energy 
transfer (BRET2) assay.  A specific mutation (M1281L) that enhances homodimerization in the 
BRET2 assay in the presence of a Nrp2a co-receptor and semaphorin-3F ligand also fails to 
rescue motor neuron patterning in PlxnA3-knockout zebrafish embryos, in contrast to the wild-
type protein.  We also demonstrate via these same techniques that a glycine-rich segment of the 
PlxnA3 TM domain modulates receptor homodimerization, competing with the dimerization 
motif of the JM domain.  Specifically, mutations to small-x3-small motifs in the PlxnA3 TM 
domain enhance dimerization of the TM + JM domains in the AraTM assay.  Mutations to both 
the TM and JM dimerization motifs demonstrate, in the context of the TM + JM system, the 
heptad repeat in the JM dominates TM + JM dimerization.  Mutations to the small-x3-small TM 
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dimerization motifs exhibit reduced functionality in the zebrafish embryo axonal guidance assay.  
Collectively, these results demonstrate that enhanced PlxnA3 dimerization does not correlate with 
enhanced function.  The TM-driven dimerization serves to weaken the JM dimer, likely allowing 
switchability between co-receptors as well as active and inactive states. 
The nrp MAM domain is also believed to contribute to the observed clustering 
phenomenon with the intact, full-length plxn receptor.  We show that cysteines in the Danio rerio 
Nrp2a MAM domain, in particular residue C711, modulate Nrp2 homodimerization, as 
determined via the BRET2 assay.  Mutation of residue C711 also disrupts ligand binding.  While 
zebrafish embryos injected with wild-type nrp2a RNA exhibit ectopic vascular branching, 
significantly fewer embryos injected with nrp2a RNA with the C711S mutation exhibit this 
overexpression phenotype. 
Collectively, this work provides insight into the dimerization mechanisms important for 
nrp and plxn activity.  The structure-function correlations determined may assist in rational 
design of targeted therapeutics to alter nrp and plxn activity. 
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Chapter 1 
Introduction to Neuropilins and Plexins, 
Transmembrane Receptors Involved in 
Development and Disease 
 
1.1 Introduction 
Neuropilins (nrps) and plexins (plxns) are two families of Type I transmembrane (TM) 
receptors involved in neuronal, vascular, and lymphatic development as well as zebrafish fin 
regeneration. Semaphorins (semas) are their ligand binding partners (1-14).     At least nine plxns 
in four different classes (A-D), two nrps (1 and 2) comprised of at least ten different isoforms, 
and twenty semas in eight classes (classes 1-8) are known to date, with classifications grouped 
based on homology (3,4,15-20).  Class A plxns are known to interact with the secreted dimeric 
class 3 semas, and in this system, nrps are necessary co-receptors (1-3,10,21).  In the plxn-nrp-
sema signaling complex, semas serve as the guidance cue, directing the plxn-nrp-expressing cell 
towards or away from the sema source.  Nrps act as the glue that joins sema and plxn and dictates 
specificity of the plxn-sema association.  Plxns serve as the enforcers; upon association with 
semas and nrps, plxns initiate a signal transduction cascade to alter cell motility (1-
3,8,10,15,16,21,22).  
 While the plxn, nrp, and sema machinery is important for development, it also has 
implications in disease (3,4,12,17,23-37).  In particular, plxns, nrps, and semas have been 
implicated in influencing development of bladder, breast, endometrial, lung, ovarian, pancreatic, 
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and prostate cancers as well as melanomas and leukemia, with effects depending on the stage and 
type of cancer (3,25-27).  Implications that plxns, nrps, and semas may regulate cancer 
progression has led to recent investigations regarding their use as anti-cancer therapeutics.  
Antibodies disrupting NRP1 and NRP2 signaling inhibited tumor growth and demonstrated anti-
metastatic potential in mouse lung tumor models (33,35). Overexpression of SEMA3F also 
disrupted tumor angiogenesis in a mouse melanoma model (28).  Hence, plxn-nrp-sema signaling 
may modulate tumor growth and metastasis.  Understanding signaling mechanisms of these 
receptors is important from a cancer therapeutic standpoint.  From understanding of plxn and nrp 
structure-function relationships, we may be able to rationally design drugs to promote the anti-
tumor and anti-metastatic effects observed with select combinations of these receptors. 
 
1.2 Current Understanding of Plexin and Neuropilin Structure-Function 
Relationships 
Structurally, nrps are comprised of two extracellular CUB (complement protein C1r/C1s, 
Uegf, and Bmp1) domains, two coagulation factor V/VIII (FA V/VIII) domains, one MAM 
(meprin, A-5 protein, and protein tyrosine phosphatase μ, PTPμ) domain, a single-spanning TM 
region, and a short cytosolic tail (Figure 1.1) (14,18,23,31,33,38-40).  In addition to interactions 
with plxns, nrps are known to interact with vascular endothelial growth factor receptors, integrins, 
and cell adhesion molecules (38,41,42).  The short cytosolic domain (CYTO) for nrps has been 
shown to be nonessential for nrp-plxn signaling (1,39); thus, in the plxn-nrp-sema signal 
transduction process, plxns are thought responsible for the intracellular signaling.  Nrp is 
necessary for extracellular ligand binding, with the sema-binding domains of class A plxns failing 
to bind semas in the  absence  of  the  nrp  co-receptor  (1-3,10,21).   By  imparting  specificity  in  
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Figure 1.1.  Clustering drives plexin-neuropilin-semaphorin activity.  This clustering is 
modulated in part by transmembrane and juxtamembrane interactions. 
 
ligand binding and co-receptor complex formation, nrp modulates the responses of class A plxns 
to extracellular cues (1,2,43,44).   
The plxn structure consists of a sema-binding domain, three plexin-semaphorin-integrin 
(PSI) domains, and three immunoglobulin, plexin, and transcription factor (IPT) domains 
extracellularly; a single-pass TM domain; and a CYTO region homologous with RasGAPs (Ras 
GTPase-activating proteins) (Figure 1.1) (1,3).  The sema-binding domain interacts with the sema 
domain of sema proteins during activation, and for PLXNA1, deletion of this domain alone or the 
entire extracellular domain leads to a constitutively active receptor, implying an auto-inhibition 
mechanism involving the sema domain and another extracellular domain (44). 
The activity of the plxn CYTO portion is characterized by its GTPase-activating protein 
(GAP) activity (7,9,15,16,45).  Structurally, the CYTO domain is comprised of an N-terminal 
juxtamembrane helix (JM) followed by a GAP domain with a RhoGTPase-binding domain 
(RBD) insert; the two halves of the GAP domain are termed C1 and C2 for the N- and C-termini, 
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respectively (7,9,11,46).  In an inactive conformation, the C1 and C2 domains form a closed 
pocket thought to be inaccessible to G-proteins, preventing plxn GAP activity (7).  Upon binding 
of sema extracellularly in conjunction with RhoGTPase (Rac1, Rnd1, or RhoD) binding to the 
intracellular RBD or possibly a juxtamembrane pocket, the plxn adopts a new conformation that 
confers GAP activity (7,9,11,46).  Previous studies suggested the G-proteins R-Ras and M-Ras 
were the objects of this activity (16,45), though recent studies suggest Rap may be the subject of 
the GTP hydrolysis (11,46). 
 Expression of the PLXNA1 CYTO domain alone in solution does not confer collapse 
activity (21,44).  In solution, the PLXNA1, PLXNA3, and PLXNB1 CYTO domains are 
monomeric or weakly dimeric or trimeric, with oligomerization affinities low enough that higher-
order structures have yet to be detected by analytical ultracentrifugation (6,7,9,46).  Though the 
PLXNA1, A2, A4, and C1 CYTO domains in solution exhibit low levels of activity in an in vitro 
RapGAP assay, forced dimerization enhances their activity, implying clustering or dimerization 
modulates activity (46).    With the addition of a cross-linker, a membrane-anchored PLXNB1 
CYTO domain also causes cellular contraction (47).  While membrane-tethering of the PLXNA1 
CYTO domain with a myristoylation anchor fails to elicit activity in the absence of 
overexpression of additional proteins, expression of the PLXNA1 TM + CYTO domains triggers 
cellular contraction in a COS-7 collapse assay (21,44).  Collectively, these observations suggest 
clustering or dimerization is a key contributing factor to plxn activity, and this phenomenon is 
modulated in part by the TM and juxtamembrane domains (Figure 1.1).  A clustered state driving 
plxn activity is supported by an early immunohistological observation that, upon addition of 
SEMA3A to chick E7 dorsal root ganglion (DRG) neurons, PLXNA1 and NRP1 associate to 
form regions with high local concentrations of receptors (2).  As such, the mechanism governing 
plxn homomeric interactions has yet to be determined.  Results collectively suggest the plxn TM 
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and juxtamembrane domains, as well as the nrp co-receptor, modulate the clustering 
phenomenon. 
While it is known that plxn-nrp co-receptor complexes form at the cell surface, the 
stoichiometry of this complex is less well understood. Recently, a low-resolution crystal structure 
of the CUB and FA V/VIII domains of NRP1 with the four N-terminal extracellular domains of 
PLXNA2 bound to SEMA3A was reported, providing insight into the structure of this complex 
(10). The structure reveals a 2:2:2 NRP1:PLXNA2:SEMA3A stoichiometry, though neither the 
NRP1 nor PLXNA2 extracellular domain fragments exhibit dimerization tendencies in solution in 
the absence of ligand-binding (10).  This is in contrast to studies on full-length NRP1 and NRP2a 
receptors, which run as dimers on western blots and can co-immunoprecipitate (co-IP) 
alternatively-tagged full-length nrp receptors (39,48-50).  NRP1 dimerization is thought to be 
partially due to the TM domain, which shows a capacity for dimerization in the ToxLuc assay and 
the bacterial adenylate cyclase 2-hybrid assay (BACTH) (22,51,52).  The NRP1 TM domain 
exhibits a ‘small-x3-small' motif, a common TM helix-packing motif first identified with 
Glycophorin A (GpA) (22,51,53).  In this motif, 'small' represents a small amino acid (typically 
glycine, alanine, or serine) and x represents any amino acid.  Alignment of the small amino acids 
on a helical face creates a groove into which ridges created by the side chains from larger amino 
acids fit, and dimerization is driven by geometric packing, promotion of additional side chain 
interactions, hydrogen bonding and reduced entropic effects (relative to interactions of larger side 
chains) (53-56).  Through use of the ToxLuc assay and the bacterial adenylate cyclase 2-hybrid 
assay (BACTH), it was demonstrated that mutations to the NRP1 TM small-x3-small motif 
disrupts TM homodimerization (51,52). 
Domain-binding and deletion studies, however, suggest additional homomeric 
interactions may be facilitated by the nrp MAM domain (39,48,49).  MAM domains in protein 
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tyrosine phosphatases and meprins have been demonstrated to modulate homooligomerization in 
their respective proteins (57-59).  In meprins and protein tyrosine phosphatases, intra- and 
intermolecular disulfide bonds shape protein structure and modulate homomeric interactions (57-
60).  The role of cysteine chemistry or another specific driving force in nrp MAM 
homooligomerization, however, is not yet understood.  How these interactions affect full-length 
receptor clustering, and their effect on the plxn-nrp-sema signaling pathway, as well as other nrp-
dependent signaling pathways, has still to be determined. 
While plxn-nrp-sema associations could promote full-length plxn clustering, it does not 
explain the ability of PLXNA1 to induce collapse upon removal of the sema domain (in the 
absence of a nrp co-receptor and sema ligand) (44).  Recent studies involving the PLXNA1 TM 
domain in the BACTH assay demonstrated this region has a weak but significant propensity to 
homodimerize (22,52).  In particular, the PLXNA1 TM domain is rich in small amino acids 
(glycines and alanines).  Simulation work suggests these amino acids can participate in alternative 
forms of small-x3-small associations, the most common motif for TM interactions, depending on 
bilayer composition and the presence or absence of the TM domain of the NRP1 co-receptor (22).  
The JM domain of PLXNs also contains a heptad repeat that likely contributes to coiled-coil 
formation  (Figure 1.2) (11).  The coiled-coil motif is characterized by a hydrophobic core formed 
by a heptad repeat, with salt bridges stabilizing the interactions.  In other words,  for residues 
ABCDEFG, residues A and D are hydrophobic, and as such, lie on the same face of a helical 
peptide; dimerization allows the hydrophobic residues to be shielded from the solvent, and salt 
bridges formed by charged residues at the B, C, E, F, or G positions stabilize these interactions 
(61).  A crystal structure of the PLXNC1 CYTO domain dimerized through a GCN4 coiled-coil 
motif also suggests that the JM may regulate plxn homooligomerization and subsequent 
signaling, though the coiled-coil portion immediately membrane-proximal was thought to be  
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flexible and not involved in dictating homomeric interactions (11).  Thus, recent studies have 
surmised that plxn TM and JM domains are involved in homooligomerization; however, research 
investigating these domain interactions thus far have been on the isolated domains themselves, 
rather than in conjunction with each other. 
 
1.3 Determination of Plexin and Neuropilin Homodimer Interfaces 
In order to determine the factors promoting clustering of nrp and plxn receptors, we have 
focused on the individual proteins to understand intrinsic homodimerization.  As signaling 
requires both extracellular and intracellular events (sema-binding extracellularly, and 
RhoGTPase-binding intracellularly), we focused on the connecting TM and juxtamembrane 
domains.  Danio rerio Nrp2a and PlxnA3 served as our model receptors for each class of protein.  
With PlxnA3, we demonstrate that the JM coiled-coil promotes homodimerization of the PlxnA3 
TM + JM domains in the context of an E. coli membrane via the AraTM assay and also promotes 
dimerization of the TM + JM domains in the context of a mammalian cell membrane with a full 
extracellular domain intact in a bioluminescence resonance energy transfer (BRET2) assay.  A 
dimer-enhancing mutation, M1281L, also enhances dimerization in the BRET2 assay in the 
presence of the Nrp2a co-receptor and SEMA3F ligand, and fails to rescue wild-type motor 
neuron patterning in PlxnA3-knockout embryonic zebrafish assay.  Additionally, mutation to 
small-x3-small interfaces in the PlxnA3 TM domain enhance dimerization of the TM + JM 
domains in the AraTM assay.  We demonstrate that in the TM + JM system, mutations to the JM 
heptad repeat are dominant over mutations to the TM small-x3-small motifs, implying TM-driven 
dimerization negatively regulates JM-driven dimerization.  The dimer-enhancing TM mutations 
also disrupt PlxnA3 function, as determined using the zebrafish axonal guidance assay. Hence, 
enhanced PlxnA3 dimerization does not correlate with enhanced function.  For Nrp2a 
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homooligomerization studies, our results indicate that a specific interface in the Nrp2a MAM 
domain, which includes a conserved cysteine (C711), plays a significant role in 
homooligomerization.  Mutation C711S enhances homodimerization, as determined via the 
BRET2 assay, reduces SEMA3F-binding in transiently-transfected COS-7 cells, and exhibits a 
decreased Nrp2a overexpression phenotype in a zebrafish embryo vascular patterning assay.  
Collectively, our results provide insights into the TM and juxtamembrane interfaces modulating 
Nrp2a and PlxnA3 homomeric interactions and subsequent function (Figure 1.1).  Such insight 
may assist in rational design of therapeutics targeting the plxn-nrp-sema signaling cascade.  These 
therapeutics may subsequently be used to disrupt tumor growth and the metastatic process. 
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Chapter 2 
A Cytosolic Juxtamembrane Interface Modulates 
Plexin A3 Oligomerization and Signal Transduction2a 
 
2aThe work in this chapter has been published as “A cytosolic juxtamembrane interface 
modulates plexin A3 oligomerization and signal transduction” by Rachael Barton, Danica 
Palacio, M. Kathryn Iovine, and Bryan W. Berger in PLOS ONE, 2015. 
 
 
Abstract 
 Plexins (plxns) are transmembrane (TM) receptors involved in the guidance of vascular, 
lymphatic vessel, and neuron growth as well as cancer metastasis. Plxn signaling results in 
cytosolic GTPase-activating protein activity, and previous research implicates dimerization as 
important for activation of plxn signaling. Purified, soluble plxn extracellular and cytosolic 
domains exhibit only weak homomeric interactions, suggesting a role for the plxn TM and 
juxtamembrane regions in homooligomerization.  In this study, we consider a heptad repeat in the 
Danio rerio PlxnA3 cytosolic juxtamembrane domain (JM) for its ability to influence PlxnA3 
homooligomerization in TM-domain containing constructs.  Site-directed mutagenesis in 
conjunction with the AraTM assay and bioluminescent energy transfer (BRET2) suggest an 
interface involving a JM heptad repeat, in particular residue M1281, regulates PlxnA3 homomeric 
interactions when examined in constructs containing an ectodomain, TM and JM domain.  In the 
presence of a neuropilin-2a co-receptor and semaphorin 3F ligand, disruption to PlxnA3 
homodimerization caused by an M1281F mutation is eliminated, suggesting destabilization of the 
PlxnA3 homodimer in the JM is not sufficient to disrupt co-receptor complex formation. In 
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contrast, enhanced homodimerization of PlxnA3 caused by mutation M1281L remains even in the 
presence of ligand semaphorin 3F and co-receptor neuropilin-2a. Consistent with this pattern of 
PlxnA3 dimerization in the presence of ligand and co-receptor, destabilizing mutations to PlxnA3 
homodimerization (M1281F) are able to rescue motor patterning defects in sidetracked zebrafish 
embryos, whereas mutations that enhance PlxnA3 homodimerization (M1281L) are not. 
Collectively, our results indicate the JM heptad repeat, in particular residue M1281, forms a 
switchable interface that modulates both PlxnA3 homomeric interactions and signal transduction.   
  
2.1 Introduction 
 Plexins (plxns) are a family of type I transmembrane (TM) receptors involved in 
neuronal, vascular, and lymphatic development as well as zebrafish fin regeneration in 
conjunction with semaphorins (semas), their ligand binding partners (1-13). Class A plxns are 
known to interact with the secreted class 3 semaphorins, and in this system, neuropilins (nrps) are 
necessary co-receptors (1-3,10,14).  In the plxn-nrp-sema signaling complex, semas serve as the 
guidance cue, directing the plxn-nrp-expressing cell towards or away from the sema source (1-
3,10,14-17).  The nrp acts to join sema and plxn, dictating specificity of the sema-plxn 
association and initiating a signal transduction cascade to alter cell motility (1-3,8,10,14-17). 
Furthermore, mutations to plxns have been reported in melanomas as well as lung, breast, 
pancreatic, and prostate cancers, suggesting their altered signaling may play a role in cancer 
development (4,18).  As such, understanding plxn-dependent signaling mechanisms are important 
both in terms of determining their role in development and disease. 
 The plxn structure consists of an extracellular sema domain, three plexin-semaphorin-
integrin (PSI) domains, and three immunoglobulin, plexin, and transcription factor (IPT) 
domains, a single-spanning transmembrane domain, and a cytosolic region (CYTO) homologous 
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with Ras GTPase-activating proteins (GAPs) (1,3). Deletion studies have shown that the CYTO 
portion of plxns confers activity provided the TM domain is intact or the CYTO domain is 
tethered to the membrane and cross-linked in a dimeric or clustered state (19,20), indicating plxn 
CYTO oligomerization is important in signal transduction. In particular, overexpression of Mus 
musculus PLXNA1 (mPLXNA1) TM + CYTO in transfected cells is enough to trigger growth 
cone collapse without the presence of nrp co-receptor or addition of a sema ligand (19).  
Similarly, fusion of human PLXNB1 (hPLXNB1) CYTO to the CD2 extracellular + TM domains 
with the addition of cross-linker also results in cellular contraction (20).  Furthermore, inducing 
dimerization of the CYTO domains of mPLXNA1, mPLXNA2, mPLXNA4, and mPLXNC1 
enhances RapGAP activity over their monomeric counterparts (21).  Overall, these results suggest 
that plxn CYTO dimerization is important for sema-dependent signal transduction (Figure 2.1A).  
 
Figure 2.1.  Clustering drives plexin activation.  (A)  Cartoon illustration indicating the 
relationship between plexin oligomeric state and function.  (B)  A cytosolic juxtamembrane 
heptad repeat in PlxnA3 is conserved across species and may regulate this phenomenon.  (C)  A 
crystal structure of the Mus musculus PLXNA3 cytosolic domain (PDB # 3IG3) with residues 
comprising a heptad repeat highlighted in green. 
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Interestingly, in vitro the CYTO portion of plxns are primarily monomeric, with 
monomer only detected by analytical ultracentrifugation for mPLXNA3 and hPLXNB1 (6,7,9).  
Likewise, the full-length mPLXNA2 extracellular domain also exhibits weak homomeric 
interactions through the extracellular membrane-proximal domains, indicating the extracellular 
domain may not provide a strong ligand-independent driving force for receptor homodimerization 
(8). A dimer of the hPLXNB1 RhoGTPase-binding domain (RBD) has been reported, though this 
dimer did not form in solution and crystal structures of the full-length hPLXNB1 CYTO domain 
suggest the contacts between loops responsible for dimerization in the RBD domain alone are 
replaced by intramolecular interactions (5,6).  A trimeric structure for the hPLXNB1 CYTO 
domain has also been reported, though in solution this oligomeric state could not be confirmed, 
suggesting a high local concentration at the membrane may be necessary for hPLXNB1 CYTO 
association into dimers and trimers (9). A recent study involving the hPLXNA1 TM domain 
demonstrated the TM region has a weak but significant propensity to interact, putatively through 
alternative forms of specific GxxxG associations that depend on bilayer composition and the 
presence or absence of the TM domain of the hNRP1 co-receptor (15). Thus, while in some 
instances homomeric interactions have been identified for plxns, a unified picture of how plxn 
homooligomerization occurs is still an area of active research.  
In this study, we consider the cytosolic juxtamembrane helix (JM) in the presence of the 
TM to examine its influence on the homomeric interactions of Danio rerio PlxnA3.  Using the 
AraTM assay (22), we examine the TM + JM interactions in cell membranes and identify an 
interface containing a heptad repeat in the JM as influential to dimerization, with mutations to 
M1281 in the heptad repeat capable of both enhancing (M1281L) or disrupting (M1281F) PlxnA3 
homodimerization.  These same interactions are also observed with the full extracellular domain 
intact with a truncated CYTO domain in a mammalian membrane using the bioluminescence 
resonance energy transfer (BRET2) assay.  In the presence of the functionally-relevant Nrp2a co-
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receptor and SEMA3F ligand (23), we find that disruption to PlxnA3 homomeric interactions via 
mutation M1281F can be corrected by the addition of a Nrp2a co-receptor and SEMA3F ligand 
such that PlxnA3 mutant M1281F homodimerizes with a signal similar to that of wild-type (WT) 
PlxnA3.  In contrast, the PlxnA3 mutant M1281L exhibits a greater extent of homodimerization 
as compared to WT PlxnA3, even in the presence of Nrp2a co-receptor and SEMA3F ligand.  To 
examine the functional effects of these mutations, we injected WT or mutant plxna3 mRNA into 
the sidetracked (set) zebrafish line, which lacks membrane-anchored PlxnA3 and exhibits 
aberrant motor neuron patterning (24), and examined rescue of WT zebrafish motor neuron 
patterning.  We find that alterations to PlxnA3 homomeric interactions are correlated with 
phenotype observed:  neutral mutations in the presence of a nrp co-receptor and sema ligand 
(M1281F) rescue zebrafish motor neuron development, whereas mutations that result in enhanced 
plxn homodimerization in the presence of a nrp co-receptor and sema ligand (M1281L) do not.  
Collectively, our results suggest the heptad repeat interface in the JM affects PlxnA3 
homooligomerization, and residue M1281 in the heptad repeat acts as a switch that modulates 
PlxnA3 oligomeric state and subsequent function.   
 
2.2 Materials and Methods 
This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocols 
used for this manuscript were approved by Lehigh’s Institutional Animal Care and Use 
Committee (IACUC) (approval date 11/8/2013). Lehigh University’s Animal Welfare Assurance 
Number is A-3877-01. All experiments were performed to minimize pain and discomfort. 
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2.2.1 Plasmids 
A full-length WT Danio rerio plxna3 nucleotide template (NCB Accession # 
AB262187.1, with a translational mutation C1090S) was provided by Dr. Michael Granato 
(University of Pennsylvania).  This construct was subsequently cloned into pcDNA3.1/V5-His-
TOPO (Invitrogen) with a C-terminal His-tag as per manufacturer’s instructions.  Full-length WT 
Danio rerio nrp2a (NCB Accession # BC162118, Thermo Scientific) was cloned similarly into 
pcDNA3.1/V5-His-TOPO with a C-terminal FLAG-tag for co-expression studies.  The plasmid 
encoding alkaline phosphatase-tagged (AP-) SEMA3F was kindly provided by Dr. Roman J. 
Giger (University of Michigan). 
 For the BRET2 assay, a truncated coding sequence for WT plxna3 (amino acids 1-1314 of 
NCB Accession # BAF81998.1) was cloned into pGFP2-N3 (BioSignal Packard) at NheI/HindIII 
and into pRLuc-N1 (BioSignal Packard) at XhoI/HindIII.  For the AraTM assay, the coding 
sequence for WT plxna3 TM + JM (amino acids 1241-1314 of NCB Accession # BAF81998.1) 
was cloned into pAraTM as SacI/KpnI inserts. 
PlxnA3 mutants were generated using the QuikChange II Site-Directed Mutagenesis Kit 
(Agilent Technologies) as per manufacturer’s instructions.  For random mutations in pAraTM 
constructs, EP-PCR was performed as previously described (25). 
 
2.2.2 AraTM Assay 
AraTM measurements were performed as previously described, with the exception that 
cultures for AraTM measurements were grown for 16-24 hours from glycerol stocks generated 
from transformed cells grown in selective lysogeny broth (Lennox) medium, rather than from 
plates.  Orientation in the membrane and level of protein expression was confirmed as previously 
described (Figure 2.2) (22).  Results are reported in terms of the average percent change from WT 
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Figure 2.2.  Expression and orientation of PlxnA3 TMCY AraTM constructs.  (A) Anti-MBP 
western blot (1:10000 dilution, NEB) of PlxnA3 TMCY AraTM constructs.  (B)  Maltose 
complementation test of PlxnA3 TMCY AraTM constructs.  (C) Spheroplast assay on the WT 
PlxnA3 TMCY AraTM construct.  Ladder markings are in kDa.  The expected molecular weight 
of PlxnA3 TMCY AraTM constructs is 67 kDa. 
 
in slope of green fluorescent protein (GFP) fluorescence vs. absorbance determined from a 
minimum of 11 independent replicates.  Standard error was determined by calculating the 
standard error of these samples and adding the standard error from WT to these values.  Figure 
2.3 illustrates a sample of non-normalized and normalized data for one round of experiments 
(three replicates) analyzed as previously described (22). 
 
2.2.3 BRET2 Assay 
COS-7 cells (ATCC) were grown to 40-90% confluency and transfected at a cell density 
of 1 x 106 cells/mL in HEPES-buffered saline using 8 µg plasmid DNA per construct and the pre-
set COS-7 parameters of the Bio-Rad Gene Pulser XCell.  Transfections were then transferred to 
2.6 mL media (for BRET2 measurements) or 1.5 mL media (for AP-SEMA3F expression).  
Cultures for BRET2 measurements were seeded in eight wells of a 96-well dish (200 µL/well) and  
 27 
 
 
Figure 2.3.  AraTM results for a three-replicate round of PlxnA3 TM + JM AraTM 
measurements.  (A) Non-normalized average slope of fluorescence vs. absorbance, with error bars 
indicating standard error determined from three replicates.  (B)  Average slope of fluorescence vs. 
absorbance represented as a percent change in slope from WT, with error bars indicating standard 
error of the mutant construct plus standard error of the WT construct.  Red bars marked with ‘*’ 
indicate non-overlapping mean +/- SEM with the WT protein in each graph. 
 
cultures for AP-SEMA3F expression consisted of six AP-SEMA3F transfections in a 100 mm 
dish.  Proteins were allowed to grow for two days following the cultivation environment 
recommended by ATCC with the addition of 1% (v/v) 100X Antibiotic/Antimycotic solution 
(100 U/mL penicillin G, 100 µg/mL streptomycin, and 0.25 µg/mL amphotericin B) (Hyclone).  
Following expression, media for BRET2 wells receiving AP-SEMA3F treatment was removed 
and replaced with 200 µL AP-SEMA3F expression media.  Treatment occurred for a minimum of 
1.5 hours at 37ºC with 5% CO2.  BRET2 measurements proceeded as previously described using a 
Tecan Infinite F200 multi-well plate reader (26,27).  Western blots were used to confirm similar 
expression levels between WT and mutant PlxnA3 BRET2 constructs following measurements 
(EGFP monoclonal antibody, Clontech, and MSX Renilla Luciferase antibody, Millipore).  Cell-
staining confirmed expression of FLAG-tagged Nrp2a (mouse monoclonal anti-FLAG antibody, 
Sigma, and Alexa Fluor 546, Life Technologies), and the presence of AP-SEMA3F in the media 
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was confirmed by testing for AP activity via dot blot and a reaction involving 5-bromo 4-chloro 
3-indolyl phosphate (Roche) and nitro blue tetrazolium (Roche) previously described (28).  AP-
Sema3F binding to Nrp2a- and PlxnA3-transfected cells was confirmed by testing for AP activity 
on parallel cultures of treated cells as previously described (Figure 2.4) (28). 
For analysis, the total luminescence in each well was analyzed, and measurements were 
only kept for wells with total luminescence values above that of mock-transfected cells.  A 
normalized energy transfer efficiency ratio was determined by calculating the ratio of green 
luminescence to magenta luminescence in a given well and dividing this value by the ratio of 
green luminescence to magenta luminescence for mock-transfected cells of that round of 
experiments.  Results presented represent the average normalized energy transfer efficiency ratio 
determined from a minimum of three independent transfections (a total of at least 21 replicates 
per condition), with standard error calculated as described for the AraTM assay. 
 
2.2.4 Zebrafish Housing and Husbandry 
Zebrafish are housed in a recirculating system built by Aquatic Habitats (now Pentair). 
Both 3L tanks (up to 12 fish/tank) and 10 L tanks (up to 30 fish/tank) are used.  
The fishroom has a 14:10 light:dark cycle and room temperature varies from 27-29°C 
(Westerfield, 1993 – full ref below). Water quality is automatically monitored and dosed to 
maintain conductivity (400-600 µS) and pH (6.95-7.30). Nitrogen levels are maintained by a 
biofilter. A 10 % water change occurs daily. Recirculating water is filtered sequentially through 
pad filters, bag filters, and a carbon canister before circulating over UV lights for sterilization. 
Fish are fed three times daily, once with brine shrimp (hatched from INVE artemia cysts) and 
twice with flake food (Aquatox AX5) supplemented with 7.5 % micropellets (Hikari), 7.5 % 
golden pearl (300-500 micron, Brine Shrimp direct), and 5 % cyclo-peeze (Argent). 
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Figure 2.4.  Expression of proteins in the BRET2 assay.  (A) Anti-GFP (1:1000 dilution, 
Clontech) western blot confirming expression of PlxnA3-GFP2 in the BRET2 assay.  The 
expected molecular weights are 176 kDa and 27 kDa for PlxnA3-GFP2 and GFP2, respectively.  
(B)  Anti-RLuc (1:2500 dilution, Millipore) western blot confirming expression of PlxnA3-RLuc 
in the BRET2 assay.  The expected molecular weights are 185 kDa and 36 kDa for PlxnA3-RLuc 
and RLuc, respectively.  (C) Anti-FLAG staining of COS-7 cells expressing FLAG-tagged 
Nrp2a.  No fluorescence was observed in mock-transfected cells.  The scale bar in the bottom left 
frame is the same for all images.  (D) Dot blot confirming alkaline phosphatase activity in media 
from cells transfected with alkaline phosphatase-tagged SEMA3F.  (E) Confirmation of alkaline-
phosphatase-tagged SEMA3F binding to COS-7 cells expressing Nrp2a and PlxnA3. 
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Heterozygous plxna3/+ parents were set up in breeding cages in the afternoon before 
gamete collection. In the morning, adult fish were lightly anesthetized with tricane 
methansulfonate, and embryos were obtained by collecting eggs and sperm separately prior to 
mixing with water.  No animals were sacrificed for this study. 
 
2.2.5 Zebrafish RNA Injections 
The set zebrafish line and genotyping protocol were provided by Dr. Michael Granato 
(University of Pennsylvania) (24,29). Capped full-length plxna3 (WT or mutant) mRNA was 
generated using the mMESSAGE mMACHINE T7 Transcription Kit (Ambion) according to 
manufacturer’s instructions using the pcDNA3.1/V5-His-TOPO plxna3 constructs linearized with 
XhoI.  Embryos from heterozygous or homozygous set zebrafish intercrosses were subsequently 
injected with the plxna3 mRNA at 1 µg/µL while in the single-cell stage and allowed to grow for 
24 hours, at which point chorions were popped and embryos were fixed in 4% paraformaldehyde 
for 2 hours at room temperature or overnight at 4ºC.  Methanol dehydration, collagenase 
treatment, and embryo staining occurred as previously described with a SV2 antibody 
(Developmental Studies Hybridoma Bank, University of Iowa) (24).  Embryos were imaged at 
20x magnification via fluorescence microscopy (Nikon Eclipse TE2000-U).  In previous studies, 
embryos were rated as positive for the plxna3-knockdown (set) phenotype if they had two or 
more branched motor nerves or at least one hemisegment with two or more motor neuron exit 
points from the spinal cord (30).  In this study, embryos were rated as positive for the set 
phenotype if they exhibited three or more clear ectopic motor neuron exit points.  Following 
imaging, embryos were genotyped with forward primer CCCTTGCAACTGGTGTTTATA and 
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reverse primer AATGTGTCCTTTAGCAGTGG and a subsequent PsiI digestion that cleaved the 
PCR product generated from set DNA. 
 
2.3 Results 
2.3.1 A Juxtamembrane Helix Promotes Oligomerization of PlxnA3 
The PlxnA3 JM domain contains two heptad repeats, which can result in oligomerization 
of α-helices driven through hydrophobic interactions by hydrophobic residues at the ‘a’ and ‘d’ 
positions within the heptad repeat (31-33).  Leucine comprises over 30% of interfacial amino 
acids found in the heptad repeats of α-helical proteins (33).  In the PlxnA3 JM, a heptad repeat 
occurs with leucines L1274, L1277, and L1284 as well as methionine M1281 (Figure 2.1B-C).  
While methionine is not commonly found in the core of a heptad repeat (33), previous studies 
have shown that methionine-containing heptad repeats can promote formation of higher-order 
oligomers rather than dimers in heptad-repeat containing helices (31). To determine if the heptad 
repeat in the JM domain influences PlxnA3 homodimerization in the context of the TM-domain-
containing receptor, we utilized the AraTM assay.  AraTM is a method used to characterize type I 
integral membrane protein dimerization in E. coli membranes, in which the receptor domain of 
interest is expressed as a fusion to a modified transcriptional activator AraC.  If the receptor 
domains interact, they form a functional AraC dimer that activates transcription of green 
fluorescent protein (GFP) under control of the PBAD promoter; hence, the level of GFP expression 
is directly proportional to dimerization (22). We expect mutations disrupting the heptad repeat 
through eliminating the hydrophobic leucine (L1274A, L1284A, L1277F) or introducing polar or 
larger side-chains instead of methionine (M1281T, M1281F) to disrupt PlxnA3 dimerization, and 
replacing methionine with the hydrophobic leucine (M1281L) to enhance PlxnA3 dimerization.  
Consistent with our prediction, we find disruption of the proposed core leucines (M1281F, 
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M1281T and L1284A) significantly disrupts dimerization, whereas introducing an additional 
leucine into the core (M1281L) enhances dimerization (Figure 2.5). Interestingly, disruptive 
effects are greatest for positions M1281 and L1284 in the heptad repeat, whereas mutations 
L1274A and L1277F have only a minor effect on dimerization. Collectively, our results indicate 
the heptad repeat is important for PlxnA3 TM + JM homodimerization, and specific mutations in 
the second heptad repeat either enhance or diminish dimerization based on their hydrophobicity. 
 
 
Figure 2.5.  Residues in the PlxnA3 JM heptad repeat promote homomeric interactions in the 
AraTM assay. Residues on the JM heptad repeat interface influence TM + JM oligomerization, as 
determined via site-directed mutagenesis.  Error bars indicate standard error as determined from a 
minimum of eleven replicates collected over the course of three experiments. 
 
To further identify residues that may impact PlxnA3 TM + JM oligomerization, we 
performed error-prone PCR (EP-PCR) on the AraTM TM + JM construct and identified either 
enhancing or disruptive mutants that exhibited significant changes in GFP expression in the assay 
relative to WT.  In particular, two mutants resulted from the EP-PCR studies which consistently 
enhanced homodimerization relative to wild-type:  V1288F and D1302Y (Figure 2.6).  Based on 
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the mPLXNA3 CYTO crystal structure (PDB # 3IG3) (7), both residues V1288 and D1302 lie 
along the same face of the JM helix as the heptad repeat (homologous residues mPLXNA3 
V1268 and D1282 in PDB # 3IG3). Thus, our unbiased search using EP-PCR identified two JM 
mutants (V1288F and D1302Y) that also alter homodimerization.  Both mutants occur on the 
same face of the JM helix as the heptad repeat based on the previously reported mPLXNA3 JM 
crystal structure (7), again consistent with a role for a specific JM interface in regulating PlxnA3 
homodimerization. 
 
 
Figure 2.6.  Random mutagenesis yielded additional mutants on the predicted JM interface that 
alter PlxnA3 homomeric interactions.  (A) AraTM results for EP-PCR mutants, where error bars 
indicate standard error as determined from four replicates.  (B) The crystal structure of the Mus 
musculus PLXNA3 cytosolic juxtamembrane domain from PDB # 3IG3 indicates the EP-PCR 
mutants (orange) lie on the same interface as hydrophobic residues involved in the 
juxtamembrane heptad repeat (green). 
 
While we were able to identify potential mutations in the PlxnA3 TM + JM that enhance 
and disrupt homodimerization, it is important to confirm these effects in the context of the 
receptor with a full-length extracellular domain in a mammalian membrane. Thus, we introduced 
mutations identified in the TM + JM region in the AraTM assay and determined their effects on 
constructs containing the extracellular, TM and JM region (amino acids 1-1314 of NCB 
Accession # BAF81998.1) using the BRET2 assay.  We chose to truncate the PlxnA3 JM in the 
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flexible loop region following the α-helix observed in the crystal structure of PlxnA3 CYTO 
(PDB # 3IG3) to minimize effects of truncations on the secondary structure of the JM region. In 
these studies, PlxnA3 is co-expressed as an N-terminal fusion to Renilla luciferase (RLuc) and 
modified GFP (GFP2).  The RLuc-tagged PlxnA3 is capable of converting DeepBlueC to 
coelenteramide, which emits light at 395 nm; if a GFP2-tagged PlxnA3 is nearby or interacting, 
this light excites the GFP2 tag and light is emitted at 510 nm.  The ratio of the light emitted at 510 
nm to light emitted at 395 nm (the BRET2 efficiency ratio) is proportional to the distance between 
receptors.  As such, we would expect mutations disruptive to dimerization to exhibit a lower 
BRET2 efficiency ratio than WT, and those that enhance dimerization to exhibit a higher BRET2 
efficiency ratio than WT (26,27).  As shown in Figure 2.7A, the JM mutation M1281L enhances 
PlxnA3 dimerization, while mutation M1281F disrupts it.  These results are in agreement with 
AraTM results for the PlxnA3 TM + JM (Figure 2.5), and suggest methionine M1281 acts as a 
switch within the JM region to regulate PlxnA3 homomeric interactions. 
To better understand the role of the JM domains in PlxnA3 oligomerization in the 
presence of Nrp2 and SEMA3F, which are known interaction partners during neuronal 
development (23), we performed BRET2 measurements on WT and mutant PlxnA3 constructs co-
transfected with full-length Nrp2a and treated with media from AP-SEMA3F-expressing cells 
(34).  The presence of Nrp2a and SEMA3F did not result in significant changes to 
homodimerization for the WT receptor, as measured by BRET2 (Figure 2.7B).  This suggests that 
if homomeric interactions of the PlxnA3 JM change upon formation of a Nrp2a-SEMA3F-
PlxnA3 co-receptor complex under the investigated experimental conditions, the change does not 
alter net distance between neighboring PlxnA3 JM domains.  However, in the presence of the 
Nrp2a co-receptor and SEMA3F ligand, mutant M1281F, which is disruptive for 
homodimerization of PlxnA3 in the absence of Nrp2a and SEMA3F (Figure 2.7A), exhibits 
increased levels of PlxnA3 homodimerization, with a BRET2 signal similar to that of WT PlxnA3  
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(Figure 2.7C). Therefore, we conclude co-receptor complex formation promotes PlxnA3 
homodimerization independent of disruptive PlxnA3 JM domain mutations such as M1281F. 
However, mutant M1281L increases PlxnA3 homodimerization independent of whether Nrp2a 
and SEMA3F are present (Figure 2.7A).  As such, PlxnA3 homodimerization is influenced by 
both intrinsic (the heptad repeat within the JM) as well as extrinsic (Nrp2a, SEMA3F) factors, 
with mutations in the JM region that enhance plxn homodimerization insensitive to the presence 
of Nrp2a and SEMA3F.   
 
2.3.2 A Juxtamembrane Heptad Repeat Influences PlxnA3 Function in Zebrafish Motor 
Neuron Development 
In zebrafish neuronal development, PlxnA3 acts as a negative guidance receptor.  
Expression of intact PlxnA3 guides motor axons to exit the spinal cord at midsegments and grow 
rostrally (24,30).  The set zebrafish line is a transgenic line in which a mutation in the plxna3 
gene results in a truncated form of the receptor incapable of signaling.  As such, motor neurons in 
homozygous set mutants exit the spinal cord at ectopic locations and branch (Figure 2.8) (24).  To 
examine if mutations to the PlxnA3 JM affecting homodimerization also affect function, we used 
the set zebrafish line in conjunction with RNA injections of WT or mutant plxna3 and examined 
embryos for ectopic exit points (24).   
Our results indicate that injection of WT plxna3 RNA at the single-cell stage of 
homozygous set zebrafish embryos rescues the phenotype of WT zebrafish (i.e. only 36% of set 
embryos injected with WT RNA exhibit ectopic exit points, compared to 80% of uninjected 
embryos, p<0.005 by Fisher’s Exact Test, FET) (Table 2.1).  Injection of plxna3 mutant M1281F 
also rescues the motor neuron patterning of WT zebrafish embryos (i.e. only 33% of M1281F 
RNA-injected embryos exhibit ectopic exit points, p<0.005 compared to uninjected by FET).  In 
contrast, injection of plxna3 mutant M1281L RNA, however, failed to rescue motor neuron 
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patterning of the set embryos (i.e. 50% of set embryos injected with M1281L RNA exhibit 
ectopic exit points, p=0.07 compared to uninjected by FET).  These results are consistent with 
PlxnA3 homodimerization results in the presence of the Nrp2a co-receptor and SEMA3F ligand, 
in which the disruptive mutant M1281F in the absence of Nrp2a-SEMA3F was capable of 
homodimerization similar to WT in the presence of Nrp2a-SEMA3F, whereas mutant M1281L 
exhibited a greater extent of homodimerization independent of Nrp2a-SEMA3F (Figure 2.7C).  
Hence, our results suggest an interface containing a heptad repeat in the PlxnA3 cytosolic 
juxtamembrane, and in particular residue M1281, influences PlxnA3 homooligomerization and 
subsequent function (Figure 2.1).  Importantly, our results suggest that promoting PlxnA3 CYTO 
homomeric interactions, as with mutation M1281L, does not necessarily enhance function, and 
that a specific conformation within a given oligomeric state is necessary for PlxnA3 function; in 
this study, the homomeric interactions and oligomeric state formed by the WT and M1281F 
PlxnA3 are preferred for nrp-plxn-sema signal transduction over the dimeric M1281L PlxnA3 
receptor. 
 
Figure 2.8.  Knockdown of plxna3 results in aberrant motor neuron patterns.  The motor neurons 
of 24 hour post fertilization sidetracked zebrafish embryos (top) exhibit ectopic motor neuron exit 
points from the motor cord (arrows) compared to WT embryos (bottom).  Asterisks indicate 
endogenous motor neuron exit points.  Embryos are oriented anterior (left) to posterior (right). 
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Table 2.1.  Percentage of Embryos Exhibiting sidetracked Phenotype2b 
Type of Injection 
Number of Embryos 
Examined 
Percentage of 
Embryos Exhibiting 
sidetracked Phenotype 
P-value Compared to 
Uninjected 
Uninjected 30 80 1 
WT plxna3 RNA 22 36 0.003 
M1281F plxna3 RNA 12 33 0.009 
M1281L plxna3 RNA 12 50 0.07 
 
2bP-values were determined using Fisher’s Exact Test. 
 
2.4 Discussion 
 Previous studies suggest plxn clustering is necessary for activation, though purified 
extracellular and cytosolic domains exhibit only weak tendencies toward homooligomerization 
(6,7,9,19-21).  Here, we demonstrate that mutations to the JM heptad repeat interface affect 
PlxnA3 TM + JM homodimerization (Figures 2.5 and 2.6), with residue M1281 acting as a switch 
to either enhance (M1281L) or disrupt (M1281F) PlxnA3 homodimerization (Figures 2.5 and 
2.7).  While the addition of Nrp2a and SEMA3F did not affect WT PlxnA3 homodimerization, 
disruption of PlxnA3 homodimerization via mutation M1281F was corrected in the presence of 
both ligand and co-receptor (Figure 2.7), and was also able to rescue zebrafish motor neuron 
patterning in set embryos (Figure 2.8 and Table 2.1).  In contrast, enhancement of PlxnA3 
homodimerization through mutation M1281L was not influenced by the presence of Nrp2a and 
SEMA3F, and was unable to rescue WT zebrafish motor neuron patterning in set embryos 
(Figure 2.8 and Table 2.1). Thus, M1281 and the associated JM heptad repeat (residues 1281-
1287) acts as a switch to regulate the extent of PlxnA3 homodimerization and suggest that 
interactions promoting weak, but specific, oligomerization of the PlxnA3 JM region are preferred 
for Nrp2a-PlxnA3-SEMA3F signal transduction versus interactions that enhance PlxnA3 
homodimerization at the expense of flexibility in homodimerization during nrp-sema co-receptor 
formation. In this sense, the JM interface required for PlxnA3 signaling resembles the type of 
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interface required for stabilization of integrin heterodimers, in which a weak, but specific, 
transmembrane interface was required for switchability between active and inactive states to 
regulate signal transduction (35). Given that class A plxns are capable of forming multiple 
parings with cognate nrp co-receptors and sema ligands (for instance, PLXNA3 participates in 
NRP1-SEMA3A interactions as well as NRP2-SEMA3F interactions) (3), the additional 
flexibility in switching between monomer and homooligomeric states for plxns may reflect the 
necessity of maintaining the flexibility required for proper co-receptor complex formation and 
subsequent signal transduction. 
 Previous analyses of the plxn JM region also indicate that switchable interactions 
involving the heptad repeat region are important for signal transduction. For mPLXNA3, the 
crystal structure of the cytosolic domain suggests the C-terminal portion of the JM (residues 
subsequent to L1280 in mPLXNA3, or homologous with residue L1310 in the Danio rerio 
PlxnA3 utilized in this study) makes extensive contacts with the mPLXNA3 GAP domain and 
mutations to the JM region disrupt function (7). When including the TM domain of PlxnA3 in the 
current study, we also find that residues more proximal to the TM influence homodimerization 
(Figures 2.5, 2.6, and 2.7), and in particular mutations at residue M1281 can enhance or disrupt 
PlxnA3 homodimerization (Figures 2.5 and 2.7).  The effects of the M1281 mutation on PlxnA3 
function described in this study (Table 2.1) are also consistent with previous functional analyses 
of the analogous region in mPLXNA3 and Drosophila plxnA (M1261R in mPLXNA3 and 
M1320R in Drosophila plxnA), in which mutants fail to induce growth cone collapse in a 
PLXNA3-NRP2-SEMA3F growth cone collapse model and exhibit only partial function in a 
Drosophila axon guidance assay (7). While the effects of arginine mutations on dimerization in 
these studies is unknown, we do find that mutations which alter the hydrophobicity of the heptad 
repeat can either enhance (M1281L) or disrupt (M1281F) dimerization, and for M1281L, impair 
PlxnA3 signaling. Thus, our results indicate a specific oligomeric state and conformation are 
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required for PlxnA3 signal transduction, and the conformation of the activated state requires 
specific interactions in the heptad repeat of PlxnA3. Conservation of methionine within the 
heptad repeat of the PlxnA3 JM, and its ability to act as an oligomeric switch, may also reflect its 
role in creating an oligomeric interface permissive to higher order oligomers versus dimers, 
thereby providing the flexibility to create a specific interface for signal transduction with 
switchable interactions. 
In summary, our AraTM and BRET2 results suggest a specific interface of the PlxnA3 
JM domain promotes oligomerization in the context of a membrane-anchored receptor.  Mutation 
to residue M1281 in Danio rerio PlxnA3 in particular can enhance or disrupt PlxnA3 
homooligomerization, dependent upon type of mutation made (Figures 2.5 and 2.7).  Such 
interaction likely contributes to plxn clustering and subsequent activation (Figure 2.1).  Our 
BRET2 co-receptor studies suggest Nrp2a and SEMA3F serve to promote PlxnA3 
homodimerization for the disruptive mutant M1281F, but not for the dimer-enhancing mutant 
M1281L.  The altered oligomeric state of M1281L in the presence of Nrp2a and SEMA3F 
correlates with PlxnA3 signaling, in which injection of M1281L mRNA into set zebrafish 
embryos failed to rescue WT motor neuron patterning. As such, residue M1281 regulates PlxnA3 
homomeric interactions and subsequent function, suggesting the JM region of plxn forms a 
specific interface required for signal transduction.  
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Chapter 3 
Interplay of Specific Trans- and 
Juxtamembrane Interfaces in PlexinA3 Dimerization 
and Signal Transduction3a 
3aThe work in this chapter has been submitted for publication. 
Abstract 
 Plexins are transmembrane proteins that serve as guidance receptors during angiogenesis, 
lymphangiogenesis, neuronal development, and zebrafish fin regeneration with a putative role in 
cancer metastasis.  Receptor dimerization or clustering, induced through extracellular ligand 
binding but modulated in part by the plexin transmembrane (TM) and juxtamembrane (JM) 
domains, is thought to drive plexin activity.  Previous studies indicate that isolated plexin TM 
domains interact through a conserved, small-x3-small packing motif, and the cytosolic JM region 
interacts through a hydrophobic heptad repeat, but the roles and interplay of these regions in 
plexin signal transduction remains unclear.  In this study, we find disruption of the small-x3-small 
motifs in the Danio rerio PlexinA3 TM domain enhances dimerization of the TM-JM domain in 
the AraTM assay by enhancing JM-mediated dimerization, whereas mutations to the cytosolic JM 
heptad repeat that disrupt dimerization do so even in the presence of TM domain mutations. 
However, mutations to the small-x3-small TM interfaces also disrupt PlexinA3 signaling in a 
zebrafish axonal guidance assay, indicating the importance of this TM interface in signal 
transduction.  Collectively, our results demonstrate that multiple TM and JM interfaces exist in 
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the PlexinA3 homodimer, and these interfaces independently regulate dimerization important in 
PlexinA3 signal transduction. 
 
3.1 Introduction 
Plexins (plxns) are a group of Type I transmembrane (TM) receptors involved in the 
guidance of neurons, vascular, and lymphatic vessels during development as well as zebrafish fin 
regeneration (1-7).  Plxns also serve a putative role in cancer metastasis, with altered expression 
levels or mutations to plxns observed in melanomas and breast, lung, pancreatic, and prostate 
cancers (8-11).  Investigations with plxns’ semaphorin (sema) ligands and neuropilin (nrp) co-
receptors have also implicated the plxn-nrp-sema pathway as influential to cancer metastasis, 
with overexpression of SEMA3F inhibiting cancer metastasis in a mouse melanoma model (4,11).  
As such, understanding the mechanisms necessary for activation of the plxn-nrp-sema signaling 
pathway may provide insight into design of novel therapeutics as well as their role in a myriad of 
developmental processes. 
Plxns contain an extracellular domain involved in ligand binding, a glycine-rich single-
spanning TM domain, and a cytosolic domain (CYTO) involved in signal transduction 
(1,2,4,12,13).  Activity is characterized by CYTO GTPase-activating protein (GAP) activity 
(3,14-16).  An early immunohistological observation that NRP1 and PLXNA1 cluster in regions 
of high local concentration upon SEMA3A addition in a chick dorsal root ganglion collapse assay 
led to the premise that receptor dimerization or clustering confers activity (2).  Indeed, a RapGAP 
activity assay on purified CYTO domains of Mus musculus PLXNA1, PLXNA2, PLXNA4, and 
PLXNC1 CYTO suggests plxn CYTO domains dimerized through N-terminal fusions exhibit 
enhanced activity over the monomeric CYTO domains (16).  
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Purified murine PLXNA2 extracellular domains and murine PLXNA1, PLXNA3, and 
human PLXNB1 CYTO domains exhibit only weak homomeric tendencies in solution, however 
(5,14-17).  Removal of the Mus musculus PLXNA1 sema-binding domain or extracellular domain 
confers sema- and nrp-independent collapse activity in a COS-7 growth cone model, indicating 
PLXNA1 exists in an autoinhibited conformation, and that in the absence of the sema-binding 
domain, the PLXNA1 TM-CYTO is sufficient for receptor activation (12).  Expression of the 
mouse PLXNA1 CYTO domain alone or with a myristoylation signal fails to induce collapse, 
though replacement of the human PLXNB1 TM domain with a membrane-anchored CD2 fusion 
followed by cross-linking enables cellular contraction (12,18,19).  As such, membrane-anchored 
plxn clustering is important for activity, and the TM and juxtamembrane (JM) regions exhibit an 
inherent tendency to promote plxn homooligomerization (Figure 3.1A).  
Previous studies indicate a heptad repeat in the CYTO JM region modulates homomeric 
interactions in the full-length receptor, with mutations to the JM of Drosophila PLXNA and 
Danio rerio PlxnA3 only showing partial activity in axonal guidance assays (14,20).  
Additionally, the human PLXNA1 TM domain alone exhibits a weak tendency to dimerize in a 
bacterial adenylate cyclase two-hybrid assay (13,21). Coarse-grained molecular dynamics 
simulations of the isolated human PLXNA1 TM domain suggest a glycine-rich segment in the 
TM region largely conserved across Class A plxns may modulate human PLXNA1 homomeric 
interactions (Figure 3.1B) (13).  In particular, this conserved glycine-rich region contains two 
motifs capable of packing via small-x3-small interfaces (13).  The small-x3-small motif is a highly 
conserved sequence-structure motif overrepresented in a wide range of helical TM protein dimers 
such as glycophorin A and the plxn co-receptor NRP1, in which small residues such as glycine, 
serine or alanine are placed along one face of the TM helix, creating a specific, ridge-and-groove 
packing structure that contributes to dimer stability (21-23).  A similar series of interfaces is also  
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Figure 3.1.  Plexin transmembrane and juxtamembrane domains contribute to receptor clustering 
and activation.  (A) Extracellular binding of a semaphorin ligand (Sema) to plexin (Plxn) and 
neuropilin (Nrp) leads to receptor clustering and activation.  (B) A small amino acid-rich region 
in the transmembrane domain and a cytosolic juxtamembrane heptad repeat are conserved across 
class A plexins and postulated to modulate homooligomerization.  (C)  Primary sequence analysis 
of the glycine-rich Danio rerio PlexinA3 transmembrane domain reveals two interfaces capable 
of participating in small-x3-small packing motifs.  Structural representation of the PlexinA3 
transmembrane domain was generated using the asymmetric Ez-3D Potential Finder.   
 
present in the Danio rerio PlxnA3 TM domain (Figure 3.1C), suggestive of a role in dimerization.  
However, the relative importance of TM versus JM and interrelationship between TM and JM 
interactions in PlxnA3 dimerization and signal transduction remain open questions. 
In this study, we examine the role of the glycine-rich region of the Danio rerio PlxnA3 
TM domain on homodimerization and the interplay of TM and JM interactions in PlxnA3 
dimerization and signal transduction. Interestingly, we find disruption of the small-x3-small TM 
packing motifs through glycine-to-leucine mutations enhances, rather than diminishes, 
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dimerization of the TM-JM domain.  Similarly, extension of the small-x3-small interfaces through 
introduction of additional on-interface glycines disrupts, rather than enhances, dimerization.  
However, mutations to the JM heptad repeat that enhance or diminish dimerization do so even in 
the presence of TM domain small-x3-small mutations, suggesting the TM dimer interface is 
distinct from that of the JM, and the two work in opposition to one another; in other words, the 
TM small-x3-small interfaces inhibit JM-mediated TM-JM dimerization. In a zebrafish axonal 
guidance assay using sidetracked (set) zebrafish embryos, which exhibit ectopic motor neuron 
exit points due to a truncation in the plxnA3 gene (24,25), mutations to the small-x3-small 
interfaces result in non-functional (mutation G1246L+G1250L) or only partially functional 
(mutation G1244L+G1248L) PlxnA3.  Collectively, our results demonstrate multiple distinct, 
functionally important interfaces exist in the PlxnA3 receptor TM and JM that regulate PlxnA3 
signaling. 
 
3.2 Materials and Methods 
3.2.1 Modelling 
A model of the Danio rerio PlxnA3 transmembrane domain (amino acids 1241-1262 of 
NCB Accession # BAF81998.1) (Figure 3.1C) was generated using the asymmetric Ez-3D 
Potential Finder (26). 
3.2.2 Plasmids 
Cloning for full-length wild-type (WT) Danio rerio plxnA3 in pcDNA3.1/V5-His-TOPO 
and the plxnA3 TM-JM domains (amino acids 1241-1314 of NCB Accession # BAF81998.1) in 
pAraTM was previously described (20).  Mutations were made using the QuikChange II Site-
Directed Mutagenesis Kit (Agilent). 
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3.2.3 AraTM Assay 
AraTM measurements and analyses were performed as previously described (20,27).  
Briefly, electrically-competent SB1676 cells were co-transformed with pAraGFP and the 
pAraTM construct of interest via electroporation.  The transformed cells were grown in selective 
lysogeny broth (Lennox) medium (LB) overnight, and glycerol stocks were made from the 
cultures.  Cultures for measurements (four per experimental round) were started from these 
glycerol stocks and allowed to grow 16-24 hours in selective LB, at which time fluorescence (485 
nm excitation, 530 nm emission) and absorbance (560 nm) measurements were taken for each 
culture (and 5-fold serial dilutions of each culture) using a Tecan Infinite F200 multi-well plate 
reader.  Results are reported as the average percent change in slope of fluorescence vs. 
absorbance from WT from three rounds of experiments, with error bars indicating the standard 
error of the samples plus the standard error of WT samples analyzed in parallel.  Expression and 
orientation in the membrane were confirmed by western blotting and maltose complementation 
tests, respectively (Figure 3.2). 
3.2.4 Zebrafish Care and Embryo Injections 
The set zebrafish line, provided by Dr. Michael Granato (University of Pennsylvania) 
was used for this study (24,25).  Care for parental zebrafish was previously described (20).  
Husbandry occurred between adult heterozygous or homozygous plxna3/+ zebrafish.  This study 
did not require animal sacrifice.  Generation of mutant plxnA3 RNA, injection into embryos, 
embryo processing (fixation, staining, imaging, and genotyping), and set phenotype classification 
requirements were as previously described (20).  We used previously reported values for 
occurrence of the set phenotype with WT plxnA3 RNA injections or uninjected set zebrafish 
embryos (20) for our statistical analyses. 
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3.3 Results 
3.3.1 Transmembrane Glycines Modulate PlxnA3 Homodimerization 
The Danio rerio PlxnA3 TM domain contains a glycine-rich region (G1244IGAGGG1250, 
Figure 3.1C) with two putative interfaces capable of promoting homodimerization via small-x3-
small packing motifs (G1244+G1248 and G1246+G1250).  Previous coarse-grained molecular 
dynamics simulations implied the homologous interfaces in the human PLXNA1 TM domain 
contribute to dimerization of the isolated TM domain (13).  To investigate the role of TM 
glycines on PlxnA3 TM-JM homodimerization, we employed site-directed mutagenesis in 
conjunction with the AraTM assay (27).  In this assay, the TM domain of interest is expressed as 
an AraC fusion.  Dimerization induced by TM homomeric interactions forms a functional AraC 
transcription factor, which in turn drives transcription of green fluorescent protein (GFP) 
regulated by a PBAD promoter.  Hence, AraTM cultures expressing TM domains with a stronger 
propensity to dimerize will exhibit an increased GFP signal over weaker dimer constructs for the 
same cell density (27). 
Our AraTM results illustrate that glycine-to-leucine mutations disrupting the small-x3-
small packing interfaces in the glycine-rich PlxnA3 TM domain actually enhance TM-JM 
dimerization, either as single point-mutations to a given interface (G1244L, G1246L, G1248L, 
G1250L; Figure 3.3A), double mutations to eliminate an interface (G1244L+G1248L, 
G1246L+G1250L; Figure 3.3B) or triple mutations to disrupt both small-x3-small interfaces 
(G1244L+G1246L+G1250L and G1246L+G1248L+G1250L; Figure 3.3B). Furthermore, 
extension of the small-x3-small motif by placing additional glycines on either interface (L1252G, 
I1254G) disrupts, rather than enhances, TM-JM dimerization (Figure 3.3A).  Collectively, our 
results indicate small-x3-small interfaces in the PlxnA3 TM domain negatively regulate TM-JM 
dimerization (Figure 3.1). 
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Figure 3.3.  (A) Disruption of small-x3-small interfaces in the PlexinA3 TM domain via point 
mutations enhance TM-JM dimerization in the AraTM assay. Similarly, extension of the small-
x3-small interfaces via introduction of glycines disrupt TM-JM dimerization. (B) Double and 
triple mutations disrupting the PlexinA3 TM small-x3-small interfaces enhance dimerization of 
the TM-JM in the AraTM assay.  Error bars indicate standard error as determined from twelve 
replicates collected over a minimum of three experiments. 
54 
 
3.3.2 TM and JM Interfaces Independently Regulate PlxnA3 Homodimerization 
Previous work has demonstrated a specific heptad repeat in the PlxnA3 JM domain 
contributes to receptor TM-JM dimerization, with residue M1281 within this heptad repeat acting 
as a dimerization “switch”, in which mutation M1281F disrupts dimerization by destabilizing 
packing in the hydrophobic core of the JM heptad repeat and mutation M1281L enhances 
dimerization through enhancing packing in the hydrophobic core of the JM heptad repeat (20).  
To determine how interactions in the JM interface influence TM-JM dimerization, and what role 
these interactions play in the observed increase in TM-JM dimerization caused by disruption of 
the TM small-x3-small interface, we compared effects of key mutations in the TM region that 
enhance TM-JM dimerization to mutations in the JM shown previously to enhance or diminish 
TM-JM dimerization.   
As shown in Figure 3.4, mutations to the JM region are dominant versus those in the TM 
domain; regardless of mutations to the two putative small-x3-small interfaces of the TM, all of 
which enhance dimerization, mutations made in conjunction with the disruptive M1281F JM 
mutation reduce TM-JM dimerization, whereas mutations made in conjunction the enhancing 
M1281L JM mutation enhance TM-JM dimerization. Furthermore, the enhancements to 
dimerization through mutation of either of the two small-x3-small interfaces (Figure 3.3) or 
M1281L (20) are non-additive; mutation to each domain individually enhances dimerization by 
less than 25% relative to WT, compared to more than 80% observed with mutation to both TM 
and JM (Figure 3.4).  This suggests the TM small-x3-small interfaces serve as competitive TM-
JM dimers to those formed by the JM heptad repeat interface.  Thus, enhancement of the small-
x3-small dimerization interface via introduction of additional on-interface glycines (L1252G, 
I1254G; Figure 3.3A) strengthens the TM dimer and pulls the TM-JM away from the JM dimer, 
whereas   disruption  or  removal   of  the   small-x3-small  interfaces  through   glycine-to-leucine  
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Figure 3.4.  Mutations to the PlexinA3 JM domain dominate dimerization tendencies of the TM-
JM in the AraTM assay.  Error bars indicate standard error as determined from twelve replicates 
collected over a minimum of three experiments. 
 
mutations (Figure 3.3) removes the TM dimer competition and strengthens the JM dimer.  
Collectively, our results are consistent with a model in which TM and JM dimerization are 
competitive, with each providing a distinct interface capable of forming a TM-JM dimer (Figure 
3.4). 
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3.3.3 Glycines in the Transmembrane Domain Modulate PlxnA3 Function in a Zebrafish Axonal 
Guidance Assay 
Zebrafish embryos failing to express membrane-anchored PlxnA3, such as homozygous 
set zebrafish embryos, exhibit anomalous motor neuron patterning, with motor neurons exhibiting 
atypical branching and ectopic exit points from the spinal cord (Figure 3.5) (24,28).  Previous 
studies demonstrated that set embryos injected with WT plxnA3 RNA show significantly fewer 
ectopic motor neuron exit points than uninjected set embryos (20).  We injected set embryos 
while in the single-cell stage with TM-mutant plxnA3 RNA and examined their motor neurons at 
24 hours post fertilization for ectopic exit points, expecting mutations to functionally relevant 
residues to fail to rescue motor neuron patterning (Table 3.1).  Comparisons to WT plxnA3 RNA-
injected and uninjected set embryos were made based on previous studies (20). 
 
Figure 3.5.  Embryos with the sidetracked phenotype exhibit ectopic motor neuron exit points 
(arrows).  Endogenous motor neuron exit points are marked with an asterisk.  Embryos were 24 
hours post fertilization at the time of fixation and are oriented (left-to-right) anterior-to-posterior. 
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Table 3.1.  Percentage of Homozygous sidetracked Embryos Exhibiting Phenotype3b 
Type of RNA 
Injection 
Number of 
Embryos 
Evaluated 
Percentage of Embryos 
Exhibiting sidetracked 
Phenotype 
P-value Compared to 
Wild-type plxnA3 
RNA-Injected 
G1244L + 
G1248L 
13 62 0.2 
G1246L + 
G1250L 
19 74 0.03 
3bP-values were computed using a Fisher’s Exact Test and previously reported values for 
uninjected and WT embryos (20). 
 
Injection of set embryos with G1246L+G1250L plxnA3 RNA results in significantly 
more embryos exhibiting the set phenotype than WT plxnA3 RNA-injected embryos (74% of 
embryos exhibited the set phenotype; p<0.05 relative to WT as determined by a Fisher’s Exact 
Test, FET).  Injection of G1244L+G1248L plxnA3 RNA partially rescues motor neuron 
patterning in set embryos (62% of embryos exhibited the set phenotype, p>0.05 compared to WT 
as determined by FET).  Neither mutation resulted in significantly fewer embryos exhibiting the 
set phenotype than the previously reported 80% of uninjected set embryos (20).  Both of these 
mutations enhanced dimerization of the TM-JM domains in the AraTM assay (Figure 3.3). Thus, 
our results are broadly consistent with a model in which destabilizing the TM dimer facilitates 
formation of a stronger, non-functional JM dimer, where both dimerization motifs contribute to 
PlxnA3 dependent signaling. 
 
3.4 Discussion 
 Previous studies suggest plxn function depends on receptor clustering, and that function 
and clustering are modulated by the TM and JM domains (Figure 3.1) (12,13,16,18-21).  In this 
study, we demonstrate that glycine-to-leucine mutations disrupting putative small-x3-small 
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packing interfaces in the TM region of Danio rerio PlxnA3 enhance dimerization of TM-JM 
domains in the AraTM assay (Figure 3.3).  Similarly, extension of the small-x3-small interfaces 
disrupts dimerization (Figure 3.3).  Mutations to the previously established dimer interface in the 
PlxnA3 JM (20) dominate dimer formation of the TM-JM, with mutations to either TM small-x3-
small interface in conjunction with JM M1281F disrupting dimerization, and mutations to the TM 
interfaces with JM M1281L enhancing dimerization (Figure 3.4). Functionally, disruption of the 
PlxnA3 TM interface fails to rescue motor neuron patterning in a zebrafish axonal guidance 
assay, with G1244L+G1248L exhibiting partial activity and G1246L+G1250L displaying no 
activity (Figure 3.5 and Table 3.1). Thus, our results point to a model for PlxnA3 dimerization in 
which the TM and JM both play important, competitive roles in regulating signal transduction 
(Figure 3.6). A recent coarse-grained molecular dynamics simulation also suggests that the 
isolated human PLXNA1 TM domain undergoes homooligomerization via two putative small-x3-
small interfaces (13), homologous to the Danio rerio PlxnA3 interfaces G1244+G1248 and 
G1246+G1250 identified in this study, although the role of the JM was not considered in the 
simulation.  Thus, the proposed interaction model for the PlxnA3 TM-JM (Figure 3.6) is 
consistent with previous work regarding plxn TM domain dimerization, as well as with both 
functional and biochemical data regarding TM-JM dimerization. Furthermore, these results 
emphasize the importance of JM interactions in describing models for receptor TM dimerization. 
Typically, mutation to small-x3-small interaction motifs disrupts dimerization, as has 
been shown with GpA and NRP1 (23,29). This motif promotes TM dimerization by providing a 
specific interface favorable to steric packing constraints as well as additional side chain 
associations (22,30-32).  Hence, the result that mutations to the PlxnA3 TM small-x3-small motifs 
enhance TM-JM dimerization is at first counterintuitive (Figure 3.3).  However, the interplay of 
TM versus JM interfaces  as distinct dimers,  but both significant in  terms of promoting  TM-JM  
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Figure 3.6.  Model for competitive TM and JM interactions in regulation of PlexinA3 signal 
transduction. 
 
dimerization, provides a model (Figure 3.6) in which multiple, competitive dimeric states occur 
for the TM-JM region, each of which are important in negatively regulating signal transduction. 
In this sense, the proposed TM-JM model resembles a “push-pull” mechanism used in describing 
the competition between integrin homo- versus heterodimerization (33). In the case of PlxnA3, 
the two states (TM dimer and JM dimer) are intrinsic to the receptor and in competition, with 
mutations that favor either of these interfaces “pulling” the receptor towards that interface and 
mutations that destabilize either of these interfaces “pushing” the TM-JM towards the other 
interface. Collectively, our results suggest glycines in the TM domain contribute to dimers driven 
by small-x3-small packing motifs that compete with JM-driven dimers, and this competition 
prevents strong JM dimerization.  This mechanism likely contributes to class A plxns flexibility 
in co-receptor heterodimerization (4,13,21) as well as regulated switchability between active and 
inactive states. 
 Our study also indicates that PlxnA3 dimerization does not necessarily correlate with 
enhanced function (Figure 3.3 and Table 3.1), similar to previous results with mutations in the 
PlxnA3 JM domain (20).  Rather, a specific, dimeric conformation is likely responsible for 
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regulating activation.  Our results for PlxnA3 are similar to previous studies with ErbB2, for 
which dimerization is required, but not sufficient, for activity; replacement of the ErbB2 TM 
domain with the GpA TM domain, though dimerized through the GpA small-x3-small motif, fails 
to elicit a transformation phenotype (34).  It is also analogous to the role of integrin TM domains 
in integrin activation (33), in which the TM domain has only a modest contribution to receptor 
dimerization, yet mutations to these TM interfaces have a significant impact on signal 
transduction (Table 3.1). 
 In summary, our AraTM results demonstrate that glycines in the Danio rerio PlxnA3 TM 
domain modulate receptor homomeric interactions (Figure 3.3).  In particular, small-x3-small 
dimerization motifs in the TM domain compete with dimerization driven by the heptad repeat in 
the JM domain (Figure 3.1).  As JM-driven dimerization is dominant in the TM-JM system 
(Figure 3.4), mutation of the small-x3-small interfaces results in overall enhancement to TM-JM 
dimerization. These interfaces both act competitively to regulate signaling, with the TM small-x3-
small interfaces exhibiting no or partial functionality in an embryonic zebrafish axonal guidance 
assay (Figure 3.5 and Table 3.1).  Hence, the interplay of TM versus JM dimerization serves as an 
important regulatory mechanism in PlxnA3 signal transduction (Figure 3.1). Given other 
receptors in which JM interactions independently, and often competitively, regulate 
transmembrane dimerization and signaling (35-38), it will be interesting to see how other receptor 
systems couple TM and JM interactions to promote both homo- versus heterodimerization as well 
as signal transduction. 
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Chapter 4 
Cysteines in the Neuropilin-2 MAM Domain Modulate 
Receptor Homooligomerization and Signal 
Transduction4a 
4aThe work in this chapter has been accepted for publication as “Cysteines in the neuropilin-2 
MAM domain modulate receptor homooligomerization and signal transduction” by Rachael 
Barton, Alyssa Driscoll, Samuel Flores, Durlav Mudbhari, Theresa Collins, M. Kathryn Iovine, 
and Bryan W. Berger with Biopolymers:  Peptide Science, 2015. 
 
 
Abstract 
Neuropilins (NRPs) are transmembrane receptors involved in angiogenesis, 
lymphangiogenesis, and neuronal development as well as in cancer metastasis.  Previous studies 
suggest that NRPs exist in heteromeric complexes with vascular endothelial growth factors 
(VEGFs) and VEGF receptors as well as plexins and semaphorins. We determined via site-
directed mutagenesis and bioluminescent resonance energy transfer assays that a conserved 
cysteine (C711) in the Danio rerio NRP2a MAM (meprin, A-5 protein, and protein tyrosine 
phosphatase μ) domain modulates NRP2a homomeric interactions.  Mutation of this residue also 
disrupts semaphorin 3F binding in NRP2a-transfected COS-7 cells and prevents the NRP2a 
overexpression effects in a zebrafish vascular model.  Collectively, our results indicate the MAM 
domain plays an important role in defining the NRP2 homodimer structure, which is important 
for semaphorin-dependent signal transduction via NRP2. 
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4.1 Introduction 
Neuropilins (NRPs) are type I transmembrane (TM) receptors that form heterodimeric 
complexes with two key classes of signaling TM receptors: plexins and vascular endothelial 
growth factor receptors (VEGFRs) (1). There are two main NRP receptors (NRP1, NRP2), with 
multiple extracellular and TM isoforms observed for each in vivo (2,3) . NRPs are comprised of 
two extracellular CUB (complement protein C1r/C1s, Uegf, and Bmp1) domains, two coagulation 
factor V/VIII (FA V/VIII) domains, one MAM (meprin, A-5 protein, and protein tyrosine 
phosphatase μ, PTPμ) domain, a single-spanning TM region, and a short cytosolic tail (Figure 
4.1A) (1,3-9).  The short cytosolic domain (CYTO) for NRPs is in contrast to VEGFRs, which 
contain a cytosolic tyrosine kinase signaling domain, and plexins, which contain a cytosolic 
guanine nucleotide exchange factor domain (1). Thus, NRPs are thought primarily to modulate 
the affinity and specificity of extracellular ligand binding upon co-receptor complex formation 
(10). In many instances, the co-receptor complex also includes additional cell adhesion molecules 
(CAMs) such as L1CAM and NrCAM as well as β1 integrins (7,11,12); thus, a functional co-
receptor complex may involve three or more receptors at the cell surface. Plexin-NRP co-receptor 
complexes bind semaphorins (Semas), which are a large class of extracellular, dimeric ligands 
(20 in total) that act as either attractive or repulsive cues during cell migration in a diverse array 
of processes including axon guidance, vascular patterning, and bone formation (13-16). 
Additionally, VEGFR-NRP co-receptor complexes bind vascular endothelial growth factors 
(VEGFs), which are an equally large family of pro-angiogenic extracellular ligands (17). Thus, 
NRPs act as key regulators of extracellular signaling through imparting specificity in ligand-co-
receptor complex formation. 
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Figure 4.1.  NRP2a is a transmembrane receptor. (A) NRP2a consists of two CUB 
domains, two factor V/VIII domains, a MAM domain, a single-spanning transmembrane 
region, and a short cytosolic tail. NRP homooligomerization may play a role in NRP-
plexin-sema and NRP-VEGFR-VEGF signal transduction by promoting aggregation. (B) 
Primary sequence of the Danio rerio NRP2a MAM domain.  The MAM domain contains 
four conserved cysteines that impact homooligomerization in other MAM domain family 
members.  
 
Given the diversity of biological processes in which Sema and VEGF modulate cell 
migration, dysregulation of NRP-dependent signaling has been linked to a variety of cancers (6). 
In particular, Sema3F has been shown to exhibit strong anti-angiogenic activity through binding 
to NRP2, with forced overexpression of Sema3F in a mouse melanoma model inhibiting tumor 
angiogenesis (18). NRP2 activation in response to VEGF-C binding is also linked to enhanced 
autophagy in cancer cells through an mTOR-dependent pathway, allowing them to survive after 
chemotherapeutic treatment (19). Additional studies have demonstrated the up-regulation of 
numerous other signaling pathways known to positively influence tumor metastasis in response to 
NRP2 activation, including chemokine receptor CXCR4 in breast cancers and insulin-like growth 
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factor-1 receptor in high-grade, PTEN-null prostate cancer (20,21). In general, it has been 
observed that NRP1 and NRP2 are both overexpressed in multiple cancer types, and in the case of 
NRP1, positively correlate with tumor progression (4,6,22).  Likewise, therapeutics targeted to 
NRP1 and NRP2 that block signal transduction have shown anti-metastatic potential in multiple 
cancer types, suggesting NRPs may serve as effective biomarkers that specifically target 
metastatic tumors (5,23,24). Thus, NRPs act as key regulators of cell migration, and 
dysregulation of NRP-dependent signaling can lead to enhanced pro-angiogenic tumor growth as 
well as cancer cell survival post-treatment. 
In the case of NRP1-PlexinA1 signaling, it has been observed that the receptors cluster 
upon Sema3A addition and subsequent signal transduction (25).  Forced homodimerization of the 
PlexinA1, A2, A4, and C1 cytosolic domains also enhances receptor GTPase-activating protein 
(GAP) activity in an in vitro RapGAP assay (26). Collectively, these results suggest plexin 
homomeric interactions are important for NRP-plexin-sema signal transduction (Figure 4.1A).  A 
low-resolution crystal structure of the CUB and FA V/VIII domains of NRP1 with the four N-
terminal PlexinA2 domains bound to Sema3A reveals a 2:2:2 NRP1:PlexinA2:Sema3A 
stoichiometry, with the CUB domains of NRP1 acting as a linker to stabilize the Sema3A-
PlexinA2 complex (27). No major structural rearrangements in NRP1 or PlexinA2 are observed 
between the Sema3A-liganded and unliganded states, and both the NRP1 and PlexinA2 
extracellular fragments in the crystal structure are monomeric in solution (27).  Similarly, plexin 
cytosolic domains appear predominately monomeric in solution with only weak homomeric 
interactions observed (26,28), implying plexin dimerization and clustering is influenced through 
the TM domain and proximal regions and/or the NRP co-receptor. 
Receptor dimerization or clustering likely influences VEGFR signaling, as well (29,30).  
Crystal structures of the VEGFR-2 ligand binding domain complexed with VEGF-A or VEGF-E 
indicate a 2:2 stoichiometry, as do crystal structures of the first NRP1 FA V/VIII domain 
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complexed with VEGF-A (31,32).  In addition to the capabilities of both VEGFR-2 and NRP1 to 
bind VEGF-A in the absence of the co-receptor, VEGFR-2 and NRP1 interact with each other in 
the absence of the VEGF-A ligand. While the co-receptor complex may affect ligand binding or 
receptor internalization upon ligand binding, another model suggests NRPs serve to promote 
clustering of VEGFRs and subsequent activation (Figure 4.1A) (29,33,34). 
The full-length NRP1 receptor appears dimeric when solubilized via western blots and 
co-immunoprecipitation (co-IP) experiments, as does the full-length NRP2 receptor (8,35-37).  
Studies on the TM domain of NRP1 indicate that mutations to TM glycines found in a conserved 
‘G-x3-G’ motif disrupt dimerization of purified NRP1 TM domain peptides, implying a role for 
the TM domain in NRP1 homodimeric interactions (38).  Domain-binding and -deletion studies 
also suggest homomeric interactions may be facilitated by the NRP juxtamembrane MAM 
domain (8,35,36).  The involvement of the MAM domain in NRP homomeric interactions is 
further supported by the inability of MAM-deletion constructs to co-IP with the full-length 
receptor and the ability of an alkaline phosphatase (AP)-tagged NRP2 MAM domain to bind COS 
cells upon expression of the full-length NRP1 or NRP2 receptors (8,35).  Thus, while the NRP 
transmembrane domain exhibits a G-x3-G motif, a driving force for NRP2 MAM homomeric 
interactions and their role in receptor clustering and activation remains unresolved. 
MAM domains are also present in meprins and protein tyrosine phosphatase (PTP) 
subclass IIB proteins.  This domain in both meprin α and PTPµ has been shown to influence 
homomeric interactions (39,40).  The MAM domains of neuropilins, PTPµ, and meprin α all 
contain four conserved cysteines, with the MAM domain of meprin α containing one additional 
cysteine (39,40).  Mutation of this fifth cysteine in a secreted truncated meprin α protein or 
addition of reducing agent to this same protein results in monomeric meprin α in SDS-PAGE 
(39).  While the PTPµ MAM domain cross-linked in solution runs as a dimer on SDS-PAGE, 
addition of reducing agent to the cross-linking reaction results in monomeric PTPµ (40).  
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Collectively, these results suggest cysteine chemistry influences MAM domain interactions in 
meprin α and PTPµ. 
In order to determine if cysteine chemistry in the MAM domain also influences 
homooligomerization of NRP2, we utilized a series of biochemical and genetic tools to identify 
the ability of cysteine-mutant constructs to self-interact. Our results indicate cysteines in the 
Danio rerio NRP2a MAM domain, in particular a conserved cysteine (C711), play a significant 
role in homooligomerization and function. Notably, we predict that a C711-dependent disulfide 
bond dictates proper formation for the activated, clustered NRP2 (Figure 4.1A).  Mutations to 
select MAM domain cysteines in the full-length receptor in a bioluminescence resonance energy 
transfer (BRET2) assay enhance dimerization.  When expressed in transiently-transfected COS-7 
cells, the NRP2a mutation C711S reduces Sema3F binding, signifying a role for this residue in 
dictating interactions necessary for the activated, clustered state. Furthermore, while injection of 
wild-type (WT) NRP2a RNA into zebrafish embryos resulted in branched intersegmental vessels 
(ISVs), injection of C711S mutant RNA resulted in significantly fewer embryos with this NRP2a 
overexpression phenotype.  Collectively, these results indicate cysteine chemistry in the NRP2a 
MAM domain contributes to the protein’s mechanisms for homooligomerization and provides 
insight into the structural organization of NRP co-receptor complexes important for signal 
transduction (Figure 4.1A). 
 
4.2 Materials and Methods 
4.2.1 Plasmids 
Zebrafish are known to express two NRP2 isoforms (a and b) (41).  Full-length WT 
Danio rerio NRP2a (NCB Accession # BC162118.1, Thermo Scientific) was generated by PCR 
for cloning into pcDNA3.1/V5-His-TOPO (Invitrogen) as per manufacturer’s instructions with a 
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C-terminal FLAG-tag, pGFP2-N3 (BioSignal Packard) as a NheI/HindIII insert, and pRLuc-N1 
(BioSignal Packard) at XhoI/HindIII.  Mutations were made using the QuikChange II Site-
Directed Mutagenesis Kit (Agilent Technologies) as per manufacturer’s instructions. 
 To generate hook-Sema3F, the hook moiety complete with an N-terminal HA-tag and 
two C-terminal myc-tags was obtained by PCR from the phook-2 plasmid (Invitrogen; residues 
2096-3066) provided by Paul Billings (University of Pennsylvania).  This construct was 
subsequently cloned into pcDNA3.1/V5-His-TOPO at HindIII/KpnI with a 5' Kozak sequence 
and a C-terminal poly-glycine linker.  Human Sema3F without a signal sequence (residues 266-
2467 of NCB Accession # XM_005265382.2) was then cloned into this plasmid at KpnI/XbaI.  
The plasmid coding for AP-Sema3F, used as a PCR template to make this construct, was 
provided by Dr. Roman J. Giger (University of Michigan).   
 
4.2.2. Mammalian Cell Culture 
COS-7 cells (ATCC) were maintained as recommended by ATCC, except media was 
supplemented with 1% (v/v) 100X Antibiotic/Antimycotic solution (100 U/mL penicillin G, 100 
μg/mL streptomycin, and 0.25 μg/mL amphotericin B) (Hyclone) and subcultivation ratios ranged 
from 1:10 to 1:20. Transfections occurred via electroporation with a Bio-Rad Gene Pulser XCell 
using pre-set COS-7 parameters. 
 
4.2.3 BRET2 Assay 
COS-7 cells were co-transfected via electroporation with a pGFP2 and a pRLuc construct 
containing a fusion to full-length NRP2a. Each transfection was split across eight wells in a 
white, flat-bottomed 96-well plate.  Each well represented one replicate, and each transfection 
represented one round for the specified condition.  Cultures were allowed to grow for two days, 
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and measurements were taken as previously described using a Tecan Infinite F200 multi-well 
plate reader (42,43).  Following measurements, levels of BRET2 protein expression were 
confirmed consistent between mutants via western blots (1:1000 dilutions of EGFP mouse 
monoclonal antibody, Clontech; mouse monoclonal anti-tubulin, Abcam; anti-mouse IgG HRP-
linked antibody, Cell Signaling; or 1:2500 dilution of MSX Renilla Luciferase, Millipore) (Figure 
4.2). 
 
 
Figure 4.2.  NRP2 BRET2 constructs are expressed in COS-7 cells upon transfection. Ladder 
markings are in kDa.    Anti-RLuc (top), anti-tubulin (top), and anti-GFP (bottom) western blots 
of cultures co-transfected with NRP2-RLuc and NRP2-GFP fusion constructs.  R = NRP2-RLuc 
fusion (140 kDa), T = tubulin (55 kDa), G = NRP2-GFP fusion (130 kDa). 
 
For analysis, we first considered the total luminescence of individual wells normalized to 
the average mock total luminescence of the wells for that round.  Cultures with total 
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luminescence values lower than that of the mock-transfected cells were eliminated from 
subsequent analyses.  The ratio of green luminescence to magenta luminescence was computed 
for each sample, then divided by the average ratio of green luminescence measurements to 
magenta luminescence measurements for the WT condition for that round of experiments. Results 
represent the average percent difference from WT and standard error of at least 24 independent 
replicates, with the standard error of WT samples added to the standard error of the mutants. 
 
4.2.4 NRP2a Overexpression in Zebrafish 
Capped NRP2a mRNA was made using the mMESSAGE mMACHINE T7 Transcription 
Kit (Ambion) as per manufacturer’s instructions, with template NRP2a DNA generated from the 
pcDNA3.1/V5-His-TOPO constructs linearized with XhoI. 
Embryos from adult fli1-GFP intercrosses were injected with either NRP2a RNA at 1 
µg/µL or miR-2188 morpholino (miR-2188-MO, Gene Tools) at 0.5 mM while in the single-cell 
stage.  At 48 hours post fertilization, chorions were popped and embryos were fixed with 4% 
paraformaldehyde for 2 hours at room temperature.  Embryos were subsequently washed 3x with 
PBS and imaged at 20X magnification.  Embryos were evaluated for ISV branching previously 
identified as a NRP2a overexpression phenotype (44).   
 
4.2.5 Semaphorin Binding 
Cells were transfected via electroporation with WT or mutant NRP2a in pcDNA3.1/V5-
His-TOPO.  Two days after transfections, all media was removed from the plate and replaced 
with 50-fold concentrated media from hook-Sema3F transfected cultures, and incubated 1.5-2 
hours at 37°C in 5% CO2.  Treated cells were rinsed three times in PBS, then fixed for 30 minutes 
at room temperature with 4% paraformaldehyde in PBS.  Cells were rinsed once in PBS, blocked 
75 
 
for one hour in PBS + 1% (w/v) BSA + 0.5% (v/v) TritonX-100 at room temperature, and 
incubated in mouse monoclonal anti-myc antibody (Cell Signaling) at 1:2000 in block solution 
over two nights.  Secondary antibody incubation (anti-mouse IgG AlexaFluor 546 or 488) took 
place over the course of one hour at room temperature. For analysis, twenty fields of confluent 
cells per condition were then imaged at 20x magnification with consistent exposure and gain per 
round; subsequently, an observer counted the total number of fluorescent cells per condition. 
 
4.3 Results 
4.3.1 Specific Cysteines in the MAM Domain Influence NRP2a Homooligomerization 
Previous research suggests the NRP2a MAM domain influences homooligomerization, 
similar to MAM domains in meprins and protein tyrosine phosphatases (8,35). In particular, four 
conserved cysteines in the MAM domains of meprin α and PTPμ have been shown to play an 
important role in stabilizing the homodimer through disulfide bond formation (39,40,45). As 
these cysteines are also conserved in the NRP2a MAM domain (Figure 4.1B), we hypothesized 
disulfide bond formation via these four conserved cysteines may also influence NRP2a MAM 
oligomerization.  Comparison of the Danio rerio NRP2a MAM domain with the PTPμ MAM 
domain suggested C636-C643 and C711-C794 are likely to form disulfide bonds (analogous to 
disulfide bonds C27-C36 and C96-C182 in the PTPμ MAM domain) (46). Therefore, we mutated 
one or both cysteines in each of the corresponding putative disulfide bonds in the NRP2a receptor 
and analyzed the effects using the BRET2 assay (42,43).  Mutations were introduced into the full-
length NRP2a receptor for both the C-terminal GFP2-fused and Renilla luciferase (RLuc)-fused 
proteins. The BRET2 assay relies upon distance between the GFP2-fused and the RLuc-fused 
proteins; upon addition of the Deep Blue C substrate, the RLuc tag catalyzes a reaction that 
causes light to be emitted at 395 nm.  This light then excites nearby GFP2 tags, causing light to be 
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emitted at 510 nm.  Results are characterized by an energy transfer ratio, or the ratio of intensity 
of light produced by GFP2 (green fluorescence at 510 nm) to the luminescence signal generated 
by RLuc (magenta luminescence at 395 nm) (42,43). 
As shown in Figure 4.3, the MAM mutants C643S, C711S, and C711S + C794S show 
significant differences from WT as an enhancement in energy transfer.  Thus, the BRET2 results 
indicate mutants C643S, C711S, and C711S + C794S enhance oligomerization of full-length 
NRP2a.  Interestingly, the double mutant C636S + C643S did not exhibit significant changes in 
energy transfer efficiency from the WT receptor, suggesting specific cysteines or combinations of 
cysteines in the MAM domain influence NRP2a homooligomerization.   Collectively, the results 
imply specific cysteines in the NRP2a MAM domain influence receptor homomeric interactions 
and subsequent clustering and activation (Figure 4.1). 
 
 
Figure 4.3.  Cysteines in the NRP2a MAM domain of influence receptor homooligomerization in 
a mammalian membrane, as determined by BRET2.  Results were collected from at least three 
separate transfections of each condition and error bars represent standard error. 
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4.3.2 Mutations to the NRP2a MAM Domain Influence Overexpression Phenotypes in 
Zebrafish Vascular Patterning 
Previous results demonstrate that knockdown of a microRNA that suppresses NRP2a 
expression (miR-2188), hence inducing NRP2a overexpression, results in irregular ISV branches 
in zebrafish embryos.  This phenotype is believed to manifest itself through the NRP2a-VEGF 
pathway (44). One model suggests NRP2a influences VEGF signaling through NRP-VEGF-
VEGFR clustering (29). To determine if our cysteine mutations affect signaling in a NRP2a-
VEGF pathway, we injected miR-2188-MO or NRP2a mRNA into zebrafish embryos and 
examined them for the NRP2a overexpression phenotype (Figure 4.4 and Table 4.1). 
Of the embryos examined, 16% of those injected with miR-2188-MO and 18% of those 
injected with WT NRP2a mRNA exhibited branches characteristic of the NRP2a overexpression 
phenotype.  This was significantly more than the 2.5% of uninjected embryos exhibiting ISV 
branches (p<0.0005, as determined via an unpaired two-tailed student t-test assuming equal 
variance).  Embryos injected with cysteine-mutant NRP2a mRNA (C643S, C711S, and C711S + 
C794S) showed significant increases in NRP2a overexpression compared to the uninjected 
embryos, as well (p<0.05 for C643S and C711S and p<0.0005 for C711S + C794S).  However, 
compared to the embryos injected with WT NRP2a mRNA, fewer embryos injected with C711S 
NRP2a mRNA exhibited the overexpression phenotype (p<0.05).  This suggests mutation C711S 
fails to elicit the same functionality as WT NRP2a, possibly due to alterations to receptor 
oligomeric state and/or tertiary structure as suggested by our BRET2 results (Figure 4.3). 
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Figure 4.4.  WT NRP2a overexpression causes ISV branching in 48 hours post fertilization 
zebrafish embryos.  
 
 
Table 4.1.  Percentage of fli1-GFP embryos exhibiting ISV branching4b 
Type of Injection 
Number of 
Embryos 
Examined 
Percentage of 
Embryos Exhibiting 
NRP2 Overexpression 
Phenotype 
P-value 
Compared to 
Uninjected 
P-value 
Compared to 
WT NRP2a 
RNA-Injected 
Uninjected 204 2.5 1 6.8 x 10-6 
WT NRP2a RNA 62 18 6.8 x 10-6 1 
C643S NRP2a RNA 54 9.3 0.021 0.19 
C711S NRP2a RNA 141 7.8 0.020 0.034 
C711S + C794S 
NRP2a RNA 
81 17 4.4 x 10-6 0.94 
miR-2188-MO 43 16 1.1 x 10-6 0.29 
 
4bP-values were determined using an unpaired equal variance two-tailed student t-test. 
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4.3.3 Mutations to the NRP2a MAM Domain Influence Sema3F Binding 
Previous work suggests the NRP1 MAM domain promotes receptor cis- or trans-
aggregation, and that these aggregates (of a higher-order than dimer) may be required for 
activation or interactions with a co-receptor (35). While crystal structures suggest a 2:2:2 
NRP1:PlexinA2:Sema3A stoichiometry (27), it is possible that activation of the full-length 
receptors requires a higher order oligomer than dimer or promotes binding of the semaphorin 
ligand (Figure 4.1A) (35). Previous results with NRP2 have shown that deletion of the MAM 
domain reduces receptor affinity for the Sema3F ligand, as determined by reduction in 
absorbance measurements of COS-7 cells transfected with NRP2 and subsequently treated with 
an AP- Sema3F (35).   To determine a possible functional role of the MAM cysteines in 
semaphorin binding, we examined Sema3F binding to COS-7 cells transfected with either WT or 
mutant Danio rerio NRP2a. Sema3F acts as a negative regulator of growth cone formation guided 
by NRP2-Plexin A3, and thus binding of Sema3F is necessary for growth cone collapse (28). 
Expression of full-length FLAG-tagged WT NRP2a or mutant C711S + C794S resulted 
in significant binding of Sema3F compared to mock-transfected cells, as determined by 
fluorescence microscopy (Figures 4.5A-B).  Significantly fewer Sema3F-bound cells were 
observed in cultures transfected with NRP2a mutant C711S for the same exposure times, 
indicating a reduction in Sema3F-binding in cells transfected with this mutant.  The reduction in 
Sema3F-binding is likely due to altered oligomeric states or conformational changes in the 
protein rather than expression levels, as western blots on NRP2a BRET2 constructs exhibit similar 
expression levels.  Our BRET2 (Figure 4.3) results point to C711 as influential to NRP2a 
homomeric interactions.  A model in which the oligomeric state of NRP2a regulates Sema3F-
binding, and C711 regulates NRP2a oligomerization, is consistent with these results (Figure 4.1). 
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Figure 4.5. Mutant C711S reduces binding of Sema3F to the full-length NRP2a receptor.  (A)  
Representative images of hook-Sema3F-bound cells.  (B)  Mutant C711S disrupts Sema3F-
binding.  Cells were transfected with water, WT, or mutant NRP2a constructs and treated with 
50x-concentrated hook-Sema3F.  Twenty random fields of view for each condition per round 
(three rounds total) were examined at an exposure time consistent within the round and the total 
number of Sema3F-bound cells were counted.  Error bars indicate standard error. 
 
4.4 Discussion 
 Previous studies have shown the NRPs exhibit an intrinsic ability to dimerize and 
aggregate (8,35-37).  Here, we identify a conserved cysteine in the MAM domain of NRP2a 
(C711) that governs homooligomerization when mutated in the context of the full-length receptor 
in a mammalian cell membrane (Figure 4.3).  This mutation also disrupts Sema3F-binding to the 
full-length receptor (Figure 4.5) and causes less of the NRP2a overexpression phenotype in 
zebrafish embryo vasculature compared to the WT receptor (Table 4.1). We also identified 
mutations to conserved cysteines (C711S + C794S) that affect receptor homomeric interactions, 
as determined by BRET2 (Figure 4.3), but do not disrupt Sema3F-binding (Figure 4.5) or a 
reduced NRP2a overexpression phenotype in zebrafish vasculature (Table 4.1). Our results 
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collectively point to a model in which the MAM domain acts as a regulator of the equilibrium 
between oligomeric states (Figure 4.1) and possibly receptor extracellular domain tertiary 
structure, thereby controlling semaphorin binding and VEGFR clustering.  Furthermore, 
conserved cysteines govern this equilibrium.  Additional structural and functional studies will 
allow further elucidation of the functional significance of the cysteine mutations.  
In particular, one of the principle observations from this work is that the C711S mutation, 
which is one of four conserved cysteines in the MAM domain, drives dimerization in the context 
of the full-length receptor (Figure 4.3), suggesting the disulfide bond involving C711 negatively 
regulates oligomerization.  Consistent with previous studies on meprin α and PTPμ MAM 
domains in which disruption of disulfide bonds resulted in decreased function (39,40,45), the 
NRP2a C711S mutant exhibits a reduction in Sema3F-binding capabilities as well as in ability to 
induce a NRP2a overexpression phenotype in zebrafish vasculature (Table 4.1 and Figure 4.5).  
In PTPμ, mutation of a conserved cysteine disrupted MAM domain interactions between 
receptors while maintaining the ability to induce cellular aggregation (40).  In meprin α, 
disrupting a conserved MAM domain cysteine resulted in decreased thermal stability of the 
enzyme, increased proteolytic degradation, and decreased activity towards protein substrates (39).  
In NRP2a, we find disruption of the C711 disulfide bond triggers oligomerization of the full-
length NRP2a receptor (Figure 4.3), which seemingly disrupts Sema3F binding (Figure 4.5) and 
reduces its ability to induce branching in zebrafish embryo vasculature (Table 4.1). It is likely 
that the C711S mutation could disrupt the equilibrium between oligomeric states and thereby 
affect ligand binding (Figure 4.1). Alternatively, the mutation could introduce a conformational 
change in the monomeric NRP2a structure itself that not only leads to NRP2a oligomerization, 
but also disrupts ligand binding sites.  Our studies do not distinguish between either possibility, 
but do suggest that residue C711 is important for defining the oligomeric state of NRP2a and the 
receptor's ability to bind Sema3F and function in a VEGF-dependent system (Figure 4.1). 
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In summary, we have shown that residues in the NRP2a MAM domain regulate the 
equilibrium between NRP2a oligomeric conformations which lead to activated, clustered states 
(Figure 4.1).  Cysteines, in particular C711, assist in regulating MAM dimerization, with intact 
disulfide bonds disrupting clustering of the full-length receptor (Figure 4.3).  Regulation of 
NRP2a MAM domain cysteine chemistry ultimately affects Sema3F-binding, as observed with 
mutation of residue C711 (Figure 4.5), as well as its ability to act in a VEGF-dependent signaling 
cascade (Table 4.1). Our results suggest that cysteine interactions in the NRP2a MAM domain 
regulate oligomeric state and may provide a target site for approaches to modulate NRP 
homomeric interactions. 
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Chapter 5 
Concluding Remarks and Future Work 
 
 
 Receptors involved in axonal guidance have recently been identified as influential during 
angiogenesis, lymphangiogenesis, skeletal development, and cancer metastasis (1-4).  
Understanding their activation mechanisms could provide insight into the development of 
biological systems and may assist in rational design of cancer therapeutics.  Here, we have 
considered two such guidance receptors, plexin A3 (PlxnA3) and neuropilin-2a (Nrp2a), and 
identified juxtamembrane and transmembrane (TM) interfaces that modulate receptor 
dimerization as well as function.  Specifically, we have demonstrated that a cytosolic 
juxtamembrane (JM) heptad repeat in Danio rerio PlxnA3 modulates homodimerization and 
signal transduction.  In particular, mutations to residue M1281 in the JM can enhance (M1281L) 
or disrupt (M1281F) dimerization, with the dimer-enhancing mutation exhibiting altered dimeric 
tendencies even in the presence of a semaphorin (sema) ligand.  This mutation also fails to rescue 
endogenous neuronal patterning in a PlxnA3-knockout zebrafish axonal guidance assay (Chapter 
2).  We have also demonstrated that the PlxnA3 TM domain modulates dimerization and function 
by competing with dimerization induced by the JM.  In particular, mutation to TM small-x3-small 
interfaces enhance dimerization of the PlxnA3 TM + JM domains, while extension of the small-
x3-small interfaces disrupt dimerization.  This is due to dominant role of the JM domain on TM + 
JM dimerization.  PlxnA3 with disruptive mutations to these small-x3-small motifs (enhanced 
dimerization of the TM + JM) is non-functional or only partially functional in the zebrafish 
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axonal guidance assay.  Hence, enhancing PlxnA3 dimerization does not necessarily enhance 
function (Chapter 3).  With Danio rerio Nrp2a, we have demonstrated that cysteines in the 
juxtamembrane MAM (meprin, A-5 protein, and protein tyrosine phosphatase μ, PTPμ) domain 
modulate receptor dimerization and ligand-binding.  Specifically, mutations to a putative 
disulfide bond involving residue C711 (mutations C711S and C711S+C794S) enhance 
dimerization of the full-length receptor.  While the double mutation binds Sema3F to a similar 
extent as the wild-type (WT) protein and exhibits a comparable degree of the Nrp2a 
overexpression phenotype in a zebrafish vascular patterning model as the WT receptor, the point 
mutation C711S exhibits reduced ligand binding and a lesser extent of the overexpression 
phenotype.  Collectively, the results suggest Nrp2a residue C711 modulates receptor 
homooligomerization as well as function (Chapter 4). 
Identification of these homomeric interfaces is only the beginning of understanding plxn 
and nrp signal transduction mechanisms.  The work presented in this thesis provides a foundation 
that may further a number of additional studies, specifically investigating [1] the role of 
dimerization vs. oligomerization vs. ligand binding on plxn function, [2] the roles of additional 
residues in the PlxnA3 TM and JM domains (such as a second small-x3-small motif in the TM 
domain and off-interface residues in the TM and JM domains) in modulating 
homooligomerization and function, [3] structural stability of the PlxnA3 TM domain and 
cooperative effects of the PlxnA3 extracellular, TM, and JM domains on structure, [4] 
cooperative effects of the Nrp2a MAM domain with the Nrp2a TM domain or other extracellular 
domains, [5] behavior of the Nrp2a MAM domain in solution and as a putative therapeutic, and 
[6] the heteromeric interaction interfaces of nrps and plxns.  Application of the knowledge 
presented in this thesis and subsequent work may augment efforts to rationally design function-
altering therapeutics to disrupt tumor growth and cancer metastasis.  Additional work with a 
peptide-based biosurfactant (Appendix A) may also provide a starting point for rational design of 
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a drug delivery system for hydrophobic active ingredients likely required to modify TM domain 
dimerization and function. 
 
5.1 The Role of Dimerization, Oligomerization, and Ligand-Binding on Plexin 
Function 
 The observation that PLXNA1 and NRP1 cluster upon addition of SEMA3A to chick E7 
dorsal root ganglion neurons led to the premise that receptor clustering promotes plxn activity (5).  
Subsequent studies have since demonstrated that dimerization of the PLXNA1, A2, A4, and C1 
cytosolic (CYTO) domains enhances RapGAP activity in solution (6).  However, our results with 
PlxnA3 TM small-x3-small and JM M1281L mutations demonstrate that enhanced dimerization 
does not necessarily correlate with enhanced function (Chapters 2 and 3).  This may be due to a 
conformation or oligomeric state of the receptor not conducive to ligand binding [a trait that 
could be investigated via an alkaline-phosphatase assay previously described (5)], or may be 
indicative of an alternate activation mechanism that relies upon higher-order oligomeric states for 
proper function. 
 Traditionally, membrane protein activation is thought to be triggered by homomeric or 
heteromeric interactions resulting from [1] translation parallel to the membrane, [2] translation 
perpendicular to the membrane, [3] rotation about the membrane (resulting in alternate crossing 
angles between interacting membrane domains), or [4] rotation within the membrane (resulting in 
alternate residue exposure between interacting membrane domains) (Figure 5.1A) (7,8).  A 
trimeric crystal structure of the PLXNB1 CYTO with an intact JM and the presence of the 
RhoGTPase Rac1, however, led researchers to postulate membrane-anchored plxns exist in the 
membrane in a trimeric state, and binding of dimeric sema extracellularly induces network 
formation by the combination of dimers and trimers (9).  This network enhances the plxn local 
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concentration (Figure 5.1B), and this increase in membrane-anchored concentration causes 
extension or retraction of the growth cone. 
 
 
Figure 5.1.  Mechanisms of transmembrane protein activation.  (A)  Traditionally, membrane 
protein activation is thought to occur through translational or rotational motion.  (B)  Activation 
of the plexin transmembrane receptor may rely upon a variation of horizontal translation that 
results in high local concentration due to clustering caused by a network of dimers and trimers. 
 
Our small-x3-small and M1281L and mutations, while enhancing PlxnA3 dimerization 
(Chapters 2 and 3), may fail to induce formation of a larger network.  Indeed, previous work with 
heptad repeats have demonstrated that the location of a hydrophobic residue in a heptad repeat as 
well as the identity of the hydrophobic residue influences oligomeric state (10,11).  For instance, 
a phenylalanine to methionine mutation in a synthetic phenylalanine zipper causes a shift in 
oligomeric state from pentamer to tetramer (10-12).  Our small-x3-small and M1281L mutations 
may enhance PlxnA3 homooligomerization but fail to promote network formation. 
 Our bioluminescence resonance energy transfer (BRET2) results with the WT receptor 
also support such a mechanism (Chapter 2).   The PlxnA3 receptors alone or co-expressed with a 
Nrp2a co-receptor and treated with a SEMA3F ligand exhibited similar energy transfer ratios, 
indicative of similar distances between PlxnA3 receptors even upon PlxnA3-Nrp2a-SEMA3F 
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complex formation.  Our observations could be due to a number of possibilities specific to the 
experiment; for instance, the concentration of SEMA3F used in the experiments may not have 
been high enough to enhance PlxnA3 dimerization (13), or that PlxnA3 does not exhibit inherent 
growth cone collapse activity in the COS-7 cells used in the BRET2 assay indicates co-expression 
with another protein in COS-7 cells is necessary to effectively assess the structure of the PlxnA3 
active state (14).  As our results were generated with a truncated receptor, we also cannot refute 
or support the possibility that the CYTO changes shape upon sema binding, as has been 
hypothesized (13).  However, a mechanism in which the plxn CYTO does not alter shape upon 
sema binding to the full-length receptor, but rather the receptors form a network, has been 
theorized in studies with the PLXNB1 CYTO domain (9) and is consistent with our findings. 
 Further work examining the oligomeric state of the PlxnA3 JM in WT and mutant forms 
may provide additional structural insight into the plxn activation mechanism.  The JM domain in 
isolation has been expressed and purified in our lab as a thrombin-cleavable maltose-binding 
protein (MBP) fusion (MBP-JM) (Figure 5.2).  Purification of the JM domain from MBP, 
followed by size exclusion chromatography (SEC), could elucidate the oligomeric tendency of 
the JM domain and the effect of mutations to residue M1281 on multimer equilibrium.  
Additionally, understanding the oligomeric equilibrium of the full-length receptor [via 
immunogold labeling (15), single molecule photobleaching (16), or receptor tracking with 
quantum dots (17)] and how the function-altering TM and JM mutations alter this equilibrium 
may elucidate the plxn signaling mechanism and assist in future work entailing rational drug 
design targeted to manipulate plxn activity. 
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Figure 5.2.  The 
Danio rerio PlxnA3 
JM was successfully 
expressed and 
purified as a 
thrombin-cleavable 
MBP fusion.  Ladder 
markings are in kDa.  
Expected molecular 
weights are 48.8 
kDa, 42.7 kDa, and 
6.1 kDa for the 
MBP-JM, MBP, and 
JM, respectively. 
 
 
5.1.1 Materials and Methods 
5.1.1.1 Plasmids 
 For the MBP-JM fusion construct, a 6-histidine tag, followed by MBP, a poly-glycine 
linker, and tobacco etch virus cleavage site was cloned into pET42 as an NdeI/BamHI insert. The 
Danio rerio PlxnA3 JM (amino acids 1264-1314 of NCB Accession # BAF81998.1) was 
subsequently cloned into this plasmid as a BamHI/XhoI insert. 
 
5.1.1.2 Expression and Purification 
 BL21(DE3) cells (Invitrogen) were transformed via electroporation and stored as glycerol 
stocks.  For expression, cultures were started from glycerol stocks and grown to saturation 
overnight at 37ºC in LB + 50 µg/mL kanamycin.  Cells were then diluted to an optical density 
(600 nm) (OD600) of 0.4 and allowed to grow an addition 3-6 hours at 20ºC, at which point 1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to the culture.  Cells were collected 16-
24 hours post-IPTG induction, re-suspended in lysis buffer (100 mM HEPES, 500 mM sodium 
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chloride, 10 mM imidazole, and 10% (v/v) glycerol) and lysed via a freeze-thaw process followed 
by tip sonication.  The soluble MBP-JM fusion protein was subsequently purified by nickel 
chromatography with chelating fast flow resin (GE Healthcare) and imidazole washes ranging 
from 10 mM to 500 mM in 20 mM HEPES, 500 mM sodium chloride, and 10% (v/v) glycerol.  
Thrombin cleavage was performed using 1 µL thrombin per 100 µL protein sample incubated at 
room temperature overnight on a rotisserie. 
 
5.2 The Role of Off-Interface Transmembrane and Juxtamembrane Residues on 
Plexin A3 Dimerization 
 Our AraTM results indicate that a glycine-rich region of the PlxnA3 TM domain and a 
heptad repeat in the JM domain modulate receptor homodimerization (Chapters 2 and 3).  
Additional residues in these domains may also modulate homodimerization, however.  First, the 
TM domain contains a second small-x3-small motif in register with the G1246 + G1250 interface; 
residues involved in this motif (A1258 and A1262) may also contribute to modulation of receptor 
dimerization (Figure 5.3A).  This second small-x3-small motif is not conserved across species or 
plxns, but may affect homodimerization of Danio rerio PlxnA3. Second, the Danio rerio PlxnA3 
TM domain contains a fifth, off-interface glycine in the glycine-rich region (G1249) that may 
modulate receptor dimerization and function (Figure 5.3A).  Finally, in the JM domain, side chain 
interactions between off-interface residues of heptad repeats cause formation of coiled-coils, with 
salt bridges stabilizing the hydrophobic core of the heptad repeat (10).  As such, amino acids 
adjacent to the JM hydrophobic core may also modulate dimerization.  Furthermore, the JM 
domain of class A plxns contains a conserved off-interface hydrophobic residue (methionine or 
leucine; L1279 in Danio rerio PlxnA3) that may compete with the hydrophobic core of the 
heptad repeat as a modulation mechanism for dimerization (Figure 5.3A-C). 
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Figure 5.3.  Off-interface residues in the TM and JM may modulate receptor dimerization.  (A) 
Sequence of the Danio rerio PlxnA3 TM (purple) and JM (green) domains.  Two small-x3-small 
interfaces in the TM domain and a heptad repeat in the JM domain (red font) modulate TM + JM 
dimerization (Chapters 2 & 3).  Additional off-interface residues, such as G1249 and A1255 in 
the TM domain, or R1276 and L1279 in the JM domain, may modulate dimerization.  Another 
small-x3-small interface in-frame with G1246 + G1250 (A1258 + A1262) may also modulate 
dimerization.  (B)  Helical wheel diagram of the PlxnA3 JM domain with the heptad repeat at the 
core of the dimer interface (Chapter 2).  (C) Helical wheel diagram of the PlxnA3 JM domain 
with an alternative leucine (L1279) at the dimer core and predicted disruptive electrostatic 
interactions (K1275 + R1276) de-stabilizing the interaction.  Helical wheel diagrams and salt 
bridge prediction were generated using DrawCoil 1.0. 
 
Using the AraTM assay performed as described in Chapters 2 and 3 and considering the 
small-x3-small motif in the PlxnA3 TM domain in register with the G1246 + G1250 interface 
(A1258 + A1262), we observe that mutation A1258L also slightly enhances dimerization of the 
TM + JM domain (Figure 5.4).  This is consistent with the model in which dimerization via 
small-x3-small motifs in the PlxnA3 TM domain competes with JM-driven dimerization.  
Mutation to these small-x3-small packing motifs enhances dimerization by allowing the dominant 
JM dimer to form (Chapter 3). 
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Figure 5.4.  Off-interface residues TM and JM residues contribute to dimerization.  (A) Off-
interface residues in the TM (purple) and JM (green) modulate TM + JM dimerization in the 
AraTM assay.  JM mutations (M1281F and M1281L, Chapter 3) dominate in mutations to both 
the TM and JM domains (blue).  Error bars indicate standard error as determined from a 
minimum of twelve replicates collected over the course of three experiments.  (B) Anti-MBP 
(1:10,000 dilution, NEB) western blots confirming expression of PlxnA3 TM + JM mutants.  
Expected molecular weight ~67 kDa.  Portions of these western blots appeared in Chapters 2 
(right) and 3 (left).  (C) Maltose complementation tests on PlxnA3 TM + JM constructs.  Each 
column represents a separate plate.  Portions of the plates (the WT or pAraCy controls) may have 
appeared in Chapters 2 and 3. 
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Interestingly, off-interface mutation G1249L also enhances dimerization of the Danio 
rerio PlxnA3 TM + JM domains in the AraTM (Figure 5.4).  Previous studies with small-x3-small 
motifs suggest that large, aliphatic residues (predominately isoleucine and valine, but also 
leucine) immediately flanking small residues participating in small-x3-small motifs enhance 
homomeric interactions (18).  This triplet pattern is also overrepresented in a database of 
transmembrane proteins (19).  Hence, mutation G1249L possibly enhances dimerization of the 
small-x3-small interfaces.  This is in contrast to our previous results in which enhancement to the 
small-x3-small interfaces disrupts dimerization of the TM + JM domains (Chapter 3), however, 
suggesting additional insight is required regarding the mechanism of G1249L enhancement to 
TM + JM dimerization.  In agreement with our previous results (Chapter 3), the impact on 
dimerization due to mutation G1249L with JM mutations trends the same as JM mutations alone, 
implying dominant JM-driven dimers in the TM + JM system. Mutation to residue A1255L, also 
off-interface to all putative small-x3-small motifs in the PlxnA3 TM domain, also enhances 
dimerization of the TM + JM domains in the AraTM assay (Figure 5.4).  Collectively, these 
results imply the overall presence of small amino acids in the PlxnA3 TM domain de-stabilize 
TM + JM dimerization.  Possibly, the prevalence of small amino acids allows for close TM-
packing of higher-order than dimer, such as the trimer postulated from the crystal structure of the 
PLXNB1 CYTO (9), which subsequently de-stabilizes JM-driven dimerization (dominant in the 
AraTM assay, Chapter 3). 
 Considering off-interface residues of the PlxnA3 JM domain, we observe that mutation 
L1279A enhances dimerization of the PlxnA3 TM + JM domains in the AraTM assay (Figure 
5.4).  This is consistent with L1279 being solvent-exposed and in competition with the heptad 
repeat residues; reduction of the hydrophobic competition through mutation L1279A enhances 
dimer formation.  Mutation R1276A, a mutation to a predicted off-interface residue, also resulted 
in enhanced oligomerization. Interestingly, this mutation is predicted to remove a putative 
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repulsive electrostatic interaction between R1276 and K1275 on PLXNA3 JM domains dimerized 
with L1279 in the hydrophobic core, as determined using DrawCoil 1.0 (Figure 5.3) (11).  Hence, 
residues L1279 and R1276 likely modulate stability of a competitive dimerization motif in the 
PlxnA3 JM, with appropriate mutation to either enhancing overall dimerization of the TM + JM 
domains. 
 Collectively, our results indicate the PlxnA3 TM + JM domains contain a number of 
additional residues (G1249, A1255, A1258, R1276, and L1279) that disrupt overall TM + JM 
dimerization.  As functional studies suggest strong dimerization inhibits PlxnA3 function 
(Chapters 2 and 3), these residues likely contribute to modulation of PlxnA3 activity.  By 
inhibiting strong dimerization of the JM domain, these residues allow for PlxnA3 switchability, 
between active and inactive states as well as amongst co-receptors.  Similar specific, but weak 
interactions govern integrin heterodimerization and function (20).  Additional insight regarding 
the effect of mutations G1249L and A1255L on TM + JM dimerization mechanisms, as well as 
additional functional tests with mutations A1255L, R1276A, and L1279A (refer to Section 5.3 for 
G1249L functional tests) may further elucidate the mechanisms modulating PlxnA3 activity. 
   
5.3 Structural Stability of the Plexin A3 Transmembrane Domain and Cooperative 
Effects on Dimerization and Function 
 Our AraTM results for the PlxnA3 TM and JM domains (Chapters 2 and 3) suggest the 
intrinsic structures of the two domains compete:  the heptad repeat in the JM domain enhances 
dimerization (Chapter 2), while the surplus of glycines in the TM domain disrupts dimerization 
(Chapter 3 and Section 5.2).  Furthermore, mutations to both the TM and JM domains result in 
non-additive AraTM signals (Figure 5.5), suggesting domain cooperativity.   
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Figure 5.5.  Mutations to both TM and JM domains (blue) are non-additive from TM mutations 
alone (purple) and JM mutations alone (green).  Values originally appeared in Chapters 2 and 3 
and Section 5.2 and are re-plotted here for clarification. 
 
 While quaternary structure is likely to depend on TM and JM domain cooperativity, it is 
also possible that the domain proximity influences the stability of secondary and tertiary 
structures.  While tertiary and quaternary structure are difficult to de-couple without a means to 
assess tertiary structure (such as crystal structure determination or small-angle x-ray scattering), 
secondary structure can be assessed via circular dichroism.  Due to the hydrophobicity and low 
dielectric constant of the membrane environment, secondary structure in TM domains is more 
stable than in proteins in an aqueous environment (21).  Backbone hydrogen bonding, resulting in 
α-helices and β-sheets, provides energetic recompense for the dehydration of the peptide bond in 
a hydrophobic environment (22). Hence, single-spanning membrane proteins, such as plxns, are 
generally considered α-helical.  While the glycines in the PlxnA3 TM would be considered 
‘helix-breakers’ in an aqueous environment due to the entropic costs of confining glycine in a 
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secondary structure (23), the enthalpic benefit from backbone hydrogen bonding induced by 
secondary structure in a membrane environment allows for their incorporation in membrane α-
helices (24).  Indeed, glycines are commonly found at the core interfaces of membrane protein 
dimers due to their small size and enhanced ability to participate in α-carbon hydrogen bonds 
(18,19,24-27).   
 Investigation of the secondary structure of the PlxnA3 TM domain indicates a propensity 
for the domain to form β-sheets in FOS-Choline-15 micelles in the absence of the juxtamembrane 
domains for concentrations of 0.2-0.6 mg/mL and temperatures of 4ºC -47ºC (Figure 5.6A-B), 
likely due to aggregation.  Addition of 40% tetrafluoroethylene or examination of the peptide in a 
1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC)/1,2-dihexanoyl-sn-glycero-3-
phosphocholine (DHPC) bilayer induces the anticipated α-helical structure (Figure 5.6C-D).  
Investigations regarding the structural stability of the PlxnA3 TM peptide in a bicelle, in WT and 
mutant form, may provide additional insight regarding plxn signaling mechanisms.  The presence 
of the JM heptad repeat [an α-helix, PDB # 3IG3, (13)] may also influence structural stability of 
the TM domain.  The Danio rerio PlxnA3 TM + JM domain has been successfully expressed and 
purified as a thrombin-cleavable ompF-fusion protein (Figure 5.7).  Purification of the TM + JM 
domain from ompF could provide insight into cooperative effects on secondary structure stability.  
Stoichiometry studies, such as SEC or cross-linking SDS-PAGE, using a purified TM + JM, a 
purified JM, and the TM peptide available in our lab may also elucidate the putative cooperative 
role of the TM and JM on modulation of PlxnA3 oligomerization and function. 
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Figure 5.6.  CD spectra of the Danio rerio PlxnA3 TM domain (A) at various concentrations in 
FOS-Choline-15, (B) at various temperatures (0.3 mg/mL in FOS-Choline-15), (C) with TFE in 
(0.3 mg/mL in FOS-Choline-15), and (D) at 0.3 mg/mL in FOS-Choline-15 micelles or 
DMPC/DHPC bicelles. 
 
 
 
Figure 5.7. The Danio 
rerio PlxnA3 TM + JM 
was successfully expressed 
and purified as a thrombin-
cleavable ompF fusion.  
Ladder markings are in 
kDa.  Expected molecular 
weights are 26.8 kDa, 17.4 
kDa, and 9.4 kDa for the 
ompF-TM + JM, ompF, 
and TM + JM, 
respectively. 
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Additionally, though the JM domain dominates in the TM + JM system (Chapter 3), and 
mutations to the JM domain in the context of the TM + JM in the AraTM assay agree with 
BRET2 results for the TM + JM domains with an intact extracellular domain (Chapter 2), the 
influence of the TM mutations on a receptor with an intact extracellular domain have not been 
investigated.  That select TM mutations exhibit partial functionality (G1244L+G1248L) whereas 
others exhibit no functionality (G1246L+G1250L), though both enhance dimerization, implies 
the possibility of an additional role for these motifs in full-length receptor function.  Furthermore, 
TM mutations exhibit the dominant functional effects, despite JM dominance in TM + JM 
dimerization (Table 5.1).  
 
Table 5.1.  Percentage of Embryos Exhibiting sidetracked Phenotype5a 
Type of Injection Number 
of 
Embryos 
Examined 
Percentage of 
Embryos 
Exhibiting the 
set phenotype 
P-value 
Compared 
to 
Uninjected 
P-value 
Compared to 
WT plxnA3 
RNA-injected 
Description 
of Result 
Uninjected5b 30 80 1 0.003 Non-
functional 
WT plxnA3 RNA5b 22 36 0.003 1 Functional 
M1281F plxnA3 
RNA5b 
12 33 0.009 1 Functional 
M1281L plxnA3 
RNA5b 
12 50 0.07 0.5 Partially 
Functional 
G1244L + G1248L 
plxnA3 RNA5c 
13 62 0.3 0.2 Partially 
Functional 
G1246L + G1250L 
plxnA3 RNA5c 
19 74 0.7 0.03 Non-
functional 
G1249L plxnA3 
RNA 
14 79 1 0.003 Non-
functional 
5aP-values were determined using Fisher’s Exact Test. 
5bValues were previously reported in Chapter 2. 
5cValues were previously reported in Chapter 3. 
 
 
 
BRET2 results indeed suggest the PlxnA3 small-x3-small TM interfaces are non-
equivalent in the context of the full extracellular, TM, and JM domains (Figure 5.8).  In contrast 
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to AraTM results with just the TM + JM anchored in a bacterial membrane, in which mutations 
G1244L + G1248L and G1246L + G1250L both enhanced dimerization (Chapter 3), in a 
mammalian membrane with the intact extracellular domain, mutation G1244L + G1248L does 
not exhibit significant changes to dimerization relative to the WT receptor, and mutation G1246L 
+ G1250L disrupts dimerization (Figure 5.8).  This is in agreement with functional test results 
with the zebrafish embryo axonal guidance assay, in which injection of G1244L + G1248L 
plxnA3 RNA into sidetracked (set) embryos resulted in partial functionality, with the number of 
embryos exhibiting the set phenotype being not significantly different from the number of 
embryos injected with WT plxnA3 RNA.  Significantly more set embryos injected with G1246L + 
G1250L plxnA3 RNA exhibited the set phenotype than those injected with WT plxnA3 RNA 
(Table 5.1), also in agreement with the BRET2 results. 
 
 
Figure 5.8. Select mutations to the Plexin A3 TM domain influence homooligomerization with a 
full extracellular domain intact (A) BRET2 results.  Error bars indicate standard error determined 
from a minimum of forty-six replicates collected over the course of six experiments. Expression 
of PlxnA3 BRET2 constructs.  (B) Anti-RLuc (1:1,000 dilution, Millipore) western blot of 
PlxnA3 BRET2 transfections.  Expected molecular weight ~185 kDa (R).  (C)  Anti-GFP (1:1,000 
dilution, Clontech) and anti-tubulin (1:1,000 dilution, Abcam) western blot of PlxnA3 BRET2 
transfections.  Expected molecular weights ~176 kDa (PlxnA3-GFP2, G) and ~50 kDa (tubulin, 
T). 
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The disruption to PlxnA3 dimerization by G1246L + G1250L in the BRET2 assay is also 
in agreement with studies on the small-x3-small TM motifs in glycophorin A (GpA) and NRP1, in 
which mutation to the small-x3-small packing motif disrupted receptor dimerization (28,29).  
Hence, with the extracellular domain intact, the TM interface G1246 + G1250 serves to drive 
receptor dimerization, even with the dominant JM-driven dimer observed in the AraTM assay 
(Chapter 3).  It is therefore possible that the extracellular domain also plays a cooperative role in 
modulating receptor dimerization. 
To further understand the role of mutations to the TM domain on dimerization with an 
intact extracellular domain, we examined the Danio rerio PlxnA3 mutant G1249L in the BRET2 
assay.  Similar to AraTM results with the TM + JM domain (Section 5.2), mutation G1249L 
enhances dimerization of the TM + JM domains with an intact extracellular domain (Figure 5.8).  
These results are consistent with previous studies of small-x3-small motifs in which a valine, 
isoleucine, or leucine immediately adjacent to residues participating in small-x3-small motifs 
(e.g., mutation G1249L is adjacent to interfaces G1244 + G1248 and G1246 + G1250) enhances 
dimerization (18).  Hence, in a receptor with the full extracellular domain, mutant G1249L may 
enhance the small-x3-small packing motif for either the G1244 + G1248 or G1246 + G1250 
interface through enhancement of the ridge in the ridge-and-groove structure characteristic of this 
motif.  Furthermore, in the zebrafish axonal guidance assay, plxnA3 RNA injections with the 
G1249L mutation also fail to rescue WT motor neuron patterning, exhibiting no functionality in 
the assay (similar to mutation G1246L+G1250L) (Table 5.1).  This result validates a role for the 
PlxnA3 TM in modulation of receptor dimerization and subsequent function.  
Collectively, these results corroborate earlier findings (Chapters 2 and 3) that enhanced 
PlxnA3 dimerization does not enhance function of the receptor (mutation G1249L; Figure 5.8 and 
Table 5.1).  Additionally, our BRET2 results indicate disruption to the small-x3-small interface 
G1246 + G1250 disrupts dimerization of the PlxnA3 TM + JM upon inclusion of the full 
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extracellular domain, in contrast to our AraTM results (Chapter 3).  This result implies 
cooperativity of the extracellular domain with the TM + JM domains in modulation of receptor 
dimerization.  As deletion of the PLXNA1 sema-binding domain renders the PLXNA1 receptor 
constitutively active (14), the sema-binding domain may also serve to modulate receptor 
dimerization in the absence of ligand.  Additional BRET2 studies with a full CYTO domain, in 
addition to investigations with TM structural stability, may further elucidate the mechanism of 
plxn activation. 
 
5.3.1 Materials and Methods 
5.3.1.1 Plasmids and Peptides 
 For the ompF-TM + JM fusion, the Danio rerio PlxnA3 TM + JM (amino acids 1241-
1314 of NCB Accession # BAF81998.1) was cloned into pOmpF (30) as a SacI/XhoI insert.  The 
TM peptide (amino acids 1238-1263 of NCB Accession # BAF81998.1, with two flanking lysines 
on each end) was synthesized at the University of Pennsylvania.  BRET2 constructs were cloned 
as previously described (Chapter 2) (31). 
 
5.3.1.2 Expression and Purification of ompF-TM + JM 
 BL21(DE3) cells (Invitrogen) were transformed with the pOmpF plasmid containing the 
TM + JM insert via electroporation and stored as glycerol stocks.  For expression, cultures were 
started from glycerol stocks and grown to saturation overnight at 37ºC in LB + 50 µg/mL 
kanamycin.  Cells were then diluted 1:1000 into ZYP + 50 µg/mL kanamycin and allowed to 
grow overnight at 37ºC.  Cells were collected 16-24 hours post-dilution, washed once in cold 1x 
PBS, then re-suspended in cold PBS and lysed via a freeze-thaw process followed by tip 
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sonication.  Following sonication, the insoluble fraction was collected by centrifugation at 
18000g for 10 minutes. 
The ompF-TM + JM fusion protein was subsequently solubilized in 2% sarkosyl in 20 
mM Tris (pH 8) by shaking incubation at 37ºC for 15 minutes, bath sonication for 15 minutes, 
and an additional shaking incubation at 37ºC for 15 minutes.  Centrifugation was used to separate 
the soluble and insoluble fractions.  The soluble fraction was subsequently passed over a nickel 
chromatography column with chelating fast flow resin (GE Healthcare), washing the material 
with 10 column volumes of 10 mM imidazole in 2% sarkosyl in 20 mM Tris (pH 8), then one 
column volume each of 50, 100, 300, and 500 mM imidazole in 1% FOS-Choline-15 in 20 mM 
Tris (pH 8).  Thrombin cleavage was performed using 1 µL thrombin per 100 µL protein sample 
incubated at room temperature overnight on a rotisserie. 
 
5.3.1.3 BRET2 Assay 
 Transfections, growth conditions, and measurement conditions for truncated PlxnA3 
homooligomerization in the BRET2 assay were previously described (Chapter 2) (31).  Results 
are reported as the average percent change in the ratio of green to magenta luminescence 
measurements from WT samples analyzed in parallel.  Only samples with total luminescence 
values greater than that of the average mock total luminescence for that round were included in 
analyses.  Results were collected from six separate transfections for each condition and a 
minimum of seven wells per transfection.  Error bars indicate standard error, calculated as 
described for the AraTM assay. 
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5.4 Cooperative Effects of the Neuropilin-2a MAM Domain with Other 
Intramolecular Domains 
 Our BRET2 results with the full-length Danio rerio Nrp2a receptor indicate select 
cysteine mutations in the MAM domain enhance receptor dimerization (Chapter 4).  Previous 
studies with the NRP1 TM domain also indicate the importance of a double small-x3-small motif 
in NRP1 TM-driven dimerization (29).  The Nrp2a TM sequence is similar to that of Nrp1; 
however, an alanine insertion alters the small-x3-small motif and introduces an alternative small-
x3-small packing mode (Figure 5.9).  To quickly screen the influence of additional cysteines in 
the MAM domain on receptor dimerization, as well as select TM domain residues, we analyzed 
WT and mutant forms of the Danio rerio Nrp2a MAM-TM-CYTO domains in the AraTM assay 
as described in Chapters 2 and 3. 
 
 
Figure 5.9. Danio rerio Nrp1 and Nrp2a transmembrane sequences.  Nrp1 exhibits two small-x3-
small motifs (red).  An alanine insertion in the Nrp2a transmembrane sequence yields an 
additional small-x3-small motif (blue). 
 
 Our results indicate that mutation of any glycine capable of participating in small-x3-
small interactions in the Nrp2a TM domain disrupts MAM-TM-CYTO dimerization (Figure 
5.10), implying the TM domain may be capable of interacting through multiple small-x3-small 
motifs.  This flexibility may contribute to switchability between co-receptors. 
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Figure 5.10. Mutations to the Nrp2a MAM and TM domains alter MAM-TM-CYTO 
homodimerization in the AraTM assay.  (A) Specific residues in the Nrp2a MAM (blue) and TM 
(purple) domains modulate homodimerization of the MAM-TM-CYTO domains, as determined 
using the AraTM assay. Results were collected over the course of at least three experiments and 
error bars indicate standard error. (B) An anti-MBP western blot on samples from a spheroplast 
protection assay reveals WT Nrp2a MAM-TM-CYTO is correctly oriented in the cell membrane.  
WC = whole cell lysate, P = periplasm, SP = spheroplast, S = supernatant, PK = Proteinase K, 
NP40 = Nonidet P-40. Ladder markings are in kDa, Nrp2a MAM-TM-CYTO is ~ 92 kDa. (C) 
Anti-MBP western blot of AraTM constructs, as expressed by SB1676 cells in AraTM 
measurements.  (D) Mutant constructs orient themselves correctly in the cell membrane, as 
determined by a maltose complementation test (growth on a plate with maltose as the sole sugar 
source signifies correct orientation). 
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Considering MAM domain cysteine mutations in the context of the MAM-TM-CYTO 
domain in a bacterial membrane, modest disruption (>20% of WT signal) to dimerization 
occurred for mutations C636S, C643S, and C711S, with greater disruptive effects (>30% of WT 
signal) observed for C794S (Figure 5.10). The double mutant C711S + C794S also disrupted 
Nrp2a MAM-TM-CYTO dimerization, whereas the double mutant C636S + C643S had 
negligible effect on dimerization. These results are broadly consistent with the observation that 
the disulfide bonds involving C711S and C794S regulates MAM oligomeric state (Chapter 4).  
While the magnitude of change from WT is similar to that exhibited by the mutations in the full-
length receptor in the BRET2 assay (Chapter 4), the directionality is inversed (cysteine mutations 
to full-length Nrp2a enhance dimerization of the full-length receptor, Chapter 4, but disrupt 
dimerization of the MAM-TM-CYTO, Figure 5.10) (Figure 5.11).  Hence, while our results 
indicate an importance for cysteines in the regulation of MAM oligomerization, the mechanism 
by which MAM disulfide bonds directly affect receptor clustering is unclear, though all results 
indicate an importance for residue C711.  Our AraTM results suggest that intact disulfide bonds 
promote dimerization of the MAM-TM-CYTO domain, whereas our BRET2 results suggest a 
disulfide bond involving C711 disrupts dimerization of the intact MAM domain and the full-
length receptor.  It is also important to note that the inversion between AraTM and BRET2 results 
with Nrp2a are thus far specific to the MAM domain; mutation to the Nrp2a TM small-x3-small 
motif disrupted dimerization in both assays (Figure 5.11).  The differences could be explained by 
differences in the assays and/or by domain cooperativity. 
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Figure 5.11. A comparison of Nrp2a MAM-TM-CYTO constructs in AraTM and full-length 
constructs in BRET2 suggest mutations to the TM domain (G872L) disrupt homodimerization in 
both assays, suggesting the switch from dimer-disrupting (AraTM) to dimer-enhancing (BRET2) 
was specific to MAM domain mutations. Error bars indicate standard error. Mutations are those 
presented in Chapter 4 and Figure 5.10, re-plotted for comparative purposes.  
 
The principles governing reporter mechanisms for the AraTM and BRET2 assays are 
fundamentally different.  The AraTM assay depends upon dimerization forming a functional 
promoter, whereas the BRET2 assay relies upon distance between interacting receptors.  Hence, 
the impact of receptor clustering vs. dimerization may impact the two assays differently.  When 
assessed via NativePAGE, less of the GFP2-fused C711S BRET2 construct runs at the apparent 
molecular weight of a dimer (compared to the WT protein) (Figure 5.12).  Given similar 
expression levels (Chapter 4), this suggests C711S tends to form higher-order structures.  This 
possibility does not broadly explain the BRET2 and AraTM discrepancies (Figure 5.11), however, 
as point mutant C643S and double mutants C636S + C643S and C711S + C794S all display 
similar oligomerization patterns to WT (Figure 5.12).  As another possible difference between the 
BRET2 and AraTM assays, while maltose complementation tests and the spheroplast assay 
confirmed orientation of the AraTM constructs in bacterial cells (Figure 5.10), surface expression 
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of the BRET2 constructs was not confirmed.  If the cysteine mutations disrupted receptor folding, 
they may have altered receptor trafficking.  A high intracellular concentration of mutant Nrp2a 
constructs in the BRET2 assay may have resulted in an artificially high signal. 
 
 
Figure 5.12. A NativePAGE western blot of Nrp2a-GFP2 constructs suggest the full-length 
receptor homo-oligomerizes, and MAM mutant C711S promotes homomeric aggregation.  
Ladder markings in kDa, expected molecular weight of monomeric WT NRP2-GFP2 is 130 kDa.  
Apparent molecular weights are marked as M (monomer), D (dimer), and T4 (tetramer). 
 
Alternatively, domain cooperativity may explain the apparent discrepancy in AraTM and 
BRET2 results (Figure 5.13).  The small-x3-small TM dimerization motif, for instance, may 
compete with the MAM-driven dimer, with the net effect resulting in a decrease in MAM-TM-
CYTO dimerization with the MAM dimer-stabilizing mutations C711S and C711S + C794S.  
Such a mechanism was observed with PlxnA3 TM and JM domains (Chapter 3).  Additional 
studies suggest the NRP1 MAM-TM-CYTO domain cannot co-immunoprecipitate (co-IP) 
membrane-anchored, glycophosphatidylinositol-linked NRP1 CUB-FA V/VIII-MAM domains, 
further indicating the possibility that MAM domain interactions can be disrupted by the presence 
of other NRP domains or that TM domain interactions are strong enough to prevent MAM 
interactions (32).  Comparing previous NRP1 domain-deletion experiments, where deletion of the 
MAM domain alone allowed for co-IP of NRP1 (32), but deletion of an additional N-terminal 57 
nucleotides  eliminated  this  ability (33),  results  would  suggest  the  region  between  the MAM  
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Figure 5.13. Cooperative effects between the MAM domain and other domains may define 
oligomeric state and conformation of the full-length receptor.  (A)  In the context of MAM-TM-
CYTO (AraTM assay), mutations to select cysteines disrupt dimerization.  MAM-driven 
dimerization (via disulfide bonds, circle pairs, or another driving force, green triangle) may 
compete with TM-driven dimerization (arrows).  An intact C711 and C794, no lone cysteines, 
and shielding of other driving forces (e.g., burial of the green triangle by intact C711 and C794 
disulfide bonds) allow for native TM interactions.  (B)  In the full-length receptor (BRET2 assay), 
select cysteine mutations enhance dimerization.  Residues C711 and C794 may cooperate with 
another extracellular domain, defining the overall shape (e.g., semi-ovals vs. squares).  A 
requirement to satisfy disulfide bonds (C643S and C711S) or better shape complementarity 
(C711S + C794S) may bring receptor cytosolic domains closer together.  The requirement to 
satisfy disulfide bonds, combined with an overall change in receptor shape, may also disrupt 
ligand binding (C711S, Chapter 4). 
 
domain and second FA V/VIII domain may play a cooperative role with the MAM domain to 
regulate receptor dimerization.  Interestingly, previous research indicates that this linker region 
contains an O-linked glycosylation site necessary for chemotactic migration of mature dendritic 
cells, suggesting glycosylation likely also plays a role in NRP function, though whether it also 
influences homooligomerization and other functions remains to be determined (34-36). The 
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hypothesis that other domains likely cooperatively influence Nrp2a MAM domain interactions 
and alter full-length receptor clustering is also consistent with previous studies on PTPμ, in which 
the MAM domain and a C-terminal Ig domain form a structural unit, and cooperativity of this 
unit with fibronectin type III repeats is necessary for homomeric interactions and functionality 
(37). Furthermore, a disulfide bond between PTPμ MAM residues C96 and C182 (homologous to 
residues C711 and C794 in the Danio rerio NRP2a MAM domain) stabilizes interdomain 
interactions and an L-shaped structure in the PTPμ extracellular domain (38).  Thus, a disulfide 
bond involving C711 may form additional interactions with residues in adjacent domains to 
regulate the dimeric versus oligomeric state.  Our studies thus far do not distinguish between the 
mechanisms, but do suggest that residue C711 is important for defining the oligomeric state of 
Nrp2a, which is critical for nrp-pxln-sema signaling (Chapters 2-4). 
A number of additional studies could be used to confirm the discrepancy between the 
AraTM and BRET2 results and elucidate the possibility of cooperativity between the MAM 
domain and other domains.  Mutations to both the MAM domain and the small-x3-small motifs in 
the TM domain could elucidate which motif dominates MAM-TM-CYTO dimerization (as was 
done to the PlxnA3 TM and JM domains to determine that the JM-driven dimer dominates in the 
TM + JM system, Chapter 3).  Confirmation of surface expression in the BRET2 assay via 
biotinylation studies or surface antibody labeling may also provide insight into the cause of the 
discrepancy.  Expression and purification of the Nrp2a extracellular domain in both WT and 
mutant form, followed by small angle x-ray scattering, may provide structural information 
regarding the role of MAM domain cysteines on overall shape of the extracellular domain.  Such 
a construct was successfully cloned into a pET28a vector in our lab; however, as bacterial 
expression systems have not yet been proven to generate a properly-folded receptor, re-cloning 
into a plasmid suitable for mammalian or insect cell expression may be required for accurate 
structural studies.  Finally, Nrp2a WT, C711S, and C711S + C794S MAM-TM-CYTO constructs 
115 
 
(rather than the full extracellular domain) could be analyzed in the BRET2 assay and compared to 
results from the AraTM assay.  In the event that the MAM-TM-CYTO BRET2 constructs exhibit 
surface expression and cysteine mutations as dimer-disrupting, consistent with the AraTM assay, 
cloning the constructs depicted in Figure 5.14, followed by analysis in the BRET2 assay, could 
identify the minimum extracellular domain length necessary for the switch from dimer-disruptive 
to dimer-promoting behavior.   
 
 
Figure 5.14. Constructs to investigate via BRET2 to elucidate putative cooperative partners of the 
MAM domain. Extracellular domain constructs could also be evaluated by small angle x-ray 
scattering if oligomerization studies imply domain cooperativity.  
 
By elucidating a mechanism for Nrp2a oligomerization, we can better define functionally 
relevant intra- and intermolecular interfaces.  Understanding domains and interfaces crucial to 
Nrp2a homooligomerization could inform rational drug design that promotes or disrupts 
clustering of nrp-plxn-sema complexes and subsequent signal activation.  Discrepancies between 
our AraTM and BRET2 results (Figure 5.11), as well as previous results with other proteins 
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containing MAM domains (38), suggest the possibility that domain cooperativity also plays a role 
in regulating oligomeric state and provides additional interfaces suitable for drug targeting. 
 
5.4.1 Materials and Methods 
5.4.1.1 Plasmids 
For the AraTM assay, nucleotide sequences of the MAM-TM-CYTO domains (residues 
629-921 of NCB Accession # AAI62118.1) of the WT construct and mutants were generated via 
PCR from the pcDNA3.1/V5-His-TOPO constructs described in Chapter 4 and subsequently 
cloned into the pAraTM plasmid (39) as an EcoRI/XhoI insert.  For expression of the Nrp2a 
extracellular domain in a bacterial system, the extracellular domain without a signal peptide 
(residues 25-796 of NCB Accession # AAI62118.1) was cloned into pET28a as an NheI/XhoI 
insert.  Likely due to a Taq error, the cloned construct contains a mutation (P62L) in the first 
CUB domain.   
For investigation of Nrp2a domain cooperativity in the BRET2 assay, ‘A’ and ‘B’ 
constructs (refer to Figure 5.14) for WT, C711S, and C711S + C794S Nrp2a have been 
successfully cloned into both a pGFP2 plasmid and a pRLuc plasmid for BRET2 studies.  The WT 
Nrp2a ‘C’ and ‘D’ constructs in a pGFP2 plasmid and the WT Nrp2a ‘D’ construct in a pRLuc 
plasmid have also been cloned.  These constructs were generated by ligation-independent cloning 
using the full-length (‘A’) constructs described in Chapter 4.  Constructs contained a predicted 
signal-peptide sequence for the full-length receptor (residues 1-27 of NCB Accession # 
AAI62118.1), followed by amino acids encoding for residues 219-927 (‘B’ constructs), 267-927 
(‘C’ constructs), 428-927 (‘D’ constructs), 593-927 (‘E’ constructs), or 629-927 (‘F’ constructs) 
of NCB Accession # AAI62118.1. 
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Domain-deletion constructs for the extracellular domain were also cloned into pET28a as 
EcoRI/XhoI inserts for domain cooperativity investigations on a bacterially-expressed soluble 
protein in the event that such an expression system is deemed useful.  These constructs lack the 
signal peptide, start with the amino acid delineated for the BRET2 constructs, and conclude with 
residue 796 of NCB Accession # AAI62118.1. 
 
5.4.1.2 AraTM Assay 
Electrically-competent SB1676 (The E. Coli Genetic Stock Center, Yale University) were 
co-transformed with the pAraGFP plasmid and the Nrp2a MAM-TM-CYTO domain subcloned 
into plasmid pAraTM. Confirmation of proper membrane integration for each construct as well as 
quantification of homodimerization was performed as previously described (31), but for maltose 
complementation, growth on maltose-supplemented plates occurred over the course of one week. 
Results are reported in terms of the average percent change from WT in slope of GFP 
fluorescence vs. absorbance determined from a minimum of 12 independent replicates.  Error bars 
indicate the standard error of these samples with the standard error from WT added to these 
values. 
 
5.4.1.3. NativePAGE Western Blots 
For full-length Nrp2a homooligomerization, cells were transfected as for BRET2 
(Chapter 4), but with the GFP2-fusion construct only and the entirety of each transfection seeded 
into one well of a gelatin-coated 6-well dish.  Each well was subsequently trypsinized and re-
suspended in 66 μL PBS.  One-fourth of this aliquot was used per condition per well on a 3-12% 
NativePAGE gel, with sample preparation performed as per manufacturer’s instructions with 1% 
n-dodecyl-β-D-maltoside and 2.5% glycerol, with and without 2.5% β-mercaptoethanol (BME) 
(reducing and non-reducing, respectively).  Electrophoresis, transfer to a PVDF membrane, and 
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subsequent processing of the membrane occurred as per manufacturer’s instructions.  Blots were 
blocked for one to two hours at room temperature in 5% milk in TBS + 1% Tween-20 (TBST).  
Antibodies were diluted 1:1000 (EGFP mouse monoclonal antibody, Clontech; mouse 
monoclonal anti-tubulin, Abcam; anti-mouse IgG HRP-linked antibody, Cell Signaling) in this 
block solution.  Incubation in primary antibody occurred overnight at 4°C, and incubation in 
secondary antibody occurred for one hour at room temperature.  Development occurred with the 
ECL Plus Western Blotting Detection System (GE Healthcare), and imaging with a Molecular 
Dynamics Storm 840.  Confirmation that roughly equivalent cell mass was present in each sample 
was determined via an anti-tubulin SDS-PAGE western blot (Figure 5.12). 
 
5.5 Behavior of the Neuropilin-2a MAM Domain in Solution 
 Our studies with cysteine mutations in the MAM domain involved this domain anchored 
to the cell membrane (Chapter 4 and Section 5.4).  Behavior of this domain in isolation may 
provide additional insight into the MAM cysteine regulatory mechanism on Nrp2a dimerization.  
Additionally, as the NRP2 MAM domain in isolation binds to NRP1 and NRP2 receptors (40), 
the purified MAM domain, or a rationally-designed homolog, may also be useful as a peptide to 
alter nrp function.  To study the MAM domain in the absence of membrane anchorage, we have 
expressed this domain using a bacterial expression system both in isolation and as an MBP-fusion 
and analyzed select constructs via NativePAGE, SDS-PAGE (as cross-linked entities), and SEC 
to examine oligomeric tendencies as well as via CD and in tryptophan fluorescence studies to 
gain insight into secondary and quaternary/tertiary structure. 
As protein migration via NativePAGE relies not only upon molecular weight, but also the 
protein’s charge distribution and shape, the actual oligomeric state cannot be directly determined 
from NativePAGE (41).  However, shifts in native oligomeric state can be assessed using this 
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technique.  As such, we used this technique to examine MBP-fused MAM domains with cysteine 
mutations or in the presence of reducing agent (Figure 5.15).  The WT Nrp2a MBP-MAM 
domain preferentially forms a complex with the apparent molecular weight as a dimer as 
observed by NativePAGE (Figure 5.15), with a higher-order oligomer and aggregates also 
observed.  The apparent dimer persisted in the presence of 2.5% BME (Figure 5.15B), suggesting 
the protein is actually monomeric or that the complex formed is independent of intermolecular 
disulfide bonds. 
 
 
Figure 5.15. NativePAGE on MBP-MAM.  (A) NativePAGE gels on purified MAM-MBP 
mutants illustrates mutations of cysteines C711 and C794 in the MAM domain influence the 
equilibrium of oligomeric states.  (B) In the presence of the reducing agent β-mercaptoethanol, a 
band at the apparent dimer molecular weight persists. Ladder markings in kDa, expected 
molecular weight of monomeric WT MAM-MBP is 62.5 kDa.  D marks apparent molecular 
weight of a dimer, H marks higher-order oligomer. 
 
To elucidate what role the conserved cysteines may play in the oligomeric potential of the 
Nrp2a MAM domain, we generated a series of purified MBP-MAM domain mutants and 
compared their ability to oligomerize via NativePAGE (Figure 5.15). For mutants C636S and 
C643S, the overall distribution of oligomeric states is similar to that of WT MBP-MAM, with the 
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major band corresponding to an apparent molecular weight of a dimer with some higher-order 
oligomer present. For C711S and C794S, however, this distribution is shifted as compared to that 
of WT, with both mutants exhibiting an increase in the ratio of amount of higher-order oligomer 
to amount of apparent dimer observed. Additionally, for C711S, the band corresponding to the 
higher-order oligomer is shifted slightly to a larger molecular weight relative to the other higher-
order oligomer bands observed for both WT and mutants. These results suggest C711 and C794 
play a role in regulating the equilibrium between homomeric interactions of the Nrp2a MAM 
domain.  These residues likely define the interfacial conformation leading to Nrp2a clustering and 
subsequent activation. 
To examine whether mutations to cysteines in the MAM domain could have additive 
effects influencing MAM oligomeric state, we made a series of double-mutants including C636S 
+ C643S, C636S + C711S, C643S + C711S, and C711S + C794S.  All double mutations 
exhibited similar distributions of apparent dimer and higher-order oligomer as WT MBP-MAM 
(Figure 5.15).  This suggests the disruptions caused by single point mutations to cysteines in the 
MAM domain are not additive in the MBP-fused peptide in a native environment, and further 
implies residues other than the conserved cysteines play a role in regulating Nrp2a MAM domain 
oligomeric states.  We speculate these other residues can correct for disruptions caused by 
missing cysteines; however, having C711 alone or C794 alone provides a driving force to shift 
the equilibrium of Nrp2a MAM oligomeric states to a higher-order.  Collectively, our 
NativePAGE results indicate that, for the MBP-MAM fusion, residues C711 and C794 contribute 
to modulation of oligomeric states. 
To examine behavior of the Nrp2a MAM domain in isolation, we employed cross-
linking, followed by SDS-PAGE for accurate molecular weight analysis of the resulting 
compounds.  The purified WT Nrp2a MAM domain preferentially forms a monomer as observed 
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by SDS-PAGE (Figure 5.16), with dimer also observed independent of the presence or absence of 
cross-linker (BS3).  Without a DTT reducing agent, monomer is observed at roughly four-fold the 
intensity of dimer, as indicated by ImageJ analyses.  The dimer persists in the presence of DTT, 
but the intensity of the dimer band is slightly reduced (<10%), suggesting cysteines may be 
involved in formation of the observed MAM dimer via SDS-PAGE.  To better understand the role 
of disulfide bonds formed by specific cysteines in Nrp2a MAM domain oligomerization, we 
examined the oligomeric state of the purified MAM domain with single and double cysteine 
mutations via SDS-PAGE.  Comparison of the Danio rerio Nrp2a MAM domain with the PTPμ 
MAM domain suggested C636-C643 and C711-C794 are likely to form disulfide bonds 
(analogous to disulfide bonds C27-C36 and C96-C182 in the PTPμ MAM domain) (Chapter 4) 
(38). Therefore, we mutated one or both cysteines in each of the corresponding putative disulfide 
bonds in the Nrp2a MAM domain to determine whether the predicted cysteines play a specific 
role in MAM monomer-dimer equilibrium.  Cross-linking and SDS-PAGE results for mutants 
C643S and C636S + C643S are both similar to WT MAM, where addition of reducing agent 
increases the ratio of monomer to dimer. The dimer band for C711S and C711S + C794S, 
however, remains slightly more pronounced in the presence of DTT than the dimer band of WT 
(<10%).  Collectively, these results suggests C711 plays a role in regulating the equilibrium 
between monomeric and dimeric states of the isolated Nrp2a MAM domain, with mutation 
C711S promoting dimer formation (consistent with our BRET2 results, Chapter 4).  This is 
consistent with the idea that a disulfide bond involving C711 in the WT Nrp2a MAM domain acts 
to negatively regulate the transition from MAM monomer to dimer.  Hence, mutation of this 
residue (C711S) promotes dimer formation (Figure 5.16 and BRET2 results, Chapter 4). 
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As a final method of analysis of the oligomeric state of the Nrp2a MAM peptide, we 
examined the WT and mutant peptides via SEC.  WT and mutant constructs exhibit peaks 
consistent with the molecular weights of monomer as well as an oligomer with a molecular 
weight consistent with that of 16 MAM domains (Figure 5.17).  While this isolated MAM domain 
oligomer likely does not reflect the oligomeric state of the full-length receptor, the MAM mutant 
C711S exhibited an increase in the ratio of the absorbance values of oligomer to monomer 
(Figure 5.17).  This is consistent with a model in which mutation C711S enhances receptor 
clustering, as was observed with the full-length receptor via NativePAGE (Section 5.4, Figure 
5.12).  Mutation C711S + C794S in the isolated MAM domain did not show significant changes 
in the ratio of oligomer to monomer absorbance from WT, consistent with our NativePAGE 
(Figure 5.15) results. 
Collectively, our results further indicate cysteine chemistry in the MAM domain 
regulates Nrp2a MAM homomeric interactions, and mutation C711S enhances 
homooligomerization, be it by enhancing dimerization of the full-length receptor (BRET2 results, 
Chapter 4), enhancing aggregation of the full-length receptor (Section 5.4, Figure 5.12), 
promoting formation of a higher-order structure when fused to MBP and analyzed via 
NativePAGE (Figure 5.15), maintaining a higher ratio of dimer to monomer when purified and 
analyzed via cross-linking and SDS-PAGE (Figure 5.16), and promoting oligomerization when 
purified and analyzed via SEC (Figure 5.17). 
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Figure 5.17. The Nrp2a MAM domain exists as monomer and oligomer in PBS, as determined by 
size-exclusion chromatography.  (A)  Chromatograms for Nrp2a MAM domain constructs.  (B)  
Ratios of absorbance intensity of oligomer to monomer for Nrp2a MAM domain constructs.  
Comparisons to WT suggest mutation C711S promotes oligomer formation. 
 
The importance of C711 in regulating Nrp2a MAM tertiary and/or quaternary structure 
was further confirmed by tryptophan fluorescence studies on the isolated peptide (Figure 5.18), 
which contains six tryptophan residues.  To note, the CD spectra of WT Nrp2a MAM and each 
individual MAM domain mutant are indistinguishable from one another, and each exhibits a 
characteristic spectra with minimum at 215 nm, indicative of a β-sheet (Figure 5.19) (42). Crystal 
structures of the MAM domains of PTPµ and promeprin β have indicated MAM domains in other 
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receptors are also largely β-sheet, consistent with the CD measurements (37,38,43). Thus, 
mutations to conserved cysteines in the MAM domain do not significantly alter the secondary 
structure of the Nrp2a MAM domain. Compared to the barycentric mean fluorescence of free 
tryptophan (368.5 ± 0.8 nm), the barycentric mean fluorescence of the MAM domain is blue-
shifted (354.0 ± 0.6 nm), as would be expected for a folded protein with buried tryptophan 
residues (Figure 5.18).  Mutants C711S and C711S + C794S exhibit red-shifted barycentric mean 
fluorescence values compared to the WT protein (356.9 ± 0.7 nm and 357.1 ± 0.7 nm, 
respectively), suggesting the tertiary and/or quaternary structures formed by these mutants do not 
quench tryptophan residues as extensively as the WT protein.  Mutants C643S and C636S + 
C643S exhibited similar barycentric mean fluorescence values as the WT protein (355.1 ± 0.7 nm 
and 354.8 ± 0.6 nm, respectively), implying similar solvent exposure as the WT protein. 
 The addition of reducing agent altered tryptophan quenching for the WT and C711S 
MAM domains, suggesting slight changes in tryptophan burial in the absence of disulfide bonds 
(Figure 5.18).  For the WT MAM domain, addition of TCEP results in a significant increase in 
integrated fluorescence intensity (38.0 ± 0.2%), consistent with a model in which intra- or 
intermolecular disulfide bonds stabilize a tertiary structure in which tryptophan residues are 
buried within the folded protein.  Interestingly, for mutant C711S, addition of TCEP decreases 
integrated fluorescence intensity (29.4 ± 0.2%).  This suggests an alternate tertiary or quaternary 
structure is formed by mutation C711S in which a disulfide bond prevents tryptophan quenching, 
unlike WT MAM.  Mutants C643S, C636S + C643S, and C711S + C794S exhibit less significant 
changes in integrated fluorescence intensity than WT or C711S (<5%), suggesting the burial of 
hydrophobic tryptophan in these mutations is not affected by specific disulfide bonds formed. 
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Figure 5.18. Tryptophan fluorescence studies on the Nrp2a MAM domain suggest mutant C711S 
exposes alternate interfaces compared to WT.  (A) Shifts in barycentric mean fluorescence values 
from free tryptophan suggest the isolated Nrp2a MAM domain tertiary and/or quaternary 
structures allow for tryptophan burial.  Mutants C711S and C711S + C794S exhibit different 
folding from WT.  Error bars indicate standard deviation from three spectral acquisitions.  (B)  
Trends in fluorescence intensity suggest disulfide bonds play a role in tryptophan burial in the 
WT and C711S Nrp2a MAM domains, with disulfide bonds allowing WT to bury more 
tryptophan and causing C711S to expose more tryptophan. 
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Figure 5.19. Circular dichroism spectra of Nrp2a MAM domains in PBS.  WT and mutant 
constructs exhibit β-sheet characteristics, in the absence (A) or presence (B) of TCEP. 
 
Collectively, our BRET2 (Chapter 4), AraTM (Section 5.4, Figure 5.10) gel 
electrophoresis (Figures 5.15 and 5.16 and Section 5.4, Figure 5.12), SEC (Figure 5.17), and 
tryptophan fluorescence (Figure 5.18) results suggest that Nrp2a MAM domain oligomerization 
relies upon cysteines that likely form disulfide bonds, and that all cysteines within the Nrp2a 
MAM domain are not equivalent.  The mutations affect quaternary structure equilibrium (gel 
electrophoresis and SEC, Figures 5.15, 5.16, and 5.17) but do not affect secondary structure (CD, 
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Figure 5.19). Under native conditions, C711 likely plays a dominant role in defining the 
equilibrium between Nrp2a oligomeric states and/or tertiary structure versus the other cysteines 
present in the Nrp2a MAM domain. 
While our results suggest cysteines play a key role in regulating the equilibrium between 
MAM oligomeric states (Figures 5.15, 5.16, and 5.17, Chapter 4, and Section 5.4), they do not 
play the only role in MAM dimerization, as is apparent by the perseverance of dimer in the 
isolated MAM domain in the presence of reducing agent (Figure 5.16).  As SDS also did not 
eliminate dimer, we can presume that hydrophobic interactions also contribute to dimer 
formation.  These results are in contrast to investigations of the PTPμ MAM domain, which runs 
as a monomer in the presence of SDS and reducing agent (44). 
To further understand our findings, and to identify other residues that putatively modulate 
homooligomerization, we developed a model for the Danio rerio Nrp2a MAM domain based on 
the crystal structure of the PTPμ MAM domain (PDB # 2C9A) (37) using MODELLER (45) and 
PyMOL (46) (Figure 5.20A).  The model suggests the four conserved cysteines (C636, C643, 
C711, C794) present in Nrp2a MAM are all arranged on the same face of the MAM domain 
(Figure 5.20A).  Our tryptophan fluorescence studies (Figure 5.18), gel electrophoresis (Figures 
5.15 and 5.16), SEC (Figure 5.17), AraTM (Section 5.4, Figure 5.10), and BRET2 results 
(Chapter 4) suggest C711 is particularly influential to this interface.  Interestingly, unlike the 
PTPμ MAM domain crystal structure, in which each of the four conserved cysteines are within 
sufficient proximity to form intramolecular disulfide bonds (44), our model suggests that the 
Nrp2a MAM cysteines C711 and C794 are sufficiently separate (9.3 Å, as determined using 
PyMOL) that they cannot form an intramolecular disulfide bond (Figure 5.20B). This hypothesis 
is supported by our experimental results illustrating mutation to C711 or C794 disrupts MAM 
domain oligomerization (Figures 5.15 and Section 5.4, Figure 5.10). Furthermore, as mutations 
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C711S and C794S in the pure MBP-MAM domain do not exhibit an enhanced propensity to form 
the higher-order oligomer over WT in the presence of 2.5% BME (Figure 5.15), the possibility 
exists that C711 and C794 form an intermolecular disulfide bond.  Further studies, such as the 
two-step alkylation procedure used previously to determine that PTPµ MAM domains form 
intramolecular disulfide bonds (44), are required to investigate this possibility.  Indeed, the 
macrophage migratory inhibitory factor protein undergoes local conformational changes in order 
to form a disulfide bond over longer-than-optimal distances (47), and as such, our model does not 
eliminate the possibility that residues C711 and C794 form an intramolecular disulfide bond.  
Such a feature may play a role in domain cooperativity, with additional extracellular domains 
forcing intramolecular disulfide bonds in the full-length receptor, and their absence in the MAM-
TM-CYTO constructs removing a driving force to form intramolecular disulfide bonds in the 
AraTM assay (Section 5.4). 
 
 
Figure 5.20. Homomeric Nrp2a interactions likely occur via a cysteine-rich interface in the 
MAM domain.   (A)  A model of the Nrp2a MAM domain, based on a crystal structure of the 
PTPμ MAM domain, supports the theory of a cysteine-rich interface that stabilizes dimerization, 
as the four cysteines lie on the same interface.  (B) Our model suggests not all cysteine pairs of 
the NRP2 MAM domain (left) are close enough to form intramolecular disulfide bonds, in 
contrast to the MAM domain of PTPμ (right). 
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Using RosettaDock (48) and the hypothesis that residues C711 and C794 both lie on the 
MAM homodimer interface, we developed a model to find low-energy configurations for the 
Nrp2a MAM dimer that contain C711 and C794 in the dimer interface. We examined the ten 
lowest dimeric energy configurations generated and selected the model with the highest 
percentage buried accessible surface area (ASA) across the dimer interface (Figure 5.21A). We 
then used this model to predict residues other than C711 and C794 that may influence Nrp2a 
MAM dimerization. In particular, we identified M713, which flanks the key residue C711 that 
regulates MAM dimerization, and N782 as key residues buried in the predicted MAM dimer 
interface.  M674, R697, and R750 are predicted off-interface residues and, as such, expected to 
have null effects on dimerization.  To test our predictions, we generated mutants (M713W, 
R750E, N782Q, M674W, and R697E) and characterized their effects on MAM-TM-CYTO 
oligomerization in AraTM. As shown in Figure 5.21B, both mutations to predicted interfacial 
residues in our dimer model (M713W and N782Q) caused significant disruption of MAM-TM-
CYTO dimerization, whereas a predicted null-mutation (M674W) had no significant effect on 
MAM-TM-CYTO dimerization. Thus, these results provide evidence to support the model for the 
Nrp2a homodimer (Figure 5.21A).  The predicted null-mutations R697E and R750E also 
disrupted dimerization.  This could possibly be due to disruption of long-range interactions that 
promote dimerization, or could be an indication of other interfaces involved in MAM 
dimerization.   
To examine our model of the Nrp2a MAM domain further, we additionally investigated 
the M713W, N782Q, and M674W mutations as MBP-MAM constructs on a NativePAGE gel 
(Figure 5.21E).  Predicted off-interface residue M674W exhibited similar oligomerization 
patterns as WT, in agreement with the AraTM results (Figure 5.21).  Predicted interfacial 
mutation M713W also appeared similar to WT, rather than mutations C711S or C794S; possibly  
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this mutation is permissive to the WT oligomeric pattern with the MAM domain alone, compared 
to with the TM-CYTO domain attached in the AraTM assay (Figure 5.21).  Predicted interfacial 
mutation N782Q disrupted formation of the construct at the apparent dimeric molecular weight.  
This change from WT oligomeric patterning is consistent with the AraTM results (Figure 5.21) 
and suggests that this residue also lies at the MAM domain homomeric interface and may be one 
of the unknown residues assisting in dimer formation.   
These results provide further evidence of the importance of electrostatic and hydrophobic 
interactions in Nrp2a MAM dimerization (identified in our cross-linking SDS-PAGE results, 
Figure 5.16), as the predicted interfacial mutations that resulted in decreased dimer formation in 
the context of the MAM-TM-CYTO domain were non-cysteines (residues N782 and M713) 
(Figure 5.21).  The results also provide further support of a possible homomeric interface 
containing C711 and C794, in agreement with our C711 and C794 NativePAGE (Figure 5.15) 
and AraTM (Section 5.4, Figure 5.10) results.  This interface regulates the intermediate dimeric 
conformation of the Nrp2a MAM domain, which can ultimately control full-length receptor 
clustering (Chapter 4).  The residues predicted by our model, as well as the MAM domain 
cysteines, in particular C711, may be adjustable residues for fine-tuning the MAM peptide for its 
use as a putative therapeutic. 
In summary, analysis of a bacterially-expressed MAM peptide has further confirmed the 
importance of MAM domain cysteines, in particular residue C711, in modulation of 
homodimerization.  We have furthermore used this information to develop a model of the Nrp2a 
MAM domain, and used this model to predict additional residues influential to MAM 
dimerization.  The MAM peptide expressed by insect or mammalian cells, in conjunction with 
domain cooperativity experiments (Section 5.4), may further define the role of the MAM domain 
in modulation of nrp signaling.  Additional functional studies with the peptide, and rationally-
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designed mutations of the peptide predicted from our model, will elucidate the feasibility of use 
of the peptide to regulate nrp-dependent signaling. 
 
5.5.1 Materials and Methods 
5.5.1.1 Plasmids 
For MBP-fusion constructs, a 6-His tag, followed by MBP, a poly-glycine linker, and 
tobacco etch virus cleavage site was cloned into pET42 as an NdeI/BamHI insert.  The pET28 
multiple-cloning site between BamHI and XhoI was subsequently cloned into this plasmid at 
BamHI/XhoI.  The Nrp2a MAM domain (residues 629-796 of NCB Accession # AAI62118.1) 
and mutants were then cloned into this plasmid as EcoRI/XhoI inserts.  To generate isolated 
MAM domain constructs, the Nrp2a MAM domain (residues 629-796 of NCB Accession # 
AI62118.1) in WT or mutant form was cloned into pET28(a) at EcoRI/XhoI. 
 
5.5.1.2 Expression and Purification of Nrp2a MAM and MBP-MAM Constructs 
Plasmids containing the Nrp2a MAM or MBP-MAM genes were transformed into 
BL21(DE3) cells (Invitrogen) and stored as glycerol stocks.  Expression and purification of MBP-
MAM was conducted using the same protocol as that for the PlxnA3 MBP-JM (Section 5.1.2.2).  
For MAM expression without the MBP fusion, cultures were started from glycerol stocks 
and grown to saturation overnight at 37°C in LB + 50 μg/mL kanamycin.  Cells were then diluted 
to an OD600 of 0.8 and allowed to grow an additional 1 hour at 18°C, at which point 1 mM IPTG 
was added to the culture.  Cells were collected 16-24 hours post-IPTG induction, re-suspended in 
PBS (pH 7.4) and lysed using freeze-thaw and tip-sonication. The MAM protein was 
subsequently extracted from the insoluble portion of the sonication using 3M urea.  The urea 
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extraction was dialyzed against 100-fold excess DNAse/RNAse buffer (10 mM Tris at pH 7.5, 
2.5 mM magnesium chloride, and 0.5 mM calcium chloride) overnight at 4°C and treated with 5 
µM DNAse I + 5 µM RNAse A for two hours at room temperature.  The protein was 
subsequently purified by nickel affinity chromatography with chelating sepharose fast flow resin 
(GE Healthcare) and imidazole washes ranging from 10 mM to 500 mM in 20 mM HEPES, 500 
mM sodium chloride, and 10% (v/v) glycerol.  Purity of at least 90% was confirmed by SDS-
PAGE using 12% polyacrylamide gels cast as previously described without addition of SDS to 
the polyacrylamide gel formulation (49); i.e.,  protein gels used to study Nrp2a MAM 
oligomerization were comprised of a resolving portion [375 mM Tris at pH 8.8, 12% (w/v) 
acrylamide:bis-acrylamide (29:1), 1 mg/mL ammonium persulfate, and 0.04% (v/v) Temed] and a 
stacking portion [125 mM Tris at pH 6.8, 5% (w/v) acrylamide:bis-acrylamide (29:1), 1 mg/mL 
ammonium persulfate, and 0.1% (v/v) Temed].  Gels were run in MES-SDS-PAGE running 
buffer (50 mM MES, 50 mM Tris, 1 mM EDTA, 0.1% SDS) at 100-250V, and staining occurred 
in Coomassie solution.  Purified protein samples were subsequently dialyzed against 0.2x PBS 
(pH 7.4), lyophilized, and re-hydrated to a 20-50X concentration with water.  Samples were then 
dialyzed against 1000-fold excess 2 mM phosphate buffer (pH 7.4; CD and tryptophan 
fluorescence) or 1X PBS (pH 7.4; SEC) overnight at 4ºC. Saturated protein concentrations were 
determined via absorbance measurements at 280 nm and normalized to 0.5 g/L.  For SEC and 
cross-linking SDS-PAGE, samples were subsequently reduced using 5% (v/v) BME and dialyzed 
against 1000-fold excess PBS (pH 7.4) for 16 hours at 4ºC.  Saturated protein concentrations 
were again determined and normalized to 0.3 g/L prior to loading for SEC. 
 
5.5.1.3 NativePAGE Gels 
Following purification, MBP-MAM samples were subsequently dialyzed against 2 mM 
Tris at pH 8 to remove imidazole.  Samples were then lyophilized and re-hydrated to a 50X 
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concentration with water.  Saturated protein concentrations were determined via absorbance 
measurements at 280 nm, and protein concentrations were normalized to 1 g/L with 100 mM Tris 
at pH 8 + 5% (v/v) BME.  Samples were then dialyzed against 1000-fold excess 20 mM Tris at 
pH 8 three times at 4°C (8 hours per round of dialysis) to remove BME.  MBP-MAM 
homooligomerization was subsequently analyzed via Coomassie-stained 3-12% NativePAGE gels 
(Life Technologies) according to manufacturer’s instructions.  Roughly 18 μg of protein and 3% 
(v/v) glycerol were loaded in the sample buffer per condition. 
 
5.5.1.4 Cross-linking 
Cross-linking experiments were performed as previously described (44), using protein at 
0.2 g/L, 20-fold molar excess BS3 (Thermo Scientific), and 25 mM DTT in reducing conditions.  
Prior to cross-linking, samples were dialyzed against 0.2X PBS (pH 7.4), lyophilized, and re-
hydrated to a 20-50X concentration with water.  Samples were then dialyzed against 1x PBS (pH 
7.4) and saturated protein concentrations were determined via absorbance measurements at 280 
nm.  Sample concentrations were normalized to 0.3 g/L with 1x PBS at pH 7.4 + 5% (v/v) BME.  
Samples were dialyzed against 1000-fold excess PBS at pH 7.4 for 16 hours at 4°C.  SDS-PAGE 
was performed using 12% SDS-PAGE gels made as described in Section 5.5.2.2 and run in MES-
SDS-PAGE running buffer (Section 5.2.2.2), and fixed, stained, and de-stained following the 
procedures for the manufacturer's instructions for NativePAGE gels (Invitrogen), but with 
staining occurring for 16 hours and de-staining for 4 hours.  Roughly 4 μg of protein and 2% 
(v/v) glycerol were loaded per condition.  Intensity of bands were determined by the gel analysis 
function of ImageJ (50). 
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5.5.1.5 Size Exclusion Chromatography 
Samples (15µL per injection) were passed over a TSKgel G3000SW column (Tosoh 
Bioscience) equipped with the appropriate guard column using an Agilent 1100 series high 
performance liquid chromatography system.  The mobile phase consisted of PBS run at 0.1 
mL/min.  Detection of MAM species occurred at 280 nm.  Fibrinogen (Sigma), bovine serum 
albumin (New England Biolabs), and RNAse A (Sigma) were used to generate a molecular 
weight calibration curve.  Serial dilutions of RNAse A were used to confirm absorbance linearity 
up to at least 8 absorbance units. 
 
5.5.1.6 Tryptophan Fluorescence Measurements 
Measurements occurred as previously described (30), but in 2 mM phosphate buffer (pH 
7.4).  Reduction of disulfide bonds occurred with 1 mM tris(2-carboxyethyl)phosphine (TCEP) 
over the course of ten minutes.  Free tryptophan measurements occurred using 0.5 g/L 
tryptophan. 
 
5.5.1.7 Circular Dichroism 
Measurements occurred as previously described (30), but at 20ºC in 2 mM phosphate 
buffer (pH 7.4) and scanned from 180 nm to 300 nm.  This buffer was also used for background 
subtraction.  Reduction of disulfide bonds occurred with 1 mM TCEP. 
 
 
137 
 
5.5.1.8 Homology Modeling and Docking 
Homology modeling of the monomeric Danio rerio Nrp2a MAM domain was performed 
using MODELLER (45) with the crystal structure of the PTPμ MAM domain (PDB 2C9A) as the 
template structure (37).  The dimer model was generated using RosettaDock (48).  Solvent-
accessible surface area (ASA) was determined using VADAR 1.8, employing the Shrake 
definitions for Van der Waals radii and polar/nonpolar/charged accessible surface area (51).  
Percentage of the ASA buried was defined by 
% 𝑏𝑢𝑟𝑖𝑒𝑑 𝐴𝑆𝐴 =  
𝐴𝑆𝐴𝐴 + 𝐴𝑆𝐴𝐵 − 𝐴𝑆𝐴𝐴+𝐵
𝐴𝑆𝐴𝐴 + 𝐴𝑆𝐴𝐵
 × 100 
where the subscripts A and B represent monomeric MAM domains utilized in building the model, 
and the subscript A+B represents the dimeric output of RosettaDock. 
 
5.6 Heteromeric Interaction Interfaces of Neuropilins and Plexins 
 Our studies thus far have investigated homomeric interactions of nrps and plxns.  With 
PlxnA3, we have identified residues in both the TM (Chapter 3) and JM (Chapter 2 and Section 
5.3) influential to homodimerization.  With Nrp2a, we have identified residues in the MAM 
domain (Chapter 4) influential to homodimerization.  However, as function relies upon both 
receptors, identification of a heteromeric interface could provide additional insight into the plxn-
nrp-sema mechanism of activation. 
 In addition to identifying nrp-plxn interaction interfaces, insight into the heteromeric 
interaction interfaces amongst nrps and plxns would also be beneficial for rational drug design.  
For instance, SEMA3C binding in sympathetic and sensory axons relies upon the presence of 
both NRP1 and NRP2 (40,52).  Studies suggest nrps may interact heteromerically via their MAM 
domains (40) as well as their TM domains (53).  A recent study also suggested PLXNA1 and 
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PLXNB1 may associate via their TM domains (53), though confirmation of this in full-length 
receptors or a functional relevance has yet to be determined. 
 The DN-AraTM assay is well-suited for studying heterodimer interfaces of TM and 
juxtamembrane domains in the context of a bacterial membrane (54).  In this assay, a TM and 
juxtamembrane domain of interest are expressed as fusions to an AraC protein (similar to the 
AraTM assay, but with an HA-tag from an ampicillin-resistant plasmid, pAraTMwt, rather than a 
myc-tag from a kanamycin-resistant plasmid) (‘TM1-AraC’).  This plasmid is co-transformed 
with [1] a spectinomycin-resistant plasmid encoding GFP regulated by a PBAD promoter and [2] a 
plasmid encoding WT or mutant form of the TM and juxtamembrane domains of an interacting 
protein, fused to an AraC protein with a mutation that disrupts its functionality as a transcription 
factor (‘TM2-AraC*’) (backbone plasmid pAraTMdn).  As such, interactions between the TM1-
AraC and TM2-AraC* constructs compete with homodimerization of TM1-AraC, the functional 
transcription factor.  This competition results in a decrease in GFP expression.  As such, 
mutations in the TM domain to TM2-AraC* that disrupt heterodimer formation exhibit a stronger 
GFP signal than an interacting WT TM domain; similarly, mutations enhancing 
heterodimerization will express less GFP than the WT TM in the TM2-AraC* construct (54). 
 To investigate the heteromeric interfaces between Danio rerio PlxnA3 and Nrp2a, the 
PlxnA3 TM + JM and Nrp2a MAM-TM-CYTO have been successfully cloned into both the 
pAraTMwt and pAraTMdn plasmids, though PlxnA3-Nrp2a heterodimer measurements are still 
needed.  Additionally, the TM-CYTO and MAM-TM-CYTO domains of five human membrane-
anchored NRP2 isoforms (NRP2a(0), NRP2a(17), NRP2a(22), NRP2b(0), and NRP2b(5); Figure 
5.22) and the MAM-TM-CYTO domains of the membrane-anchored NRP1 isoform have also 
been cloned into the pAraTMwt plasmid (‘-AraC’ constructs) for investigation of nrp heteromeric 
interfaces.  The MAM-TM-CYTO domains of NRP2a(22), NRP2b(0), and NRP1 have also been 
cloned into the pAraTMdn plasmid (‘-AraC*’ constructs). 
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Figure 5.22. Primary sequence comparison of human neuropilins.  (A) Alignment of human 
membrane-anchored neuropilin MAM-TM-CYTO sequences. TM-CYTO domains are indicated 
by red font, whereas MAM-TM-CYTO domains are both black and red font.  Bolded residues are 
those predicted to be in the membrane environment.  (B)  The primary sequence of all NRP TM 
domains exhibit at least one small-x3-small motif.  Different colors indicate different small-x3-
small motifs. 
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Considering first homodimerization (where higher slopes of GFP fluorescence vs. 
absorbance equate with increased dimerization), our studies thus far indicate the NRP2b 
constructs (TM-CYTO or MAM-TM-CYTO) homodimerize to a stronger extent than the 
equivalent NRP2a constructs (Figure 5.23A).  Additionally, for the NRP2a TM-CYTO 
constructs, the shorter the isoform, the stronger it dimerizes, though better western blotting is 
needed to confirm equivalent expression levels before we can make this conclusion.  If 
expression levels are equivalent, it is possible that the presence of additional residues creates a 
steric disruption to TM dimerization.   Our results may suggest that the NRP2 TM-CYTO 
domains dimerize more strongly than the MAM-TM-CYTO domains; however, this may be an 
artifact of unequal expression levels (Figure 5.23B). 
 To better understand NRP2a, NRP2b, and NRP1 homodimer and heterodimer interfaces, 
we considered the primary sequences of the TM domains.  All exhibit at least two small-x3-small 
TM motifs (Figure 5.22).  We made a series of mutations to the NRP2a(22), NRP2b(0), and 
NRP1 MAM-TM-CYTO-AraC* (heterodimer competition) constructs to disrupt (glycine, 
alanine, or serine to leucine mutations) or enhance (alanine to glycine mutations) the small-x3-
small motifs. The NRP1 and NRP2a(22) WT- and mutant-AraC* constructs were co-expressed 
with WT NRP1, NRP2a(22), or NRP2b(0) MAM-TM-CYTO-AraC constructs to assess 
heterodimerization. 
 As indicated in Figure 5.24, both WT NRP1 and WT NRP2a(22) MAM-TM-CYTO 
domains heterodimerize with NRP1, NRP2a(22), and NRP2b(0) MAM-TM-CYTO domains, as 
indicated by the decrease in GFP signal compared to the homodimer constructs upon heterodimer 
co-expression.  Considering first the NRP1 homodimer interface (Figure 5.25), we observe that 
NRP1 G868L MAM-TM-CYTO-AraC* does not heterodimerize with WT NRP1 MAM-TM-
CYTO-AraC as well as the WT NRP1 MAM-TM-CYTO-AraC* heterodimer competition 
(indicated by the higher GFP expression upon NRP1 MAM-TM-CYTO-AraC co-expression with  
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Figure 5.23. DNAraTM measurements of human NRP2 homodimerization and NRP1-NRP2 
heterodimerization.  (A)  DNAraTM measurements for NRP2 TM-CYTO-AraC 
homodimerization, NRP2 MAM-TM-CYTO-AraC homodimerization, and NRP2 MAM-TM-
CYTO-AraC heterodimerization with NRP1 MAM-TM-CYTO-AraC*.  Results represent 
average values of a minimum of 15 samples collected over the course of three experiments.  Error 
bars indicate standard error.  (B)  An anti-HA (1:1,000, Cell Signaling) western blot indicates 
NRP2 TM-CYTO-AraC constructs may express better than NRP2 MAM-TM-CYTO-AraC 
constructs.  (C) NRP2 MAM-TM-CYTO-AraC constructs express in equivalent levels 
independent of NRP1 MAM-TM-CYTO-AraC* co-expression, as indicated by an anti-HA 
(1:1,000, Cell Signaling) western blot.  (D) NRP1 MAM-TM-CYTO-AraC* is expressed in all 
heterodimer conditions tested in the DNAraTM assay, as indicated by an anti-myc (1:1,000, Cell 
Signaling) western blot.  Expected molecular weights are roughly 75 kDa for TM-CYTO-AraC 
constructs and 90 kDa for MAM-TM-CYTO-AraC and MAM-TM-CYTO-AraC* constructs. 
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Figure 5.24.  NRP1 and NRP2a(22) MAM-TM-CYTO-AraC* constructs heterodimerize with 
NRP1, NRP2a(22), and NRP2b(0) MAM-TM-CYTO-AraC constructs in the DNAraTM assay, as 
indicated by decreased level of GFP expression for a given culture density upon co-expression of 
MAM-TM-CYTO-AraC* with the MAM-TM-CYTO constructs.  Values represent average 
slopes of fluorescence vs. absorbance collected from a minimum of 22 replicates collected over 
the course of six experiments.  Error bars indicate standard error. 
 
the G868L NRP1 MAM-TM-CYTO-AraC* heterodimer construct, compared to NRP1- MAM-
TM-CYTO AraC co-expression with the WT NRP1 MAM-TM-CYTO-AraC* heterodimer 
construct).  Hence, residue G868 likely contributes to the NRP1 dimer interface.  This is in loose 
agreement with a previous study in which triple mutation to all three residues participating in the 
NRP1 small-x3-small motif (G868, G872, and G876) disrupted dimerization.  Constructs G872L 
NRP1 MAM-TM-CYTO-AraC* and G876L NRP1 MAM-TM-CYTO-AraC* heterodimerize 
with the WT NRP1 MAM-TM-CYTO-AraC to the same extent as WT NRP1 MAM-TM-CYTO-
AraC*, suggesting these residues may be less influential in defining the NRP1 homodimer 
interface.  However,  our current  results  do  not  measure the  extent of  homodimerization of the  
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Figure 5.25.  NRP1 MAM-TM-CYTO-AraC heterodimerization with NRP1 MAM-TM-CYTO-
AraC* competition.  Results represent the average value from a minimum of 22 samples collected 
over the course of six experiments.  Error bars indicate standard error. 
 
mutant constructs and hence cannot rule out the possibility that mutations G872L and G876L 
homodimerize less strongly than the WT receptor. 
 Mutation G868L to NRP1 MAM-TM-CYTO-AraC* also disrupts heterodimerization 
with NRP2a(22) MAM-TM-CYTO-AraC (Figure 5.26), as does NRP1 mutation G872L.  These 
results suggest NRP1 residues G868 and G872 are important for NRP1-NRP2a(22) dimerization.  
In contrast, mutations G868L, G872L, and G876L to NRP1 MAM-TM-CYTO-AraC* enhance 
heterodimerization with NRP2b(0) MAM-TM-CYTO-AraC (Figure 5.27).  Possibly, 
homodimerization of the WT NRP1 MAM-TM-CYTO-AraC* via a small-x3-small motif disrupts 
its capacity to heterodimerize with NRP2b(0).  By disrupting the small-x3-small motif with 
mutations G868L, G872L, and G876L, we make the NRP1 MAM-TM-CYTO-AraC* construct 
more accessible to interactions with the NRP2b(0) MAM-TM-CYTO-AraC construct.  Additional  
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Figure 5.26.  NRP2a(22) MAM-TM-CYTO-AraC heterodimerization with NRP1 MAM-TM-
CYTO-AraC* competition.  Results represent the average value from a minimum of 22 samples 
collected over the course of six experiments.  Error bars indicate standard error. 
 
 
Figure 5.27.  NRP2b(0) MAM-TM-CYTO-AraC heterodimerization with NRP1 MAM-TM-
CYTO-AraC* competition.  Results represent the average value from a minimum of 22 samples 
collected over the course of six experiments.  Error bars indicate standard error. 
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simulation work may elucidate how our mutagenesis results correlate with receptor 
heterodimerization. 
 Considering NRP2a(22) MAM-TM-CYTO-AraC heterodimerization with NRP2a(22) 
MAM-TM-CYTO-AraC* constructs (Figure 5.28), we observe that mutation G876L disrupts 
heterodimerization relative to the WT NRP2a(22) MAM-TM-CYTO-AraC* construct, whereas 
mutations G880L and A884L (both on the same putative small-x3-small interaction interface as 
G876) enhances heterodimerization.  Our results suggest that the G876-G880-A884 interface 
influences dimerization; the mechanism, however, is unclear.  The mutation enhancing this small-
x3-small motif (A884G) does not alter heterodimerization relative to the WT NRP2a(22) MAM-
TM-CYTO-AraC* construct, nor do disruptive mutations to the second putative small-x3-small 
interface  (A881L and  G885L).   Previous research indicates that  introduction of  large  aliphatic 
 
 
Figure 5.28.  NRP2a(22) MAM-TM-CYTO-AraC heterodimerization with NRP2a(22) MAM-
TM-CYTO-AraC* competition.  Results represent the average value from a minimum of 22 
samples collected over the course of six experiments.  Error bars indicate standard error. 
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residues at locations immediately preceding or anteceding residues forming the interface of the 
small-x3-small motifs can enhance dimerization (18). Preference for the location of the large 
residue depends on the size of other off-interface residues.  It is possible that mutations G880L 
and A884L enhance dimerization by promoting small-x3-small dimerization via residues A881 + 
G885, such that the dimerization motif is [Large][Small]xx[Large][Small], as has been observed 
as an over-represented motif in backbones with predominately alanine at the second ‘x’ position 
(18).  Alternatively, some other packing motif may drive dimerization.  Integrin 
heterodimerization, for instance, relies upon an intact V-x3-I-x3-G interface (20).  Simulation 
studies may provide further insight into the NRP2a(22) TM dimerization mechanism. 
If we consider mutations to NRP2a(22) affecting NRP2a(22) MAM-TM-CYTO-AraC* 
heterodimerization with NRP1 MAM-TM-CYTO-AraC (Figure 5.29), we observe that mutations 
G876L and G880L (on the same small-x3-small interface) as well as mutation G885L (on a 
different small-x3-small interface) disrupt heterodimerization relative to the WT NRP2a(22) 
MAM-TM-CYTO-AraC* construct.  Neither mutation A881L (on the same small-x3-small 
interface as G885) nor mutations A884L and A884G (on the same small-x3-small interface as 
G876 and G880) affect heterodimerization.  As such, maintaining intact glycines appears to be of 
greater importance than total maintenance of the small-x3-small dimerization motif.  Again, 
simulation studies would clarify the meaning of this result and possibly elucidate a packing motif 
different than the small-x3-small dimer interface. 
In the NRP2a(22)-NRP2b(0) heterodimer interface (Figure 5.30), we find two NRP2a(22) 
mutations disruptive to NRP2a(22) MAM-TM-CYTO-AraC* and NRP2b(0) MAM-TM-CYTO-
AraC heterodimerization:  G876L and A884G.  Both residues lie on the same helical face; 
however, if we expected this interface to participate in a standard small-x3-small packing motif, 
mutation A884G should have enhanced dimerization.  Hence, the dimerization mechanism is still 
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Figure 5.29.  NRP1 MAM-TM-CYTO-AraC heterodimerization with NRP2a(22) MAM-TM-
CYTO-AraC* competition.  Results represent the average value from a minimum of 22 samples 
collected over the course of six experiments.  Error bars indicate standard error. 
 
 
 
 
Figure 5.30.  NRP2b(0) MAM-TM-CYTO-AraC heterodimerization with NRP2a(22) MAM-
TM-CYTO-AraC* competition.  Results represent the average value from a minimum of 22 
samples collected over the course of six experiments.  Error bars indicate standard error. 
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elusive.  It is possible that an alternating small-large dimer interface, as has been observed with 
integrins (20), may govern NRP2a(22)-NRP2b(0) heterodimerization. 
Collectively, our results indicate a role for the small residues in the NRP1 and 
NRP2a(22) TM domains in modulation of receptor dimerization, though further work is needed to 
elucidate a mechanism.  Simulation studies will provide additional insight, as will DN-AraTM 
results on investigations of mutagenesis to NRP2b(0) MAM-TM-CYTO-AraC* 
heterodimerization with NRP1, NRP2a(22), and NRP2b(0) MAM-TM-CYTO-AraC constructs.  
Mutations to the NRP2b(0) putative small-x3-small interfaces were recently cloned in our lab for 
such studies.  This work could provide a foundation for understanding NRP heteromeric 
interfaces, providing structural insight into their activation mechanisms as co-receptor complexes. 
 
5.6.1 Materials and Methods 
5.6.1.1 Plasmids 
 The pAraTM multiple cloning site (SacI through KpnI) was cloned into both pAraTMdn 
and pAraTMwt for ease of use.  In pAraTMwt, a linker (sequence RQLPTAAPEPAK, and a 
methionine to valine mutation immediately following) was also cloned between the multiple 
cloning site and the AraC protein.  Subsequently, nrp TM-CYTO or MAM-TM-CYTO domains 
as designated by Table 5.2 were cloned between EcoRI and XhoI. 
 
Table 5.2.  Neuropilin Cloning Domains in the DNAraTM Assay. 
Gene Source NCBI 
Accession Number 
TM-CYTO Residues MAM-TM-CYTO 
Residues 
NRP1 NP_003864.4 800-923 643-923 
NRP2a(0) AAC51788.1 791-909 640-909 
NRP2a(17) AAI43609.1 791-926 640-926 
NRP2a(22) NP_957718.1 791-931 640-931 
NRP2b(0) AAG41403.1 791-901 640-901 
NRP2b(5) AAG41404.1 791-906 640-906 
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5.6.1.2 DN-AraTM Measurements 
 DN-AraTM measurements and western blotting to confirm expression (Figure 5.31) were 
performed as previously described (54), except 24 hours lapsed between IPTG-induction and 
sample measurement, rather than 6 hours. 
 
 
Figure 5.31.  Anti-myc (1:1,000, Cell Signaling) western blot confirming expression of (A) 
NRP1 and (B) NRP2a(22) MAM-TM-CYTO-AraC* DNAraTM constructs.  Expected molecular 
weights of WT constructs are 91 kDa and 92.5 kDa for NRP1 and NRP2a(22), respectively.  
Ladder markings are in kDa. 
 
 
5.7 Final Remarks 
 Understanding plexin and neuropilin signal transduction mechanisms is of interest from a 
developmental biology perspective as well as in the study of cancer metastasis.  Transmembrane 
dimerization, via the membrane or juxtamembrane domains, is one modulation mechanism for 
receptor activity.  We demonstrate that, in the plexin-neuropilin system: 
150 
 
[1] A cytosolic juxtamembrane heptad repeat modulates PlxnA3 homodimerization, with a 
conserved methionine preventing strong receptor dimerization.  The core of the heptad 
repeat forms a switchable interface that modulates homooligomerization and activity. 
[2] A series of small residues in the PlxnA3 transmembrane domain offer dimerization 
motifs that compete with dimerization induced by the juxtamembrane heptad repeat.  
These residues prevent strong receptor dimerization, allowing for switchability between 
binding partners and active/inactive states.  Mutation of these residues disrupts PlxnA3 
function; as such, enhanced dimerization does not correlate with heightened function. 
[3] Cysteines in the Nrp2a MAM domain modulate homomeric interactions, with mutations 
disrupting ligand binding and signal transduction. 
Our results provide insight into the mechanisms regulating plexin-neuropilin signaling and 
demonstrate that enhancing receptor dimerization is not sufficient for increasing receptor activity.  
Our work defining the receptor homomeric interfaces will hopefully augment future efforts to 
modulate activity, allowing for rational design of targeted therapeutics. 
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Appendix A 
 
Understanding Biosurfactant Sequence and Structural 
Features for Enhanced Targeted Drug Delivery 
 
 
 Surfactants play an important role in the food, biopharmaceutical, and energy industries, 
but little is known about their structure-function relationships apart from their amphiphilic nature. 
Biosurfactants are amphiphilic molecules naturally secreted by a wide range of bacteria and 
fungi; these molecules offer a ‘green’ surfactant with potential additional built-in functionalities 
in their peptide chains. They have applications in bioremediation, as synthetic vaccines, as 
vaccine adjuvants, and in drug delivery (1-5). Identification of the characteristic regions of 
biosurfactants responsible for surface activity and the sequence features responsible for 
stabilizing their surface-active structures may provide insight for novel surfactant production. 
With this knowledge, we could engineer a biomimetic surfactant that incorporates alternative 
functionalities to make it a switchable system and responsive material. Such engineered 
functionalities could provide beneficial drug delivery technology, with engineered side-chain 
interactions incorporating pH-dependent self-assembly in the biosurfactant as well as ligand 
recognition triggering drug release and the ability to effectively solubilize hydrophobic drug 
substance in a micellar drug delivery system while maintaining bioactivity of the drug substance. 
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The hydrophobin HFBII from Trichoderma reesei could serve as a template biosurfactant for 
structure-function relationship studies (1,2,5,6). 
The HFBII protein is a class II hydrophobin and hence considered a hydrophilic 
biosurfactant (relative to less soluble, class I hydrophobins) (1,5).  An α-helix and four β-sheets 
constitute the HFBII secondary structure, and the tertiary structure of HFBII consists of a 
hydrophobic patch comprised of side chains from aliphatic residues (Figure A1) (1,5,6).  Four 
disulfide bridges are believed to maintain tertiary structure stability (Figure A1) (1,5,6). 
Mutations to disrupt disulfide bonds, secondary structure, or the hydrophobic patch may result in 
a controllable biosurfactant, with amphiphilicity regulated by pH or temperature. 
 
 
Figure A1.  Structure of HFBII, a naturally-occurring peptide biosurfactant (PDB # 1R2M).  
Tertiary structure is maintained by disulfide bonds (cyan), and amphiphilicity is a result of a 
patch of aliphatic side chains (orange). 
 
We have successfully expressed a modification of HFBII (HFBII.2) as a thrombin-
cleavable ompF-fusion using a bacterial expression system (7).  The ompF portion contains a 
poly-histidine tag, allowing for purification of the fusion via immobilized metal-ion affinity 
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chromatography (IMAC) (Figure A2).  HFBII.2 is dissimilar to HFBII in that one cysteine from 
each of the four disulfide pairs in the native HFBII protein (four cysteines in total) was removed 
via truncation or mutation. 
 
 
Figure A2.  OmpF-HFBII.2 can be expressed using a bacterial expression system.  (A)  
Coomassie-stained SDS-PAGE gel and (B) anti-His (1:1,000, Cell Signaling) western blot 
confirming expression and cleavage of ompF-HFBII.2.  The poly-histidine tag is on the ompF 
fragment of the the fused protein; bands present on the Coomassie-stained gel and absent on the 
western blot may be HFBII.2-only (green boxes:  monomeric HFBII.2; yellow box:  oligomeric 
HFBII.2 without ompF).  The addition of 1% β-mercaptoethanol reduces, but does not eliminate, 
oligomerization.  Expected monomeric molecular weights are 7.4 kDa, 17.4 kDa, and 24.8 kDa 
for HFBII.2, ompF, and ompF-HFBII.2, respectively. 
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SDS-PAGE gels provide some insight into the behavior of the ompF-HFBII.2 fusion 
protein.  OmpF-HFBII.2 oligomerization is apparent on SDS-PAGE gels before and after 
thrombin cleavage (Figure A2).  While the oligomers in the thrombin-cut sample may be ompF, 
uncut ompF-HFBII.2, or complexes of ompF, HFBII.2, and ompF-HFBII.2, at least two are likely 
due to HFBII.2 only, as the bands (visible via Coomassie-staining) fail to appear in an anti-His 
western blot (yellow box, Figure A2).  Our SDS-PAGE results also suggest the ompF-HFBII.2 
protein is capable of forming disulfide-dependent oligomers, as indicated by a reduction to 
oligomerization upon addition of 1% β-mercaptoethanol (BME) (Figure A2).  As the ompF tag 
lacks cysteines, this disulfide bonding is due to the HFBII.2 peptide.  Oligomerization is not 
eliminated in the presence of BME, however, suggesting ompF-HFBII.2 oligomerizes via 
disulfide-independent mechanisms.  Purification of HFBII.2 from thrombin and ompF may 
provide additional insight regarding the oligomic potential of the peptide.  Preliminary work 
suggests ompF and HFBII.2 can be separated via reverse-phase chromatography, as indicated by 
MALDI-TOF results (Figure A3).  As this could be due to different ionization potentials of the 
peptides, a method for confirming HFBII.2 purification (such as SDS-PAGE) is also needed.  
Upon successful purification, structural analyses of HFBII.2, such as circular dichroism and 
tryptophan fluorescence mapping of the peptide at variable temperatures and pH’s, may help to 
assess structural stability and switchability. 
Preliminary macroscopic emulsification studies suggest the thrombin-cleaved ompF + 
HFBII.2 solution exhibits surfactant behavior.  Direct interpretation of results is convoluted due 
to the presence of FOS-Choline-15 in the samples (from the IMAC chromatography), and a 
technique to remove it must be developed for future functional studies.  However, our results 
suggest the thrombin-cleaved ompF-HFBII.2 peptide in FOS-Choline-15 emulsifies nonane better 
than  FOS-Choline-15 alone, as is apparent by a single phase in the presence of  thrombin-cleaved  
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Figure A3.  MALDI-TOF spectra of thrombin-cleaved ompF-HFBII.2 subjected to reverse phase 
chromatography with an (A) acetonitrile or (B) isopropanol gradient.  Expected m/z for HFBII.2 
is 7.4. 
 
ompF-HFBII.2, but persistence of three phases in its absence.  Thrombin-cleaved ompF-HFBII.2 
in FOS-Choline-15 poorly emulsifies mineral oil and hexane relative to FOS-Choline-15 alone, as 
indicated by the decreased depth of the emulsified (white) layer.  Additional functional studies on 
a purified HFBII.2 protein or the ompF-HFBII.2 protein in the absence of detergent should be 
performed to characterize activity.  In addition to emulsion studies, contact angle measurements 
and solubilization studies of hydrophobic materials, such as Oil Red O or, for drug delivery 
studies, ketoprofen, could also provide insight into HFBII.2 structure-function relationships. 
Changes to the HFBII on its primary structural level could result in a utilizable on-off 
functionality switch and a responsive system capable of carrying a drug substance until 
recognition of a specific receptor site. The genetically-engineered biosurfactant could facilitate 
incorporation of monodispersed hydrophobic drug substances in a micellar drug delivery system. 
This system could have a high-degree of control over its molecular properties through genetic 
alteration of the peptide primary sequence,  and be easily manipulated for other applications  once  
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Figure A4.  A preliminary macroscopic emulsion study suggests the presence of HFBII.2 affects 
oil emulsification.  Enhanced emulsification is indicated by the persistence of a middle (white) 
layer, whereas the appearance of three layers (a clear layer on the top and bottom) indicates poor 
emulsification. 
 
the primary structure is understood. Furthermore, as biosurfactants naturally occur in organisms 
used for fermentation in the biopharmaceutical industry, the production process would be 
scalable. The combination of all of these phenomena will result in a novel and efficient targeted 
drug delivery system. 
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A1.1 Materials and Methods 
A1.1.1 Plasmids 
 For ompF-HFBII.2, HFBII.2 (residues 20-86 of Trichoderma reesei HFBII, NCB 
Accession # XP_006962048.1, with mutations C29S, C58S, and C67S) was cloned into pOmpF 
(7) at restriction sites SpeI and XhoI. 
 
A1.1.2 Expression and Purification 
 Expression, IMAC purification, thrombin-cleavage, and SDS-PAGE were conducted 
following the methods employed for the Danio rerio plexin A3 transmembrane and cytosolic 
juxtamembrane domains fused to ompF (ompF-TM+JM, Section 5.3).  Reverse phase 
chromatography was conducted using a C4 column on an Agilent 1100 series high performance 
liquid chromatography system and an acetonitrile or isopropanol concentration gradient 
(increasing from 10 to 100% solvent over the course of 25 minutes following a 5-minute loading 
time for the sample and equilibration).  MALDI-TOF spectra represent samples collected 
between 26 and 40 minutes.  A sinapinic acid matrix was used for MALD-TOF analyses. 
A1.1.3 Emulsion Studies 
 For emulsion studies, 200µL of oil (hexane, octane, nonane, decane, or mineral oil) were 
combined with 100µL of 1% FOS-Choline-15 in 20 mM Tris at pH 8 with or without thrombin-
cleaved ompF-HFBII.2.  Mixtures were subsequently vortexed, bath sonicated for 30 minutes, 
incubated for 30 minutes with agitation at 37ºC, then centrifuged for 30 minutes.  Samples were 
then incubated overnight in a shaking incubator at 37ºC prior to imaging. 
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